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ABSTRACT 
Plantazolicin (PZN) is a ribosomally synthesized and post-translationally modified peptide 
(RiPP) natural product that exhibits extraordinarily narrow-spectrum antibacterial activity towards 
the causative agent of anthrax, Bacillus anthracis. During PZN biosynthesis, a cyclodehydratase 
catalyzes cyclization of cysteine, serine, and threonine residues in the PZN precursor peptide 
(BamA) to azolines. Subsequently, a dehydrogenase then oxidizes most of these azolines to 
thiazoles and (methyl)oxazoles. The final biosynthetic steps consist of leader peptide removal and 
dimethylation of the nascent N-terminus. 
To simultaneously establish the structure−activity relationship of PZN and the substrate 
tolerance of the biosynthetic pathway, an Escherichia coli expression strain was engineered to 
heterologously produce PZN analogs. 72 variant BamA peptides were screened by mass 
spectrometry to assess post-translational modification and export by E. coli, from which 29 PZN 
variants were detected. The modifying enzymes were exquisitely selective, installing heterocycles 
only at predefined positions within the precursor peptides while leaving neighboring residues 
unmodified. Nearly all substitutions at positions normally harboring heterocycles prevented 
maturation of a PZN variant. No variants containing additional heterocycles were detected, 
although several peptide sequences yielded multiple PZN variants as a result of varying oxidation 
states of select residues. Eleven PZN variants were produced in sufficient quantity to facilitate 
purification and assessment of their antibacterial activity, providing insight into the structure-
activity relationship of PZN. 
Using heterologously expressed and purified heterocycle synthetase, the BamA peptide 
was processed in vitro concordant with the pattern of post-translational modification found in the 
naturally occurring compound. Using a suite of BamA-derived peptides, including amino acid 
substitutions as well as contracted and expanded substrate variants, the substrate tolerance of the 
heterocycle synthetase was elucidated in vitro, and the residues crucial for leader peptide binding 
were identified. Despite increased promiscuity compared to what was previously observed in E. 
coli, the synthetase retained selectivity in cyclization of unnatural peptides only at positions which 
correspond to those cyclized in the natural product. A cleavage site was subsequently introduced 
to facilitate leader peptide removal, yielding mature PZN variants after enzymatic or chemical 
dimethylation. In addition, we report the isolation and characterization of two novel PZN-like 
natural products whose existence was predicted by genome sequencing. 
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CHAPTER 1: 
Lessons learned from the transformation of natural product discovery to a genome-driven endeavor1 
 
1.1 Introduction 
 Natural products have played a significant role in medicine, and fittingly, the discovery of 
novel natural products continues to hold great promise for the development of new drugs (1). 
Forward natural product discovery relies on the presence of an observable phenotype or chemical 
property, such as biological activity, color, or a known mass, which can be tracked through 
successive rounds of isolation. Successful “grind and find” isolation of a natural product can be 
followed by identification of the genes responsible for the biosynthesis of the compound of 
interest. This method was remarkably productive in its early years, but has been met with 
increasing frustration by researchers as the rediscovery of known compounds has become 
commonplace, as many of the easily accessible natural products have already been isolated (2).  
Meanwhile, the increasing ease of DNA sequencing has led to an explosion of fully 
sequenced genomes and identified biosynthetic pathways over the last 20 years. In many cases, 
the biosynthetic genes responsible for well-known and long-studied natural products have been 
identified only recently (Figure 1.1). Furthermore, the elucidation of biosynthetic pathways for 
natural products is by no means complete, as a number of important compounds (e.g. morphine, 
paclitaxel) still have major gaps in what is known of their biosynthesis (Figure 1.1). Biosynthetic 
genes for plant natural products are often particularly difficult to identify because plants do not 
commonly cluster the responsible genes as bacteria and fungi often do, and plant genomes are 
much larger than those of bacteria and fungi (3). That is not to say the task is easy in lower 
organisms, as history has shown us that characterization of bacterial and fungal pathways requires 
immense time and effort. A noteworthy example is the bottromycin family, whose biosynthetic 
gene cluster was identified by four independent groups in 2012, which was 55 years after the first 
report of its isolation (4-7). Likewise, the genes responsible for the production of the thiopeptide 
antibiotics remained unknown until being reported upon nearly simultaneously by four 
independent research groups in 2009 (8-11). In the case of thiostrepton, a well-known thiopeptide, 
this report came 53 years after its initial isolation.  
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Figure 1.1. Timeline of traditional “forward” natural product discovery, highlighting the 
frequently decades-long gap between isolation of a novel natural product and identification of its 
biosynthetic genes. A date above the arrow indicates when isolation of the indicated natural 
product was first reported, with the date of structure elucidation (if different) in parentheses. A 
date below the arrow indicates when the biosynthetic genes were first identified for the natural 
product, with the years since isolation in parentheses. This figure is not meant to be exhaustive but 
instead to provide a representative sample of natural products spanning multiple biosynthetic 
classes, biological targets, and producing organisms. NRP, non-ribosomal peptide; RiPP, 
ribosomally synthesized and post-translationally modified peptide; *, majority of biosynthetic 
pathway remains unknown. 
 
 With the advent of inexpensive, massively parallel sequencing, a new route to discover 
natural products has emerged. The genomic revolution has fueled a shift in methods for identifying 
natural products from the traditional, phenotype-driven “forward” procedure to a genotype-driven, 
“reverse” discovery process, during which identification of the biosynthetic genes precedes and 
informs isolation of the natural product. With the availability of the of Streptomyces coelicolor 
and Streptomyces avermitilis genome sequences (12, 13), it became clear that even some highly-
studied strains whose biosynthetic capabilities had appeared to be exhausted harbored a surprising 
number of previously unknown biosynthetic gene clusters. For example, only three natural product 
gene clusters had been identified on the S. coelicolor chromosome prior to the completion of its 
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genome sequence: those for actinorhodin (14, 15), prodiginine (16), and calcium-dependent 
antibiotic (17). Genome sequencing of S. coelicolor revealed a number of “cryptic” gene clusters 
without known associated natural products (sometimes called orphan gene clusters). In total, S. 
coelicolor carries the potential for 29 structurally complex natural products (Figure 1.2) (13, 18). 
Many of these biosynthetic gene clusters remain cryptic to the present day, over a decade later, 
indicating that the biosynthetic capabilities of this and other organisms still have yet to be fully 
understood. 
 
 
 
Figure 1.2. Schematic representation of the linear 8.7 Mb Streptomyces coelicolor A3(2) 
chromosome, highlighting the locations of all known natural product biosynthetic gene clusters. 
Names in brackets indicate putative compounds for which no predicted structure appears in the 
literature (18). 
 
 The number of complete bacterial genome sequences available in the National Center for 
Biotechnology Information (NCBI) database increased approximately 25-fold, to over 2500, 
between 2003 and 2013. With the ready availability of sequenced genomes, particularly those from 
bacteria, it is increasingly possible to identify putative biosynthetic genes, use their sequence to 
predict the structure and properties of the potential product, and use those predictions to guide 
efficient isolation and characterization. One interesting example of this is the case of bacillaene, 
whose structure eluded scientists due to its chemical instability (19). The genetic sequence of the 
bacillaene producer led to identification of the protein sequences responsible for its biosynthesis, 
which in turn enabled a structural prediction for bacillaene that guided purification based on the 
perceived physical properties. Ultimately, this procedure was successful, and the structure was 
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solved (20, 21). In addition, the prototypical reverse-discovered natural product, coelichelin had 
its structure predicted with a reasonably high degree of accuracy several years prior to its isolation 
(22, 23).  
 Table 1.1 presents an extensive list of natural products that have been reverse discovered. 
For more detailed discussion of many of these natural products, we direct the reader to a number 
of reviews on this topic (24-26), in addition to those contained in the current issue of this journal. 
Many of the natural products listed in this table were discovered in 2008 or later, reflecting the 
exponential rise in available genome sequences. A number of these natural products are from well-
studied model organisms (S. coelicolor, Aspergillus nidulans). Most are from bacteria, consistent 
with the larger number of sequenced bacterial genomes relative to fungi and plants. 
 
Table 1.1. Reverse-discovered natural products, organized by year of reported isolation. In cases 
where more than one species is known to produce a particular natural product, only the strain from 
which the compound was first isolated is listed. 
 
Name Class Producer Year isolated 
(Year 
predicted,  
if different) 
Genome 
sequenced 
Reference(s) 
hopene Polyketide Streptomyces 
coelicolor A3(2) 
2000 2002 (13, 65) 
collinone Polyketide Streptomyces collinus 
DSM 2012 
2001 n/a (66) 
geosmin Terpenoid Streptomyces 
coelicolor A3(2) 
2003 2002 (13, 67) 
desferrioxamine Other Streptomyces 
coelicolor A3(2) 
2004 2002 (13, 68) 
halstoctacosanolides Polyketide Streptomyces 
halstedii HC34 
2004 n/a (69, 70) 
SapB RiPP Streptomyces 
coelicolor A3(2) 
2004 2002 (13, 71) 
tetrahydroxy-
naphthalene 
Polyketide Streptomyces 
coelicolor A3(2) 
2004 2002 (13, 72) 
thalianol Terpenoid Arabidopsis thaliana 2004 2000 (73, 74) 
aurafurons Polyketide Stigmatella 
aurantiaca DW4/3-1 
2005 2011 (75, 76) 
coelichelin NRP Streptomyces 
coelicolor A3(2) 
2005 (2000) 2002 (13, 22, 23) 
ECO-02301 Polyketide Streptomyces 
aizunensis NRRL B-
11277 
2005 n/a (77) 
myxochromides S NRP Stigmatella 
aurantiaca DW4/3-1 
2005 2011 (76, 78) 
aspoquinolones Alkaloid Aspergillus nidulans 2006 2005 (43, 79) 
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Table 1.1. (cont.)      
bacillaene Polyketide/NRP Bacillus 
amyloliquefaciens 
FZB42 
2006 2007 (20, 21, 45) 
DKxanthenes Polyketide/NRP Myxococcus xanthus 
DK1050 
2006 2006 (80, 81) 
ECO-501 Polyketide Amycolatopsis 
orientalis ATCC 
43491 
2006 n/a (82) 
germicidins Polyketide Streptomyces 
coelicolor A3(2) 
2006 2002 (13, 83) 
haloduracin RiPP Bacillus halodurans 
C-125 
2006 2000 (54, 84, 85) 
penocin A RiPP Pediococcus 
pentosaceus ATCC 
25745 
2006 2006 (86, 87) 
terrequinone A NRP Aspergillus nidulans 2006 2005 (43, 88) 
trichamide  RiPP Trichodesmium 
erythraeum IMS101 
2006 2006 (89) 
aeruginosides NRP Planktothrix agardhii 
CYA126/8 
2007 Draft (90) 
aspyridones Polyketide/NRP Aspergillus nidulans 2007 2005 (43, 47) 
CBS-40 Polyketide Streptomyces sp. 
CB2544 
2007 n/a (91) 
orfamide A NRP Pseudomonas 
fluorescens Pf-5 
2007 2005 (92, 93) 
aerucyclamide C RiPP Microcystis 
aeruginosa PCC7806 
2008 Draft (94) 
albaflavenone Terpenoid Streptomyces 
coelicolor A3(2) 
2008 2002 (13, 95) 
capistruin RiPP Burkholderia 
thailandensis E264 
2008 2005 (35, 96) 
diazepinomicin (ECO-
4601) 
Other Micromonospora sp. 2008 n/a (97) 
emericellamide Polyketide/NRP Aspergillus nidulans 2008 2005 (43, 98) 
2-methylisoborneol Terpenoid Streptomyces 
coelicolor A3(2) 
2008 2002 (13, 99) 
microcyclamide 
7806A, B 
RiPP Microcystis 
aeruginosa PCC7806 
2008 Draft (100) 
thailandamides Polyketide Burkholderia 
thailandensis E264 
2008 2005 (96, 101) 
vibi A-K RiPP Viola biflora 2008 n/a (102) 
asperfuranone Polyketide Aspergillus nidulans 2009 2005 (42, 43) 
atrochrysone Polyketide Aspergillus terreus 2009 Draft (103) 
emodin Polyketide Aspergillus nidulans 2009 2005 (43, 104) 
F9775 A/B (blecanoric 
acid) 
Polyketide Aspergillus nidulans 2009 2005 (43, 104, 
105) 
lecanoric acid Polyketide Aspergillus nidulans 2009 2005 (43, 106) 
lichenicidin RiPP Bacillus licheniformis 2009 2004 (55, 107-
109) 
monodictyphenone Polyketide Aspergillus nidulans 2009 2005 (43, 104) 
Mra4, 5 RiPP Melicytus ramiflorus 2009 n/a (110) 
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Table 1.1. (cont.)      
nygerone A Polyketide/NRP Aspergillus niger 
CBS 513.88 
2009 2007 (111, 112) 
orsellinic acid Polyketide Aspergillus nidulans 2009 2005 (43, 105, 
106) 
anacylamides RiPP Anabaena sp. 90 2010 2012 (113, 114) 
aspernidine Alkaloid Aspergillus nidulans 2010 2005 (43, 115) 
aureusimine NRP Staphylococcus 
aureus 
2010 2008 (27, 28, 46) 
Bsa RiPP Staphylococcus 
aureus 
2010 2004 (116, 117) 
coelimycin P1 Polyketide Streptomyces 
coelicolor A3(2) 
2010 (2007) 2002 (13, 118, 
119) 
csypyrone B1 Polyketide Aspergillus oryzae 2010 2005 (120, 121) 
diorcinol Polyketide Aspergillus nidulans 2010 2005 (43, 105) 
erythrochelin NRP Saccharopolyspora 
erythraea NRRL 
2338 
2010 2007 (122-124) 
gerfelin Polyketide Aspergillus nidulans 2010 2005 (43, 105) 
Globa A, B RiPP Gloeospermum 
blakeanum 
2010 n/a (125) 
microcin H47 RiPP Escherichia coli 
(various strains) 
2010 n/a (126) 
microcin M RiPP Escherichia coli 
(various strains) 
2010 n/a (126) 
microviridin L RiPP Microcystis 
aeruginosa NIES843 
2010 2007 (127, 128) 
pneumococcin RiPP Streptococcus 
6neumonia R6 
2010 2001 (129, 130) 
prochlorosins RiPP Prochlorococcus 
marinus MIT9313 
2010 2003 (40, 131) 
TP-1161 RiPP Nocardiopsis sp. 
TFS65-07 
2010 n/a (132) 
venezuelin RiPP Streptomyces 
venezuelae 
ATCC10712 
2010 2011 (133, 134) 
austinol Polyketide/ 
terpenoid 
Aspergillus nidulans 2011 2005 (43, 135) 
desmethylbassianin A Polyketide Beauveria bassiana 2011 Draft (136) 
grisemycin RiPP Streptomyces griseus 
IFO 13350 
2011 (2010) 2008 (137-139) 
(iso)flavipucine Polyketide/NRP Aspergillus terreus 2011 Draft (140) 
koranimine NRP Bacillus spp. 2011 n/a (141) 
plantazolicin RiPP Bacillus 
amyloliquefaciens 
FZB42 
2011 (2008) 2007 (30, 31, 45) 
stambomycins Polyketide Streptomyces 
ambofaciens 
ATCC23877 
2011 Draft (49) 
thailandepsin Polyketide/NRP Burkholderia 
thailandensis E264 
2011 2005 (96, 142) 
alternariol Polyketide Aspergillus nidulans 2012 2005 (43, 143) 
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Table 1.1. (cont.)      
astexin-1 RiPP Asticcacaulis 
excentricus 
2012 2010 (38) 
azanigerones Polyketide Aspergillus niger 2012 Draft (144) 
burkholderic acid Polyketide/NRP Burkholderia 
thailandensis E264 
2012 2005 (96, 145) 
catenulipeptin RiPP Catenulispora 
acidiphila DSM 
44928 
2012 2009 (146, 147) 
cichorine Polyketide Aspergillus nidulans 2012 2005 (43, 143) 
curvopeptin RiPP Thermomonospora 
curvata 
2012 2011 (148, 149) 
elgicin RiPP Paenibacillus elgii 
B69 
2012 Draft (150) 
fusarielins F-H Polyketide Gibberella zeae 2012 Draft (151) 
geobacillin RiPP Geobacillus 
thermodenitrificans 
NG80-2 
2012 2007 (152, 153) 
luminmycin Polyketide/NRP Photorhabdus 
luminescens subsp. 
laumondii TT01 
2012 2003 (154, 155) 
malleilactone Polyketide Burkholderia 
thailandensis E264 
2012 2005 (48, 96) 
O-methyldiaporthin Polyketide Aspergillus oryzae 2012 2005 (121, 156) 
pre-shamixanthone Polyketide Aspergillus nidulans 2012 2005 (43, 157) 
rhizopodin Polyketide/NRP Stigmatella 
aurantiaca Sg a15 
2012 Draft (158) 
caulosegnins RiPP Caulobacter segnis 2013 2010 (36) 
flavipeptin RiPP Kribbella flavida 2013 2010 (159, 160) 
flavopeptins NRP Streptomyces 
flavogriseus ATCC 
33331 
2013 2011 (161) 
fumicycline 
A/neosartoricin A 
Polyketide Aspergillus fumigatus 2013 2005 (162-164) 
neosartoricins B-D Polyketide Trichophyton 
tonsurans 
2013 2012 (165, 166) 
thailanstatins Polyketide/NRP Burkholderia 
thailandensis 
MSMB43 
2013 Draft (167) 
 
In this review, we focus on seven lessons for the community to keep in mind during the 
reverse-discovery of natural products: 1) structure prediction, 2) accurate annotation, 3) continued 
study of model organisms, 4) avoiding genome size bias, 5) genetic manipulation, 6) heterologous 
expression, and 7) potential engineering of analogs. To illustrate the utility of these lessons, we 
highlight five natural products from the recent literature (aureusimine, plantazolicin, astexin-1, the 
prochlorosins, and asperfuranone; Figure 1.3) representing three prominent natural product 
classes: polyketides, non-ribosomal peptides (NRPs), and ribosomally synthesized and post-
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translationally modified peptides (RiPPs), as well as a variety of producing organisms (bacteria 
and fungi).  
 
 
Figure 1.3. Biosynthetic gene clusters (A) and structures (B) of select reverse-discovered natural 
products. Gene clusters in panel A are shown to scale and are shown with the name of the organism 
in which they were first identified. 
 
1.2 Lesson 1: Structure prediction 
Access to a predicted structure facilitated the isolation of the aureusimines, founding 
members of the pyrazinone class of natural products, by enabling mass spectrometry-guided 
isolation. These compounds are biosynthesized by a non-ribosomal peptide synthase (NRPS) 
pathway in the human pathogen Staphylococcus aureus (Figure 1.3A) (27, 28). The aureusimine 
biosynthetic gene cluster was discovered by genome mining to identify possible NRPSs that are 
highly conserved among sequenced S. aureus strains. Homologous gene clusters have been found 
in over 50 S. aureus strains as well as other human pathogenic Staphylococcus species (27). Prior 
to its isolation, the structure of aureusimine A was predicted based on the sequence of the NRPS 
gene and the previously established amino acid specificities for NRPS adenylation domains. The 
presence of a putative reductase domain at the C-terminus of the S. aureus NRPS was also factored 
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into the structural prediction, as it indicated that the dipeptide was likely released from the 
synthetase as an aldehyde with the potential to spontaneously cyclize. This prediction was 
confirmed with the solved structures of aureusimines A and B (Figure 1.3B) (27).  
Structural prediction and mass spectrometry-guided isolation also proved useful in the 
isolation of plantazolicin, a member of the thiazole/oxazole-modified microcin (TOMM) subclass 
of RiPP natural products (29). TOMM biosynthesis is characterized by the post-translational 
modification of ribosomally synthesized precursor peptides to generate thiazol(in)e and 
(methyl)oxazol(in)e heterocycles from the side chains of select cysteine, serine, and threonine 
residues (30). The gene cluster for plantazolicin (Figure 1.3A) was identified in 2008 during a 
search for genes with homology to the biosynthetic gene cluster responsible for the production of 
streptolysin S and microcin B17, which are TOMMs from Streptococcus pyogenes and 
Escherichia coli, respectively (30). Like other RiPPs, the sequence of a predicted precursor peptide 
gene enabled mass spectrometric-guided separation to isolate plantazolicin from organic surface 
extracts of modified strains of B. amyloliquefaciens FZB42 (31) and aided significantly in the 
elucidation of its structure (Figure 1.3B) (32, 33). 
A concluding example of the utility of structure prediction during natural product discovery 
is provided by coelichelin, a prominent early example of a reverse-discovered natural product, 
which had its structure predicted several years prior to its isolation from S. coelicolor (22). 
Although the initial structure was not entirely correct (23), the ability to predict structure based on 
genetic sequence is playing a growing role in reverse natural product discovery, whether by 
providing insight into possible extraction conditions or by simplifying identification by mass 
spectrometry. 
 
1.3 Lesson 2: Accurate sequence annotation 
Regardless of how many genome sequences are available, they are useless without 
interpretation. Complete and accurate sequence annotation also play crucial roles in the efficient 
reverse discovery of natural products. RiPP precursor peptide genes, in particular, are typically 
short and are often unannotated in published genomes (29, 34), complicating their identification 
during genome mining. For example, the open reading frame (ORF) encoding the plantazolicin 
precursor peptide was unannotated at the time of the initial report (30). The same has also proven 
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to be the case for the precursors of several lasso peptides, an emerging subclass of RiPP natural 
products (35, 36). 
 Despite the potential difficulty of identifying unannotated precursor genes, the discovery 
of the lasso peptide astexin-1 through a precursor-guided screen provides a promising avenue for 
future genome mining in the pursuit of novel RiPP natural products. Lasso peptides are 
characterized by the post-translational formation of a polypeptide loop structure with a covalent 
bond between the N-terminus of the precursor peptide and a specific aspartate or glutamate side 
chain elsewhere on the peptide. The C-terminal end of the precursor peptide is then threaded 
through the loop and often held in place by the side chains of bulky residues in the tail region (29). 
The resulting threaded structure typically confers unique heat stability on the lasso peptides (37). 
Genome mining for RiPP biosynthetic gene clusters commonly focuses on identifying homologs 
of a known modifying enzyme, as was the case for the lasso peptide capistruin (35), the 
prochlorosins, and plantazolicin. However, in the case of astexin-1, a genetic screen for precursor 
peptides was employed. This screen identified short ORFs, some unannotated, containing amino 
acid patterns consistent with the sequences of known lasso peptides. When a potential lasso peptide 
precursor was found, nearby regions of the genome were then searched for homology to the 
maturation enzymes (38). This endeavor resulted in the identification of 79 putative lasso peptide 
gene clusters distributed across nine bacterial phyla and one archaeal phylum (38). 
 The identification of precursor peptide genes located outside of the primary gene cluster 
further underscores the advantage of searching widely for all possible biosynthetic genes during 
reverse natural product discovery (39). Such was the case for the prochlorosins, a group of 
lanthipeptide RiPPs produced by some marine cyanobacteria species, most notably 
Prochlorococcus marinus (40). The hallmark of lanthipeptide biosynthesis is the formation of 
(methyl)lanthionine rings between select cysteines and dehydroalanine or dehydrobutyrine 
residues, which arise from the dehydration of serines and threonines, respectively. Dehydration 
and lanthionine ring installation on the ribosomal precursor peptide may be catalyzed by one or 
more biosynthetic enzymes (29). The gene clusters responsible for prochlorosin biosynthesis 
(Figure 1.3A) were identified in P. marinus and related species through a bioinformatic search for 
bifunctional lanthipeptide synthetase homologs (40) and, independently, through the homology of 
prochlorosin precursor peptides to the Nif11 nitrogen-fixing proteins (41). However, only seven 
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of these 29 putative precursor peptide genes are clustered with the lanthipeptide synthetase gene 
(40), contrary to the norm for biosynthetic genes in bacteria and fungi. 
 
1.4 Lesson 3: Continued study of model organisms 
The sequencing of the S. coelicolor genome, which brought to light the silent majority of 
biosynthetic gene clusters, also provides a reminder not to discount continued investigation into 
well-studied model organisms during the search for new natural products. These strains may 
contain the genetic potential to synthesize many more natural products than are superficially 
detectable. The fungus Aspergillus nidulans (42) was a highly-studied model organism even prior 
to the sequencing of its genome, and since that time, it has been determined that A. nidulans FGSC 
A4 contains 24 PKS genes and 3 PKS-like genes (43, 44). Several pairs of PKS genes are adjacent 
to each other (Figure 1.3A), indicating a strong possibility that the pairs might work in concert, 
though A. nidulans was not previously known to produce any polyketides arising from the 
combined action of two PKS enzymes. The producer of plantazolicin, B. amyloliquefaciens 
FZB42, also produces a number of natural products (45), including the polyketide/NRP hybrid 
bacillaene, which likewise is a reverse-discovered natural product (20, 21). 
 
1.5 Lesson 4: Avoiding genome size bias  
 One common assumption in the natural products field has been that organisms with small 
genomes are unlikely to produce structurally complex natural products. Indeed, bacteria with 
larger genomes, such as S. coelicolor (8.7 Mb), are recognized as prolific producers of secondary 
metabolites (13). However, species with small genomes should not be ignored in the search for 
natural products, as exemplified by the isolation of structurally complex compounds from 
organisms whose genomes are a fraction the size of the traditionally recognized “natural product 
powerhouses”. These species with smaller genomes, such as S. aureus (2.8 Mb) (46), are presumed 
to be less able to devote genome space to large biosynthetic gene clusters such as NRPSs, making 
the identification of a single NRPS gene that occupies 0.25% of the S. aureus genome even more 
surprising (27). 
 Maintenance of multiple precursor genes and the ability to modify them with a single 
enzyme enables organisms with compact genomes, such as prochlorosin producer P. marinus (2.4 
Mb), to produce a variety of structurally complex molecules without the need for large biosynthetic 
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gene clusters. Indeed, the precursor hypervariability of the prochlorosin system endows P. marinus 
MIT9313 with the potential to produce as many natural products as S. coelicolor, which bears a 
genome nearly four times as large (13, 40). 
 
1.6 Lesson 5: Genetic manipulation 
 In many instances, natural products are difficult to detect under laboratory cultivation, due 
to low production levels or masking by the presence of other, more abundant, natural products. In 
such cases, genetic manipulation may be used to activate these silent gene clusters. The reverse 
discovery of the polyketide asperfuranone (Figure 1.3B) illustrates how silent gene clusters can be 
activated via promoter engineering within the native host. In this case, the native promoter for a 
predicted transcriptional activator gene within the PKS cluster (Figure 1.3A) was replaced with an 
inducible promoter (42). As asperfuranone was not produced to any significant extent during 
laboratory cultivation, it would have been unlikely to identify this compound via any phenotype-
driven effort. Other silent biosynthetic gene clusters that have been successfully activated by 
promoter engineering include those responsible for producing aspirydone (47), malleilactone (48), 
and stambomycin (49). A limitation of this strategy is that it requires a genetically tractable host. 
Another common genetic manipulation used for natural product discovery is biosynthetic 
gene disruption. Arguably, the most powerful method to establish gene function is to evaluate the 
phenotypes of the parent (wild-type) and the genetic deletion (mutant) strains. This reverse 
genetics method is often employed during the genome-guided discovery of natural products. The 
phenotype compared between parent and mutant is typically either the metabolite profile (usually 
obtained by mass spectrometry) or the bioactivity of chromatographic fractions. The detection and 
isolation of plantazolicin demonstrated a secondary use of such a method to identify a novel 
compound whose production had been masked by other, more abundant compounds. When 
production of all known bioactive compounds was eliminated, the remaining bioactivity indicated 
that at least one additional biosynthetic gene cluster had yet to be identified (31, 50).  
 
1.7 Lesson 6: Heterologous expression 
In cases where genetic manipulation in the native host is not feasible, the transfer of 
biosynthetic genes clusters to a genetically tractable host has the potential to facilitate compound 
production. The biosynthetic gene cluster for the lasso peptide astexin-1 (Figure 1.3A) was 
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identified in the freshwater α-proteobacterium Asticcacaulis exentricus, although compounds with 
the expected mass could not be detected after laboratory cultivation of this organism, necessitating 
an alternate expression method (38). Astexin-1 was successfully expressed, purified, and 
structurally characterized using E. coli as a heterologous host (Figure 1.3B) (37, 38). Following 
extensive variation of culture conditions, a recent study succeeded in producing astexin-1 from A. 
exentricus, albeit at low levels compared to those from E. coli (37). Likewise, successful high-
level production of a number of prochlorosins required heterologous expression in E. coli and 
reconstitution in vitro, ultimately enabling structural confirmation of these natural products (Figure 
1.3B) (40, 51). 
For further discussion and examples of heterologous expression, the interested reader is 
directed to other reviews specifically focused on this topic, also in this Special Issue (52, 53). 
 
1.8 Lesson 7: Potential engineering of natural product analogs 
Beyond simply providing a novel natural product, identification of new biosynthetic gene 
clusters also has the potential to facilitate rational engineering of unnatural natural product 
variants. The production of prochlorosins from P. marinus MIT9313 is notable among 
lanthipeptides because of the exceptionally high number of precursor peptides (29) (40). While it 
is not unusual for a lanthipeptide gene cluster to harbor more than one precursor peptide, these 
typically require multiple lanthionine synthetases to modify all the precursor peptides (54, 55). 
Indeed, 17 prochlorosins from P. marinus MIT9313 have been successfully biosynthesized both 
in vitro and in vivo using this single lanthipeptide synthetase, (40). The potential for a single 
lanthipeptide synthetase enzyme to effect modification of up to 29 precursor peptides suggests that 
the prochlorosin synthetase is remarkably promiscuous, indicating that it may be a prime candidate 
for engineering novel lanthipeptides. 
In addition to the natural combinatorial biosynthesis of prochlorosin and its potential use 
in engineering, several other examples presented in this review have shown promise for the future 
engineering of natural product variants. The NRPS responsible for aureusimine production has 
been heterologously expressed and used to explore the pyrazinone assembly line using alternate 
substrates (56, 57). The enzymes responsible for asperfuranone biosynthesis have also provided a 
compliant system for the engineering of unnatural polyketides by domain swapping, an endeavor 
which has historically been challenging due to the complex nature of the requisite megasynthase 
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enzymes (58). The heterologous expression of plantazolicin in E. coli has also been achieved and 
exploited using precursor peptide replacement to generate unnatural variants (59). In summary, 
the thorough understanding of biosynthetic gene clusters afforded by reverse natural product 
discovery has the potential to expedite the production of unnatural variants for applications in 
medicinal chemistry and structure-activity relationship studies. 
 
1.9 Outlook 
 The sequencing and annotation of new genomes will continue to provide ample opportunity 
for the discovery of new natural products through genotype-based methods. It is possible, 
eventually, that natural product discovery will reach a point of diminishing returns from the 
investigation of new species, but the steadily increasing rate of reverse natural product discovery 
(Table 1.1) indicates that the field is still far from that point. While it is relatively straightforward 
to identify new putative PKS and NRPS clusters through sequence homology, other classes of 
natural products will require more sophisticated methods. For RiPP natural products, 
bioinformatics tools such as BAGEL (60) are useful in identifying genes for potential novel 
compounds, but less well-characterized and yet-to-be-discovered classes of natural products will 
require significant future investigation. The genes responsible for the biosynthesis of new or poorly 
understood natural products may currently be annotated as hypothetical proteins or domains of 
unknown function. The use of tools to group these unknown genes together by sequence homology 
(61), coupled with improved annotation in sequenced genomes, may allow for entirely new 
biosynthetic pathways to be discovered. 
As the field of reverse natural product discovery moves forward, we anticipate an 
increasing dependence on structure prediction to facilitate isolation of interesting natural products 
and to provide starting points for structure elucidation. Structure prediction for new RiPP natural 
products is largely enabled by identification of the precursor peptide sequence, while programs 
such as ClustScan (62) utilize known domain specificities to predict the structure of novel PKS 
and NRPS gene clusters. While not strictly a method for reverse natural product discovery, 
peptidogenomics may also be helpful in this endeavor by identifying new peptide natural products 
and linking those to their respective biosynthetic genes (63). Perhaps most widely useful, however, 
are comprehensive tools such as antiSMASH (antibiotics and Secondary Metabolite Analysis 
Shell), which incorporate information about many natural product classes beyond the 
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comparatively well-studied PKS, NRPS, and RiPP systems. As the collective knowledge of the 
natural product discovery field increases, the predictive power of these tools will likewise increase 
and create a positive feedback loop to further enable the future isolation of novel compounds. 
Natural product discovery will also be aided by the development of new genetic tools. To 
set a lofty goal, it would be of enormous utility to have a universal, user-friendly DNA 
manipulation platform for deleting genes of interest. Not only would this platform greatly enable 
deletion-guided approaches to natural product discovery, the whole of biology would benefit 
immensely from the development of a simple method for constructing genetic knockouts 
applicable to a broad range of organisms. If such a technique were developed and freely shared 
with the community, research groups focused on the chemical aspects of natural product research 
would now have the ability to construct useful strains without specialized knowledge in genetic 
manipulation.  
Perhaps the most significant hurdle to isolating reverse-discovered natural products is that 
many gene clusters are silent (expression is undetectable) under laboratory cultivation. In such 
cases, no novel natural product is readily observable in extracts from cultures of the organism 
harboring the biosynthetic genes of interest. In order to isolate the compound in question, the genes 
responsible for its production must be activated. A number of methods have been developed to 
activate silent clusters, including variation of culture conditions, heterologous expression, 
promoter engineering, induction with gamma-butyrolactones, and co-culturing with other 
organisms to stimulate production, among others (24, 25, 44, 64). One persistent issue with the use 
of heterologous hosts is the potential for inefficient export of the natural product, which may be 
addressed in part by the development of greater numbers of genetically tractable heterologous 
hosts. These tools will help to streamline the identification and production of natural products from 
gene clusters which are difficult, if not impossible, to express under laboratory culture conditions. 
 
1.10 Conclusion 
 Rather than relying on the observation of a phenotype, reverse (genotype-driven) natural 
product discovery bases isolation of the compound(s) of interest on knowledge of the associated 
biosynthetic genes. The examples of reverse-discovered natural products presented in this review 
represent several biosynthetic classes, producing organisms, and biological targets. It is plausible 
that none of the discussed examples would have been discovered by the traditional phenotype-
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driven method due to unknown biological activity or activity that is extremely selective so as to 
preclude detection during bioassay-guided isolation. Perhaps more significantly, most of these 
examples, as well as others listed in Table 1.1, required some measure of genetic manipulation 
(promoter engineering, comparison of genetic deletion strains, heterologous expression, etc.) in 
order to produce useful levels of the natural product of interest. In some cases, a low level of 
production was masked by other, more prominent compounds, while in others, the biosynthetic 
gene cluster of interest was entirely silent despite extensive modification of culture conditions. 
The emergence of novel natural products even from well-studied model organisms indicates that 
the potential for production of structurally complex compounds remains largely untapped at this 
point, and the constantly increasing number of publicly available genomes will certainly provide 
a surplus of avenues for natural product discovery. 
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CHAPTER 2: 
Engineering unnatural variants of plantazolicin through codon reprogramming1 
 
2.1 Introduction 
 The clinical deployment of antibiotics revolutionized medical practice in the 20th century, 
but beginning in the late 1960s, the development of new classes of antibiotics slowed drastically 
while bacteria continued to acquire resistance (1). Natural products have historically been the most 
valuable source of antibiotics and still today present a promising avenue to combat the growing 
problem of infections caused by antibiotic-resistant bacteria. Indeed, of the new antibacterial 
compounds approved by the FDA between 1981 and 2010, 66% were natural products or natural 
product-derived (2). In recent years, the increased ease of bacterial genome sequencing has 
facilitated the development of new strategies to tap into unexplored regions of natural product 
chemical space (3). Natural product biosynthesis can potentially be “reprogrammed” to produce 
novel variants through genetic manipulation and/or supplying alternate substrates. Natural product 
engineering in modular biosynthetic pathways, such as polyketide synthases or non-ribosomal 
peptide synthetases, remains difficult due to the complex nature of the multi-domain 
megasynthases (4-7). In contrast, the reprogramming of ribosomally synthesized and post-
translationally modified peptides (RiPPs) is straightforward, as the natural product structure is 
directly encoded by the sequence of the precursor peptide gene (8). Thus, site-directed mutagenesis 
leads to a predictable outcome in the resultant natural product, provided the modification enzymes 
tolerate the unnatural sequence.  
Precursor peptide replacement in vivo has been used to study multiple RiPPs, most notably 
the lantibiotic nisin (9-11), leading to the identification of multiple variants with increased activity. 
Similar approaches have also been applied to the study of other lanthipeptides, including lacticin 
3147 (12, 13), mersacidin (14), lichenicidin (15), and actagardine A (16). This strategy has also 
garnered recent attention outside of the lanthipeptide family, where it has been successfully 
employed to engineer novel variants and explore the substrate requirements for the precursor 
peptides of several thiopeptides (17-21), cyanobactins (22) and microcin J25 (23). 
The thiazole/oxazole-modified microcins (TOMMs) (8) comprise one RiPP subfamily 
characterized by thiazoline, (methyl)oxazoline, and the corresponding 2-electron oxidized azoles, 
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deriving from cysteines, serines, and threonines (Figure 2.1) (24). A trimeric enzymatic complex 
of a cyclodehydratase (C and D proteins) and a FMN-dependent dehydrogenase (B protein) 
catalyzes heterocycle formation and oxidation (Figure 2.1c) (24, 25). Plantazolicin (PZN), a 
TOMM produced by the soil bacterium, Bacillus amyloliquefaciens FZB42, displays a unique 
polyheterocyclic structure. After heterocycle formation, the unmodified N-terminal (leader 
peptide) region of the precursor peptide is proteolytically removed, likely by the putative peptidase 
(E protein) encoded in the gene cluster (Figure 2.1a) (26, 27). Lastly, two methyl groups are 
installed onto the new N-terminus of the core peptide by an S-adenosylmethionine (SAM)-
dependent methyltransferase (L protein) to yield the mature natural product (Figure 2.1d), which 
is then predicted to be exported by a dedicated transporter (G and H proteins), also within in the 
gene cluster (26, 27).  
PZN exhibits highly discriminating antibacterial activity against the causative agent of 
anthrax, Bacillus anthracis (27). The spectrum of PZN activity excludes all Gram-negative strains 
and most Gram-positive strains tested thus far. Exploration within the closely related B. cereus 
subgroup revealed B. anthracis as the only strain significantly susceptible to PZN (27). To date, 
similar biosynthetic gene clusters have been identified in four other bacterial species, indicating 
that these species have (or had at one time) the genetic capacity to produce PZN-like compounds, 
although only B. pumilus has been shown to do so during laboratory cultivation (27). The precursor 
peptides in these species display a high degree of sequence similarity to the PZN precursor peptide 
(BamA), including many conserved residues in the core peptide (Figure 2.1b) (27). However, the 
role that these conserved residues play in the posttranslational modification of PZN and their im-
portance in the bioactivity of the mature compound remained unknown. The current study sought 
to simultaneously address the structure-activity relationship of PZN and establish the substrate 
requirements for the biosynthetic pathway using heterologous expression of PZN analogs in E. 
coli. 
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Figure 2.1. Genetics and enzymology of PZN biosynthesis. (a) The 10 kb PZN biosynthetic gene 
cluster from Bacillus amyloliquefaciens FZB42. (b) The precursor peptides for PZN and potential 
analogs from other species exhibit remarkable similarity. Bam, B. amyloliquefaciens FZB42; 
Bpum, B. pumilus ATCC 7061; Cms, Clavibacter michiganensis subsp. sepedonicus; Cur, Coryne-
bacterium urealyticum DSM 7109; Blin, Brevibacterium linens BL2. Color-coding (predicted for 
Cms, Cur, and Blin): green, Nα,Nα-dimethylarginine; red, thiazoles; blue (methyl)oxazoles; brown, 
methyloxazoline; *, peptidase cleavage site. (c) Posttranslational modification of cysteine, serine, 
and threonine residues in TOMM biosynthesis proceeds by cyclodehydration (mass loss of 18 Da) 
and subsequent oxidation (additional mass loss of 2 Da). (d) The chemical structure of PZN. Color-
coding is identical to panel (b).  
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2.2 Heterologous production of PZN 
Although B. amyloliquefaciens FZB42 exhibits natural competency (28), the inability to 
replicate plasmids, coupled with low transformation efficiency of integrative plasmids, 
necessitated the development of a heterologous system for facile expression and screening of PZN 
variants. Genomic DNA from the RS32 strain of B. amyloliquefaciens, in which the precursor 
peptide gene (bamA) is insertionally disrupted by a spectinomycin resistance cassette (26), was 
digested and ligated into a DNA vector backbone to generate a fosmid library in E. coli. A fosmid 
bearing the ΔbamA PZN biosynthetic gene cluster (Figure 2.2) was identified through PCR 
screening of this library. The bamA PZN cluster fosmid was under rhamnose-dependent copy 
control in E. coli (29, 30), while the PZN biosynthetic genes were under control of the native 
FZB42 promoters. To determine whether the fosmid-borne PZN biosynthetic enzymes were 
capable of modifying BamA supplied in trans, the PZN precursor peptide gene, bamA, was cloned 
into E. coli expression vector pBAD24 with an N-terminal fusion to maltose-binding protein 
(MBP) using standard methods. Expression of bamA from this construct was under the control of 
the arabinose-inducible promoter, Para (31). 
 
Figure 2.2. Heterologous production of PZN in E. coli via trans-complementation. Shown are 
MALDI mass spectra of methanolic surface extracts from E. coli containing a fosmid bearing the 
PZN cluster ΔbamA both alone (top, blue) and with the pBAD24-MBP-BamA plasmid construct 
grown in the absence (middle, green) and presence (bottom, red) of 10 mM arabinose. These data 
indicate the successful rescue of PZN production by the plasmid-borne, MBP-tagged bamA gene. 
Although not strictly quantitative, the intensity of ions is a crude measure of analyte abundance, 
as these spectra were acquired with identical laser power and number of laser shots, and are shown 
to scale. The small but detectable amount of PZN produced in the absence of arabinose (middle, 
green spectrum) is likely due to the leakiness of the Para promoter. Omission of rhamnose from the 
culture produced data indistinguishable from the “fosmid alone” spectrum (blue). 
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Following growth in Luria-Bertani (LB) media supplemented with rhamnose and 
arabinose, PZN was obtained from the cell surface of the E. coli host by non-lytic methanolic 
extraction. Successful production and export of mature PZN was detected by high-performance 
liquid chromatography (HPLC) and matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-MS) analysis (Figures 2.2-2.3), albeit at ~5% of the 200-300 µg L–1 output 
from the native B. amyloliquefaciens producer (27). It is plausible that the lower production level 
stems from an inefficient usage of B. amyloliquefaciens promoters by E. coli. E. coli cells 
containing the ΔbamA PZN fosmid only produced PZN when complemented with pBAD24-MBP-
BamA after induction with rhamnose and arabinose (Figure 2.2). As short peptides have poor half-
lives in E. coli when lacking a fusion partner (32, 33), inclusion of MBP was necessary for 
detection of PZN produced from plasmid-borne BamA. When the MBP tag was omitted, 
heterologous production of PZN was below the detection limit within the context of the crude cell 
surface extract, <20 pg (data not shown). 
 
Figure 2.3. Purification of heterologously expressed PZN. (a) UV chromatogram (266 nm) from 
HPLC purification of PZN produced from E. coli bearing the PZN cluster ΔbamA fosmid and the 
pBAD24-MBP-BamA plasmid construct. Dashed lines indicate the fraction collected for isolation 
of purified PZN. (b) MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. The 
m/z 1354 species derives from methyloxazoline hydrolysis, yielding a reinstated threonine residue 
(27).  
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To provide an internal standard for evaluating the production level of PZN variants, a 
second fosmid was constructed bearing the PZN biosynthetic gene cluster from B. amylolique-
faciens FZB42 with the precursor peptide gene (bamA) intact. MALDI-MS and HPLC analysis of 
methanolic surface extracts from E. coli bearing this fosmid indicated production and export of 
mature PZN, even in the absence of the pBAD24-MBP-BamA construct (Figure 2.4). 
 
 
Figure 2.4. Production of PZN from E. coli containing the entire PZN cluster fosmid (including 
bamA). (a) MALDI-MS of a methanolic surface extract from E. coli containing a fosmid bearing 
the entire PZN cluster grown in LB supplemented with 10 mM rhamnose and 10 mM arabinose, 
indicating heterologous production of PZN. (b) Single-ion monitoring of m/z 1336 during LC-MS 
analysis of the surface extract shown in panel a. The peak at 25.55 minutes co-elutes with an 
authentic PZN standard (data not shown). 
 
2.3 Design and evaluation of BamA mutants 
In order to assess the ability of the PZN posttranslational pathway to accept alternate BamA 
substrates, nine residues in the core region of BamA were targeted for mutagenesis, based on the 
sequence similarity among the potential PZN producers (Figure 2.1b, Figure 2.5). This subset of 
the precursor peptide was selected in order to (i) include the most-conserved as well as the least-
conserved residues; (ii) cover both heterocyclized and non-heterocyclized positions; and (iii) span 
the length of the precursor peptide core region. Rather than employ saturation mutagenesis, 
directed mutant panels were designed at eight of these positions (Figure 2.5). Each panel contained 
conservative and non-conservative mutations in order to sufficiently explore the available 
chemical space without generating an unnecessarily large number of mutants. Mutants were 
prepared by site-directed mutagenesis using primers with rationally chosen degenerate codons at 
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select positions of pBAD24-MBP-BamA. Following mutagenesis, polyclonal plasmid collections 
were transformed into competent E. coli cells bearing the complete PZN gene cluster fosmid. A 
medium-throughput method was employed to screen clones in groups of 20-40 for production of 
unnatural PZN analogs. Individual clones were cultured, PZN biosynthetic gene expression was 
induced with rhamnose and arabinose, and unnatural PZNs were isolated by non-lytic methanolic 
surface extraction, conditions which preclude isolation of intracellular contaminants. MALDI-MS 
was used to screen the surface extracts for unnatural PZN variants (Figure 2.6) and the positive 
clones were subjected to DNA sequencing (Figure 2.7). In addition, a selection of plasmids which 
did not produce a PZN variant were also sequenced in order to identify which precursor peptides 
were not processed by the posttranslational modifying enzymes (Figure 2.7). The confirmed DNA 
sequence and the observed masses enabled deduction of the number and type of posttranslational 
modifications for each variant (Figure 2.6). Using data from MALDI-MS analysis, comparison of 
the peak heights of wild-type PZN (fosmid-borne BamA, m/z 1336) and mutant PZN (plasmid-
borne mutant BamA, variable mass) yielded a qualitative measure of production levels of the PZN 
variants (Figure 2.7). This preliminary assessment of production level enabled determination of 
which variants most warranted large-scale expression and purification, circumventing the time- 
and labor-intensive process of doing so with every variant.  
 
 
Figure 2.5. Design of site-directed PZN mutant panels. Mutagenesis was performed using primers 
containing the indicated degenerate codons, resulting in a panel of plasmids containing bamA 
genes with selected positions individually replaced by the designated amino acids. N = any nucleic 
acid; B = C, G, or T; K = G or T; M = A or C; S = C or G; V = A, C, or G; Y = C or T. 
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Figure 2.6. Representative MALDI mass spectra of PZN analogs. (a) Methanolic surface extracts 
from E. coli containing the PZN cluster ΔbamA fosmid plus BamA mutant plasmids. Color-coding: 
red, I34X mutants; blue, T40X mutants; green, F41X mutants. As indicated by the peak labels and 
the lack of m/z 1336 in each sample, production of PZN variants is only possible from plasmid-
borne mbp-bamA. The m/z 1336 signal in the T40C spectrum corresponds to a variant containing 
a thiazole at position 40. The peaks at m/z 1324 and 1340 in the F41C spectrum correspond to 
oxidized C-terminal Cys (R-SOxH, x = 2-3). Other labeled peaks correspond to PZN variants with 
wild-type-like modifications. (b) Same as panel a, but with the full PZN cluster fosmid plus BamA 
mutant plasmids. Wild-type PZN (m/z 1336) appears in every sample. 
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Figure 2.7. Summary of PZN variant production. PZN variants were heterologously expressed in 
E. coli prior to methanolic surface extraction and MALDI-MS analysis. Using this method, 29 
point mutants of BamA were successfully converted to PZN variants (listed above core sequence), 
while 43 were not detected (listed below core sequence). Colored outlines indicate modifications 
to the altered residue as specified in the figure legend. Of the 29 analogs produced above the limit 
of detection (>20 pg in crude surface extracts), 10 were produced at levels greater than or equal to 
that of wild-type PZN (bold outlines), as assessed by relative peak heights during MALDI-MS 
analysis. The T40C variant produced two analogs, one with a thiazole at position 40 and the other 
with a thiazoline. 
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Assessment of the 72 mutants of BamA resulted in 29 clones that successfully produced 
and exported PZN variants within our detection limit (Figure 2.7). In this in vivo production 
system, a mutant precursor peptide must be successfully accepted as a substrate by multiple steps 
of the biosynthetic pathway (cyclodehydration, dehydrogenation, and leader peptidolysis), in 
addition to export, in order to yield a detectable product. Failure of any of these processes to accept 
an unnatural precursor peptide substrate led to an absence of detectable PZN variant. It is worth 
noting that such a result would not likely arise from failure at the methylation step of the 
biosynthetic pathway, as desmethylPZN can be successfully exported by B. amyloliquefaciens 
(27). Of the 29 clones that successfully produced mature PZN variants, 26 had masses consistent 
with “wild-type-like” modifications: nine azole rings, one azoline ring, leader peptidolysis N-
terminal to Arg28, and N-terminal dimethylation (Figure 2.1d). Three exceptions, PZN-T40A, -
T40I, and -T40V, all produced MALDI-MS data consistent with the presence of one fewer 
heterocyclizable residue (nine azoles, no azolines) than wild-type PZN, as expected (Figure 2.7). 
Three other clones, I34M, T40C, and F41C, each yielded one or more modifications over “wild-
type-like” processing, consistent with varying oxidation states at the mutated position (Figures 
2.6a, 2.8-2.10).  
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Figure 2.8. High resolution, Fourier transform mass spectrometric (FTMS) analysis of PZN-T40C 
variants. (a) Structure, predicted fragments, and the calculated monoisotopic masses for PZN-
T40C (deca-azole variant). One of the fragments was derived from multiple bond cleavages, 
denoted by the superscript. (b) Same as panel a, but for PZN-T40C (thiazoline variant). The 
thiazoline moiety is shown in orange. (c) Collision-induced dissociation of PZN-T40C (deca-azole 
variant, C62H65N17O12S3, calc. m/z 1336.4239; expt. m/z 1336.4243, error 0.2 ppm) was consistent 
with the predicted structure. (d) Collision-induced dissociation of PZN-T40C (thiazoline variant, 
C62H67N17O12S3, calc. m/z 1338.4395; expt. m/z 1338.4395, error 0.0 ppm) was consistent with the 
predicted structure, including localization of the thiazoline to position 40.  
 
39 
 
 
 
Figure 2.9. Fourier transform mass spectrometric (FTMS) analysis of PZN-F41C. (a) Structure, 
predicted fragments, and calculated monoisotopic masses for a sulfonic acid derivative of PZN-
F41C. One of the fragments was derived from multiple bond cleavages, denoted by the superscript. 
(b) Collision-induced dissociation of PZN-F41C (sulfonic acid derivative, C57H65N17O16S3, calc. 
m/z 1340.4036; expt. m/z 1340.4035, error 0.1 ppm) permitted localization of the sulfonic acid 
moiety to position 41.  
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Figure 2.10. Purification of heterologously-expressed PZN-I34M. (a) UV chromatogram (266 
nm) from HPLC purification of PZN-I34M produced from E. coli engineered to produce the I34M 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-I34M. 
(b) MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. The m/z 1370 species 
derives from air oxidation of the methionine side chain to a sulfoxide.  
 
Notably, the mutant bamA sequences differed by three nucleotides at most (out of 1394 bp, 
including MBP tag) and did not contain any rare E. coli codons (34). Thus, the expression levels 
of the MBP-BamA peptides were expectedly comparable (Figure 2.11). The lack of detectable 
PZN variants for some mutants is attributed to the selectivity of the biosynthetic pathway and not 
to poor expression of the precursor peptide. Ten of the 29 variants which were produced in the 
greatest quantity (Figure 2.7), as defined by ion intensity in MALDI-MS relative to that of the 
PZN internal standard (fosmid-borne bamA), were purified by HPLC (Figures 2.10, 2.12-2.20). 
Subsequent tandem, high-resolution Fourier transform mass spectrometry (FTMS) data were 
consistent with the predicted structures (Figures 2.8, 2.9, 2.21-2.29). Eight of the ten PZN variants 
that were produced at “high” levels in E. coli harbored mutations at positions in PZN that do not 
receive side chain modifications: Ile34, Ile35, and Phe41 (Figure 2.7). This production level trend 
suggested that the biosynthetic pathway was more tolerant to variation at non-cyclized positions 
relative to cyclized positions. The two remaining high production variants, PZN-S38C and -T40C 
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(Figure 2.7), both replace a Ser/Thr with the heterocycle-competent Cys. In each case, the 
increased production level of the PZN variant was consistent with the increased nucleophilicity of 
the Cys side chain, which typically enhances the rate of cyclodehydration (35-37).  
 
 
Figure 2.11. Protein expression of select MBP-BamA mutants compared to wild-type levels. MBP 
tagged proteins were purified by amylose affinity chromatography from E. coli bearing the PZN 
cluster fosmid and pBAD24-MBP-BamA, following growth with arabinose (to induce expression 
from pBAD24) and rhamnose (to induce greater copy number of the fosmid). Equal volumes of 
purified protein extracts were analyzed by SDS-polyacrylamide gel electrophoresis and detected 
by Coomassie staining. 
 
Figure 2.12. Purification of heterologously-expressed PZN-I34T. (a) UV chromatogram (266 nm) 
from HPLC purification of PZN-I34T produced from E. coli engineered to produce the I34T 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-I34T. (b) 
MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. 
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Figure 2.13. Purification of heterologously-expressed PZN-I34V. (a) UV chromatogram (266 nm) 
from HPLC purification of PZN-I34V produced from E. coli engineered to produce the I34V 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-I34V. (b) 
MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. 
 
Figure 2.14. Purification of heterologously-expressed PZN-I35V. (a) UV chromatogram (266 nm) 
from HPLC purification of PZN-I35V produced from E. coli engineered to produce the I35V 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-I35V. (b) 
MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. 
43 
 
 
 
Figure 2.15. Purification of heterologously-expressed PZN-S38C. (a) UV chromatogram (266 
nm) from HPLC purification of PZN-S38C produced from E. coli engineered to produce the S38C 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-S38C. 
(b) MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. 
 
Figure 2.16. Purification of heterologously-expressed PZN-T40C. (a) UV chromatogram (266 
nm) from HPLC purification of PZN-T40C produced from E. coli engineered to produce the T40C 
analog of PZN. Dashed lines indicate the fractions collected for isolation of purified PZN-T40C 
variants. The peak at 23 min corresponds to the T40C variant containing a thiazoline at position 
40, while the peak at 25.5 min corresponds to the variant containing a thiazole at position 40. (b) 
MALDI-MS spectra of the fractions denoted by dashed lines in panel a. 
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Figure 2.17. Purification of heterologously-expressed PZN-F41A. (a) UV chromatogram (266 
nm) from HPLC purification of PZN-F41A produced from E. coli engineered to produce the F41A 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-F41A. 
(b) MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. 
 
Figure 2.18. Purification of heterologously-expressed PZN-F41L. (a) UV chromatogram (266 nm) 
from HPLC purification of PZN-F41L produced from E. coli engineered to produce the F41L 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-F41L. 
(b) MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. 
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Figure 2.19. Purification of heterologously-expressed PZN-F41V. (a) UV chromatogram (266 
nm) from HPLC purification of PZN-F41V produced from E. coli engineered to produce the F41V 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-F41V. 
(b) MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. 
 
Figure 2.20. Purification of heterologously-expressed PZN-F41Y. (a) UV chromatogram (266 
nm) from HPLC purification of PZN-F41Y produced from E. coli engineered to produce the F41Y 
analog of PZN. Dashed lines indicate the fraction collected for isolation of purified PZN-F41Y. 
(b) MALDI-MS spectrum of the fraction denoted by dashed lines in panel a. 
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Figure 2.21. Mass spectrometric analysis of PZN-I34M. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-I34M. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-I34M. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
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Figure 2.22. Mass spectrometric analysis of PZN-I34T. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-I34T. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-I34T. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
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Figure 2.23. Mass spectrometric analysis of PZN-I34V. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-I34V. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-I34V. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
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Figure 2.24. Mass spectrometric analysis of PZN-I35V. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-I35V. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-I35V. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
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Figure 2.25. Mass spectrometric analysis of PZN-S38C. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-S38C. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-S38C. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
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Figure 2.26. Mass spectrometric analysis of PZN-F41A. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-F41A. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-F41A. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
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Figure 2.27. Mass spectrometric analysis of PZN-F41L. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-F41L. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-F41L. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
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Figure 2.28. Mass spectrometric analysis of PZN-F41V. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-F41V. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-F41V. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
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Figure 2.29. Mass spectrometric analysis of PZN-F41Y. (a) High resolution, Fourier Transform 
MS was used to structurally characterize PZN-F41Y. A m/z scan showed an ion in the 1+ charge 
state with the observed monoisotopic m/z value. (b) After isolating the peak observed in panel a, 
collision-induced dissociation produced the given spectrum. (c) Predicted fragments and their 
calculated monoisotopic m/z for observed ions from MS/MS in panel b were consistent with the 
predicted structure of PZN-F41Y. Some of the observed fragments are derived from multiple bond 
cleavages, denoted by superscripts. 
 
2.4 Substrate tolerance at heterocyclized positions 
As the majority of analyzed mutant sequences failed to yield mature PZN variants, the PZN 
biosynthetic enzymes were less promiscuous in vivo than expected based on studies of other 
TOMMs (17, 35, 37, 38). Cys29 and Cys31, which are invariant throughout the PZN class (Figure 
2.1b) (27), were critical for posttranslational processing of BamA. No mutation at position 29 or 
31 led to detectable PZN product formation in vivo (Figure 2.7). Even conservative mutations of 
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Cys to Ser/Thr, or to the azol(in)e mimic Pro (38), failed to produce mature analogs (Figure 2.7), 
demonstrating an unusual chemoselectivity for cysteine at these positions (35-37, 39). Multiple 
attempts to isolate intermediates in the posttranslational cascade through utilization of the MBP 
tag via amylose affinity purification, coupled with MALDI-MS, were unsuccessful. For both 
accepted and unaccepted sequences, only the full-length unmodified BamA peptide could be 
detected in cell lysates. Identical results where obtained even when the arabinose concentration 
was lowered (serial dilutions to a final concentration of 3 µM) in an attempt to prevent any 
processed peptide signal from being overwhelemed by newly synthesized BamA (31). This result 
implies that failure to cyclize a particular residue aborts downstream modification required for 
maturation and export, and that cyclodehydration is the first committed step in PZN maturation, 
but this hypothesis will require further confirmation.  
In contrast to the invariant Cys at positions 29 and 31 (Figure 2.7), the PZN biosynthetic 
pathway tolerated conservative, heterocyclizable mutations at Thr33 and Ser38, but allowed more 
non-conservative mutations at Thr40 (Figure 2.7). Consistent with the variation at these positions 
in other PZN-like precursor peptides (Figure 2.1b), all other heterocyclizable residues substituted 
at these three positions resulted in full (“wild-type-like”) maturation of the PZN analog, including 
cyclodehydration of the substituted residue (Figure 2.7). The absence of -nucleophile-containing 
amino acids at these positions disrupts the contiguous polyheterocyclic structure of PZN. In the 
case of Thr33 and Ser38, we posit that this disruption prevents the formation of downstream 
heterocycles, as observed for other TOMM natural products (37, 40). However, the relative 
promiscuity of the cyclodehydratase was markedly increased at Thr40, as several non-cyclizable, 
nonpolar residues (Ala, Val, Ile) were tolerated by the biosynthetic pathway, in addition to other 
heterocyclizable residues (Cys, Ser). The above-described intolerance towards mutations at Cys29 
and Cys31, contrasted with the promiscuity at Thr40, suggests N- to C-terminal processing for 
PZN, which is the canonical direction of RiPP modification (36, 37, 41). Alternatively, if position 
40 is not the last position to be cyclodehydrated, other modifications of PZN certainly do not 
depend on position 40 being cyclized, unlike the case for positions 29 and 31.  
In native PZN, Thr40 is converted to a methyloxazoline (Figure 2.1d) and is the only 
heterocycle to evade dehydrogenation (27). Initial MALDI-MS results found that the PZN-T40S 
and -T40C variants each contained an azoline, presumably at position 40 (Figure 2.7). Given that 
thiazolines hydrolyze under mildly acidic conditions much more slowly than the corresponding 
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(methyl)oxazolines (42, 43), we wondered if differential hydrolysis would be useful to rapidly 
assess the azoline content of natural products (44). Upon exposing native PZN, -T40S, and -T40C 
to mild aqueous acid, only T40C was hydrolytically stability under the conditions employed 
(Figure 2.30). Intriguingly, when the T40C analog was produced in the strain bearing the PZN 
ΔbamA fosmid, the absence of wild-type PZN (m/z 1336) permitted observation of a fully-oxidized 
variant (deca-azole, m/z 1336), which was unreactive towards acid hydrolysis (Figure 2.30). 
FTMS/MS analysis confirmed the proposed structures (Figure 2.8). 
 
 
Figure 2.30. Hydrolytic stability of PZN analogs varied at Thr40. In naturally occurring PZN, 
Thr40 exists as a methyloxazoline. (a) MALDI-MS spectra from methanolic surface extracts of E. 
coli engineered to produced native PZN, -T40S, and -T40C. (b) Same as panel a, after treatment 
with 0.2% HCl for 4 h at 23 °C to induce hydrolysis. Under these conditions, the 
(methyl)oxazolines were virtually quantitatively hydrolyzed while the T40C thiazoline was 
minimally hydrolyzed. The deca-azole variant contains a thiazole at position 40, which was 
unreactive towards hydrolysis.  
 
2.5 Substrate tolerance at non-cyclized positions 
As Thr40 could be substituted with noncyclizable residues, the substrate tolerance at 
naturally occuring noncyclizable residues was evaluated. Ile34 and Phe41 both lie on the C-
terminal side of a contiguous polyazol(in)e moiety (Figure 2.1d), prompting the question of 
whether an additional heterocycle could be formed at these positions. While substitution with 
cyclizable residues was tolerated at these positions, the side chains did not undergo 
cyclodehydration (Figure 2.7), demonstrating that the PZN cyclodehydratase is remarkably 
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regioselective. These structural assignments were supported by MS/MS data on the PZN-F41C 
and -I34T analogs (Figures 2.9, 2.22). The free thiol of PZN-F41C was clearly susceptible to 
oxidation, as indicated by the MS-based detected of the sulfinic (R-SO2H) and sulfonic (R-SO3H) 
acid derivatives (Figures 2.6a, 2.9). Installation of a stop codon at position 41, however, failed to 
produce the expected PZN truncation (Figure 2.7), suggesting that the biosynthetic pathway 
required the presence of a C-terminal flanking residue for a cyclized position, as previously 
observed for other TOMMs (37, 39).  
In the case of PZN-I34T, the newly installed Thr at position 34 could not be definitively 
proven to remain uncyclized, due to the difficulty of obtaining dissociation between heterocycles 
during MS/MS (Figure 2.22). However, the data were consistent with the presence of five fully-
oxidized heterocycles in the N-terminal half of the molecule, as seen in wild-type PZN (27). Thus, 
if the substituted Thr was cyclized, it would require the omission of a normally-installed 
heterocycle, which seems unlikely. Although the PZN biosynthetic enzymes could tolerate PZN-
I34S/T, the pathway was unable to fully process PZN-I34C (Figure 2.7). It is possible that 
cyclodehydration of this newly installed Cys resulted in an intermediate that was incompatible 
with downstream processing. Unfortunately, all attempts to isolate potential biosynthetic 
intermediates of PZN-I34C resulted in the detection of only the full-length unmodified peptide 
(data not shown). Indirect support for the incompatibility of cyclization from PZN-I34C comes 
from variant -I34P, the only other assessed mutant at position 34 that did not produce PZN (Figure 
2.7). As proline is known to mimic azol(in)e heterocycles, the intolerance towards PZN-I34P 
suggests the inability of the biosynthetic pathway to cope with the lack of conformational 
flexibility at this position (37, 38).  
Among the four residues with unmodified side chains in the core sequence of wild-type 
BamA, the PZN biosynthetic pathway was least tolerant to mutation at Ile35 and Arg28 (Figure 
2.7). Only conservative mutations were tolerated at Ile35: Ala, Val, and the sterically similar Asn 
(Figure 2.7). Many of the substitutions tolerated at Ile34 did not yield detectable mature PZN 
analogs when probed at Ile35, including Gly, aromatic residues, and polar residues. This trend was 
consistent with the flanking residue requirements observed with other TOMM cyclodehydratases 
(37, 39), where the constraints for the residue in the –1 (N-terminal) position flanking a heterocycle 
are stricter than for the residue in the +1 (C-terminal) position. In PZN, with its two contiguous 
polyazol(in)e moieties, Ile35 occupies the –1 position for the C-terminal ring system, while Ile34 
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and Phe41 lie in +1 positions. By extension, Arg28 (Nα,Nα-dimethylarginine in mature PZN) is in 
the –1 position for the N-terminal ring system (Figure 2.1d). The most conservative mutation 
possible, R28K, was not tolerated by the PZN biosynthetic pathway, and as such, did not garner 
further attention (Figure 2.7). Conceivably, the failure to process the R28K mutant was due to its 
proximity to the leader peptidase cleavage site, thus inhibiting leader peptide cleavage and export. 
Numerous attempts to detect intracellular PZN intermediates with intact leader peptides by affinity 
chromatography were unsuccessful. Post-proteolysis, the methylation state of PZN should not 
affect export, as desmethylPZN was successfully exported in a ∆bamL strain of B. 
amyloliquefaciens (26, 27).  
 
2.6 Pathway tolerance for variations in substrate length  
In the continued interest of exploring the substrate tolerance of the PZN biosynthetic 
pathway, several BamA analogs were constructed to expand the PZN sequence by one residue in 
the middle of each polyazol(in)e moiety, between the two central Ile residues, and at the C-
terminus (Figure 2.31a). Production of PZN variants based on these peptides was assessed as 
described above. BamA peptides expanded by an internal alanine residue were not processed. 
However, expansion of the peptide by a single residue at the C-terminus was tolerated in all cases 
tested, with the exception of proline (Figure 2.31b). In addition to these expanded substrates, a 
contracted version of BamA was constructed by deletion of Ser38, potentially reducing the C-
terminal polyazole system from five heterocycles to four. However, this substrate also eluded 
processing. Taken together with the failure to process substrates truncated at positions 35 and 41 
(Figure 2.7), these data indicated that one or more of the PZN biosynthetic enzymes have precise 
length requirements as to the arrangement of heterocyclized residues within the BamA precursor 
peptide. In this regard, PZN biosynthesis stands in stark contrast to several other characterized 
TOMM biosynthetic pathways (18, 37, 39). 
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Figure 2.31. Tolerance of the PZN biosynthetic pathway towards expanded substrates. (a) PZN 
variants were heterologously expressed in E. coli prior to methanolic surface extraction and 
MALDI-MS analysis. Peptides elongated by a single residue at the C-terminus were modified and 
exported, with the exception of Pro. Internally expanded peptides were not tolerated by the 
biosynthetic pathway. Color-coding: same as in Fig. 3. (b) MALDI-MS of methanolic surface 
extracts of E. coli engineered to produce PZN with one residue added at the C-terminus. Addition 
of Ala, Gln, Glu, or Gly to the C-terminus of PZN led to the appearance of a +43 Da species. 
Although this species remains to be characterized, a +43 mass shift is consistent with 
carbamylation (45-48). Peaks at m/z 1336 correspond to wild-type PZN (dashed line). Peaks at m/z 
1363 and 1385 derive from the E. coli host and are not related to PZN. 
 
2.7 Production of other PZN-class natural products 
Although four other publicly available bacterial genomes encode PZN-like biosynthetic 
gene clusters (Figure 2.1), to date, only Bacillus pumilus has been shown to produce PZN during 
laboratory cultivation (27). The amino acid sequences of the core peptides from B. pumilus ATCC 
7061 and B. amyloliquefaciens FZB42 are identical (Figure 2.1b) (27), rendering it necessary to 
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look to the other potential PZN producers in order to determine if E. coli could biosynthesize non-
Bacillus PZN compounds. As substrate binding is mediated by the leader sequence (38, 49-51), 
the PZN biosynthetic enzymes from B. amyloliquefaciens were unlikely to accept significantly 
different leader peptides as substrates. Indeed, attempts to heterologously produce the Clavibacter 
michiganensis subsp. sepedonicus (Cms) encoded PZN (via pBAD24-MBP-CmsA) using the 
FZB42 biosynthetic pathway (fosmid-borne) proved unsuccessful. To circumvent the potential 
failure of leader peptide recognition during E. coli heterologous expression, precursor peptide 
chimeras were generated that consisted of the leader peptide sequence from the native producer 
(FZB42) and the core peptide sequence from other family members, yielding BamA-CmsA, 
BamA-CurA, and BamA-BlinA (Cur, Corynebacterium urealyticum DSM 7109; Blin, 
Brevibacterium linens BL2, Figure 2.32). Similar strategies employing precursor peptide chimeras 
have been previously used in other RiPP systems to enable the processing of unnatural core 
peptides (37, 38). Surprisingly, none of the products from the PZN chimeras were detected, 
although production of the unmodified peptides was verified by MALDI-MS (Figure 2.33). The 
inability to detect PZN-class natural products derived from the chimeric precursor peptides, despite 
their overall similarity to BamA/PZN, provided further evidence for the extraordinary specificity 
exhibited by the FZB42 biosynthetic pathway. 
 
 
Figure 2.32. Sequence alignment of PZN chimera peptides. The BamA leader peptide was used 
to replace the naturally occurring sequences for other members of the PZN class of natural 
products. Green, predicted dimethylation; blue, predicted heterocycles; red, mutation made to 
BamA-CmsA chimera; *, leader peptide cleavage site (assumed for chimeric peptides). Bam, B. 
amyloliquefaciens; Cms, Clavibacter michiganensis subsp. sepedonicus; Cur, Corynebacterium 
urealyticum; Blin, Brevibacterium linens. 
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Figure 2.33. Expression of PZN chimera peptides. MBP-tagged proteins were purified by amylose 
affinity chromatography from E. coli bearing the PZN cluster fosmid and pBAD24-MBP-BamA-
CmsA, MBP-BamA-CurA, and MBP-BamA-BlinA, following growth with arabinose and 
rhamnose. After cleavage by TEV protease, the purified proteins were analyzed by MALDI-MS, 
which indicated that the peptides had not been processed by the PZN biosynthetic enzymes. The 
experimentally determined (Exp) versus calculated (Calc) masses deviate due to the measured 
masses falling outside of reflector mode calibration range (900-3700 Da).  
 
To shed further light on the inability of the chimeric peptides to produce PZN variants in 
E. coli, efforts were focused on the PZN cluster from C. michiganensis. This cluster bears the 
highest degree of sequence conservation to FZB42 (aside from B. pumilus) among: (i) the 
precursor peptide (51/80; % identity / % similarity), (ii) the heterocycle-forming proteins (B: 
57/87, C: 41/77, D: 57/76; % identity / % similarity), (iii) the other modifying enzymes (E: 16/55, 
L: 25/60), and (iv) the export apparatus (G: 33/71, H: 19/59) (27, 52, 53). In an effort to render the 
BamA-CmsA chimera more similar to BamA, two constructs were generated. These included the 
point mutant BamA-CmsA-S32T and truncation of the C-terminal Gly, BamA-CmsA-G42term 
(Figure 2.32). Unexpectedly, these altered BamA-CmsA sequences also failed to produce PZN 
analogs, indicating that neither of these positions was individually responsible for the failure of 
BamA-CmsA to be tolerated by the FZB42 pathway. The previously analyzed mutants BamA-
I34V and -S38T both yielded mature PZN analogs (Figure 2.7), indicating that the Val34 or Thr38 
residues found in CmsA (Figure 2.32) were also not responsible for processing failure. It is not 
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obvious how the two residues in BamA-CmsA flanking Thr38 (i.e. Thr37 and Cys39) could pose 
an obstacle to posttranslational modification. Trp41 also seems an unlikely problem, given that 
PZN variants at position Phe41 were successfully biosynthesized with a wide variety of amino 
acid replacements (Figure 2.7). Taken together, these data indicate that the failure of the PZN 
pathway to process the BamA-CmsA chimera was not due to a single residue difference in the 
precursor peptide, but instead a culmination of several amino acid changes. 
 
2.8 Antibacterial activity of PZN analogs 
Of the 29 PZN variants detected, ten were produced in sufficient quantity (Figure 2.7) to 
permit assessment of their antibacterial activity against B. anthracis Sterne. These ten analogs, as 
well as the wild-type BamA sequence, were expressed in conjunction with the PZN ΔbamA 
fosmid, extracted in methanol, and purified by HPLC (Figures 2.10, 2.12-2.20), each yielding 3-5 
µg of purified PZN analog per 15 cm diameter plate of LB agar. The minimum inhibitory 
concentrations (MICs) of the purified PZN analogs were then determined by microbroth dilution 
assay against B. anthracis Sterne (Table 2.1). The activity of heterologously produced wild-type 
PZN was in good agreement with the published value for PZN from the native host (27). The 
analogs exhibited a range of antibacterial potencies, although no analogs were observed to have 
increased potency against B. anthracis. 
 
Table 2.1. Antibacterial activity of PZN analogs against B. anthracis Sterne. 
 
Variant MICa (µg mL–1) 
heterocycle at 40 
MIC (µg mL–1)
Thr at 40 
PZN     2    32b 
I34M   32 >32 
I34T     8 >32 
I34V     8 >32 
I35V   16   32 
S38C   32 >32 
T40C (thiazoline)     8 N.D.c 
T40C (thiazole)   32 N/Ad 
F41A     8   32 
F41L     4 >32 
F41V   16   32 
F41Y >32 >32 
aMIC = minimum inhibitory concentration. bRef. (27). cN.D. = not determined. dN/A = not applicable.  
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As expected, conservative mutations to the non-cyclized Ile residues (I34V, I34T, I35V) 
resulted in relatively modest reductions (four- to eight-fold) in antibacterial potency (Table 2.1). 
In contrast, PZN-I34M, which lacks a -methyl side chain substituent, resulted in a 16-fold 
reduction in potency, indicating that this region of the PZN structure does contribute to the anti-B. 
anthracis activity. Similarly, relatively conservative mutations to the C-terminal Phe (F41A, F41L, 
F41V) also led to modest reductions (two- to eight-fold) in potency. Surprisingly, a conservative 
mutation at this position, F41Y, abolished the antibacterial activity of PZN (Table 2.1). The 
similarly conservative S38C mutation (replaces an oxazole with a thiazole) also resulted in a 16-
fold reduction in activity (Table 2.1). As these moieties are isosteric, the altered activity of the 
PZN analog must arise from electronic effects.  
Analysis of PZN-T40C yielded two analogs differing in heterocycle oxidation at the 
penultimate position (Figure 2.8). These species were separable by HPLC (Figure 2.16) and tested 
for anti-B. anthracis activity. PZN-T40C(thiazoline) resulted in a four-fold reduction in anti-B. 
anthracis potency, while the presence of the fully oxidized, “deca-azole” T40C(thiazole) resulted 
in a 16-fold reduction in activity (Table 2.1). These data indicate that the posttranslational status 
of position 40 plays an important role in the activity of PZN. These results concur with the 
previously noted 16-fold loss of activity upon hydrolysis of the Thr40 methyloxazoline in native 
PZN (Table 2.1) (27). As expected, none of the oxazoline-containing PZN variants assayed in this 
study exhibited significant anti-B. anthracis activity (MIC <32 µg/mL) when hydrolyzed (Table 
2.1). Analogs lacking a heterocycle at position 40 (PZN-T40A, -T40I, and -T40V; Figure 2.7) 
were not isolated in sufficient quantity (>10 g) to facilitate purification and subsequent 
determination of antibacterial potency. However, based on the results for hydrolyzed PZN 
(reinstated Thr at position 40) and T40C, it is likely that these mutations would also severely 
reduce, if not abolish, activity. In accord with the observation that desmethylPZN had no 
measurable activity (27), it is clear that multiple regions of PZN, including both N- and C-termini, 
as well as the internal Ile residues and the polyazole(in)e moieties, collectively contribute to the 
observed anti-B. anthracis activity. 
 In conclusion, we have developed a facile system for the heterologous expression of PZN 
in E. coli, which enabled the production of analogs from variant precursor peptides. Using this 
system, we have elucidated the scope of substrate tolerance in the PZN biosynthetic pathway and 
found it to be much less permissive than previously characterized RiPPs. From PZN analogs that 
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were successfully produced, we have also provided significant insight into the structure-activity 
relationship for the PZN pharmacophore. This heterologous expression system has the potential to 
be applied to the study of any RiPP natural product by facilitating production of analogs in E. coli. 
 
2.9 Methods 
2.9.1 Genomic DNA extraction and fosmid construction 
Genomic DNA (gDNA) for fosmid construction was prepared from Bacillus 
amyloliquefaciens strains FZB42 and RS32 (26) using cells grown in 40 mL Luria-Bertani (LB) 
broth [for RS32, supplemented with spectinomycin (90 μg mL–1), chloramphenicol (7 μg mL–1), 
and erythromycin (1 μg mL–1)] for 16 h at 37 °C. Harvested cells were resuspended in 9.5 mL TE 
buffer (10 mM Tris, 1 mM EDTA, pH 8.0) with 20 mg lysozyme (Sigma) and incubated for 20 
min at 37 °C. 0.5 mL of 10% (w/v) sodium dodecyl sulfate and 50 μL of 20 mg mL–1 proteinase 
K (New England Biolabs) were added to the tube and incubated at 37 °C for 1 h. After the addition 
of 1.8 mL of 5 M aqueous NaCl and 1.5 mL of 10% (w/v) aqueous cetyl trimethylammonium 
bromide solution, the sample was incubated at 65 °C for 20 min. The resulting lysate was 
sequentially extracted with buffer saturated phenol, chloroform, and isoamyl alcohol (25:24:1) and 
chloroform and isoamyl alcohol (24:1). Genomic DNA was precipitated from the aqueous layer 
by addition of 0.1 volumes 5 M NaCl and 0.7 volumes isopropanol, spooled onto a glass rod, 
washed three times with 70% (v/v) EtOH and once with neat EtOH, dried, and resuspended in 
water.  
Fosmid construction was performed as previously reported (29). In this heterologous 
expression system, supplementing of the growth medium with rhamnose induces the fosmid copy 
number to increase approximately twenty-fold (from 1-2 copies per cell to 25-50). Fosmid libraries 
were selected using chloramphenicol (12.5 μg mL–1) for FZB42 or chloramphenicol (12.5 μg mL–
1) and spectinomycin (90 μg mL–1) for RS32. Positive clones were screened by PCR for the 
presence of the PZN biosynthetic cluster using primers for bamF and bamL (Table 2.2). The gDNA 
sequence from RS32 covered on the PZN ΔbamA cluster fosmid spans RBAM_007350 through 
RBAM_007570 (nucleotides 719228 to 745050). The gDNA sequence from FZB42 covered on 
the full PZN cluster fosmid spans RBAM_007190 through RBAM_007560 (partial) (nucleotides 
708,082 to 743,407). 
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2.9.2 Cloning and mutagenesis  
The gene encoding the BamA precursor peptide was amplified by PCR from B. 
amyloliquefaciens FZB42 genomic DNA using Taq polymerase and primers “BamHI BamA fw” 
and “NotI BamA rv” (Table 2.2). The purified insert was digested with restriction enzymes 
BamHI-HF and NotI-HF (New England Biolabs) and ligated into a similarly digested modified 
pET28 vector containing an N-terminal maltose-binding protein (MBP) fusion with a TEV 
protease site (pET28-MBP) (24). From this pET28-MBP-BamA construct, the gene encoding 
MBP-BamA was amplified by PCR using Pfu polymerase and primers “SalI MBP fw” and 
“HindIII BamA rv” (Table 2.2). The purified insert was digested with restriction enzymes SalI-HF 
and HindIII-HF (New England Biolabs) and ligated into similarly digested pBAD24 (gift of John 
Cronan, UIUC) (31) using T4 DNA ligase (New England Biolabs) to construct the pBAD24-MBP-
BamA plasmid. DNA sequences encoding chimeric peptides BamA-CmsA, BamA-BlinA, and 
BamACurA were codon optimized and commercially synthesized by GenScript and PCR 
amplified using Pfu polymerase and “BamHI BamA (opt) fw” with the appropriate “HindIII rv” 
primer (Table 2.2). PCR amplicons were digested with BamHI-HF and HindIII-HF (New England 
Biolabs) and ligated into similarly digested pET28-MBP using T4 DNA ligase. These pET28-
MBP-chimera constructs were then used as templates for PCR amplification using Pfu and primers 
“SalI MBP fw” and the appropriate “HindIII rv” primer (Table 2.2). PCR amplicons were digested 
with SalI-HF and HindIII-HF (New England Biolabs) and ligated into similarly digested pBAD24 
using T4 DNA ligase (New England Biolabs).  
All site-directed mutagenesis of BamA and BamA-CmsA was performed on pBAD24- 
MBP-BamA or the pBAD24-MBP-BamA-CmsA construct using either (i) the Quikchange™ 
method with Pfu Turbo polymerase (Agilent) and primer pairs listed in Table 2.3, or (ii) subcloning 
analogous to initial generation of the pBAD24-MBP-BamA construct using the “SalI MBP fw” 
primer (Table 2.2) and the “HindIII rv” primers (Table 2.3). For degenerate mutagenesis, clones 
in E. coli DH5α were pooled prior to isolation of plasmid DNA to generate polyclonal plasmid 
libraries. All DNA sequencing was performed by ACGT, Inc. (Wheeling, IL) or the UIUC Core 
Sequencing Facility using the primer “MBP fwd” (Table 2.3), which anneals near the 3’ end of the 
mbp gene, upstream of the bamA sequence. 
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Table 2.2. DNA sequences used for cloning and fosmid screening. 
Oligonucleotide Sequence (5’ to 3’) 
BamHI BamA fw AAAAGGATCCATGGAGGAGGTAACAATTATGACTCAAATTAAAGTGC 
NotI BamA rv AAAAGCGGCCGCTTAAAACGTAGATGAACTAGAGATGATTGTGGTACAGG 
SalI MBP fw AAAAGTCGACAATGGGCAGCAG 
HindIII BamA rv AAAAAAGCTTTTAAAACGTAGATGAACTAGAG 
BamHI BamA (opt) fw AAAAGGATCCATGACCCAGATTAAAGTGCC 
HindIII BlinA rv AATTAAGCTTTTAACCGCCAGAACAGC 
HindIII CmsA rv AATTAAGCTTTTAGCCCCAGGTGC 
HindIII CurA rv AATTAAGCTTTTAACCGCCGCAACAG 
BamA-BlinA CCATGGCGATGACCCAGATTAAAGTGCCGACGGCACTGATCGCGAGCGTTC
ATGGCGAGGGTCAGCACCTGTTTGAACCGATGGCGGCACGTTGCAGCTGTA
CCACGCTGCCGTGCTGTTGCTGTTCTGGCGGTTAACCCGGG 
BamA-CmsA CCATGGCGATGACCCAGATTAAAGTGCCGACGGCACTGATCGCGAGCGTTC
ATGGCGAGGGTCAGCACCTGTTTGAACCGATGGCGGCCCGTTGCACCTGTA
GCACGGTGATTTCTACCACGTGCACCTGGGGCTAACCCGGG 
BamA-CurA CCATGGCGATGACCCAGATTAAAGTGCCGACGGCACTGATCGCGAGCGTTC
ATGGCGAGGGTCAGCACCTGTTTGAACCGATGGCGGCCCGTTGTTCTTGCAC
CACGATTCCGTGCTGTTGCTGTTGCGGCGGTTAACCCGGG 
BamF fw AAAAGGATCCATGCCAAATCAGAATTTTC 
BamF rv AAAACCCGGGTTACTCATTTCCTTGCC 
BamL fw AAAAGGATCCATGGAAATTGAAACAATTGTCAGAGAGT 
BamL rv AAAAGCGGCCGCTCACGTATACCTTTTGTTTTTTATAATCCAAC 
 
 
 
 
 
 
67 
 
Table 2.3. DNA sequences used for generating core peptide mutants. 
Oligonucleotide Sequence (5’ to 3’) 
C29-NBT fw GAGCCAATGGCTGCACGCNBTACCTGTACCACAATCAT 
C29-NBT rv ATGATTGTGGTACAGGTAVNGCGTGCAGCCATTGGCTC 
C31-NBT fw AATGGCTGCACGCTGTACCNBTACCACAATCATCTCTAGT 
C31-NBT rv ACTAGAGATGATTGTGGTAVNGGTACAGCGTGCAGCCATT 
T33-NBC fw GCTGCACGCTGTACCTGTACCNBCATCATCTCTAGTTCATCTACG 
T33-NBC rv CGTAGATGAACTAGAGATGATGVNGGTACAGGTACAGCGTGCAGC 
I34-NNC fw CACGCTGTACCTGTACCACANNCATCTCTAGTTCATCTACG 
I34-NNC rv CGTAGATGAACTAGAGATGNNTGTGGTACAGGTACAGCGTG 
I35-NNC fw CGCTGTACCTGTACCACAATCNNCTCTAGTTCATCTACGTTTTA 
I35-NNC rv TAAAACGTAGATGAACTAGAGNNGATTGTGGTACAGGTACAGCG 
S38-NBC fw GTACCTGTACCACAATCATCTCTAGTNBCTCTACGTTTTAAAAGCTTGGC 
S38-NBC rv GCCAAGCTTTTAAAACGTAGAGVNACTAGAGATGATTGTGGTACAGGTAC 
T40-NBC fw TACCACAATCATCTCTAGTTCATCTNBCTTTTAAAAGCTTGGCTGTTTTGGCG 
T40-NBC rv CGCCAAAACAGCCAAGCTTTTAAAAGVNAGATGAACTAGAGATGATTGTGG
TA 
F41-KNS fw CAATCATCTCTAGTTCATCTACGKNSTAAAAGCTTGGCTGTTTTGGCGG 
F41-KNS rv CCGCCAAAACAGCCAAGCTTTTASNMCGTAGATGAACTAGAGATGATTG 
BamA T33 HindIII rv TTTTAAGCTTTTAAAACGTAGATGAACTAGAGATGATGHNGGTACAGGTAC
AGCGTG 
BamA S38 HindIII rv TTTTAAGCTTTTAAAACGTAGAABNACTAGAGATGATTGTGGTACAG 
BamA T40 HindIII rv TTTTAAGCTTTTAAAACRKAGATGAACTAGAGATGATTGTGGT 
BamA I34V fw CTGCACGCTGTACCTGTACCACAGTCATCTCTAGTT 
BamA I34V rv AACTAGAGATGACTGTGGTACAGGTACAGCGTGCAG 
BamA I34A fw ACGCTGTACCTGTACCACAGCCATCTCTAGTTCATCTACG 
BamA I34A rv CGTAGATGAACTAGAGATGGCTGTGGTACAGGTACAGCGT 
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Table 2.3. (cont.)  
BamA I34M fw GCTGTACCTGTACCACAATGATCTCTAGTTCATCTACG 
BamA I34M rv CGTAGATGAACTAGAGATCATTGTGGTACAGGTACAGC 
BamA I35* fw GCACGCTGTACCTGTACCACAATCTAGTCTAGTTCATCTACGTTTTAAAAG 
BamA I35* rv CTTTTAAAACGTAGATGAACTAGACTAGATTGTGGTACAGGTACAGCGTGC 
BamA S38T fw TACCTGTACCACAATCATCTCTAGTACGTCTACGTTTTAAAAGCTTGG 
BamA S38T rv CCAAGCTTTTAAAACGTAGACGTACTAGAGATGATTGTGGTACAGGTA 
CmsA S32T fw CGGCCCGTTGCACCTGTACCACGGTGATT 
CmsA S32T rv AATCACCGTGGTACAGGTGCAACGGGCCG 
CmsA G42* fw ATTTCTACCACGTGCACCTGGTAATAAAAGCTTGGCTGTTTTGGC 
CmsA G42* rv GCCAAAACAGCCAAGCTTTTATTACCAGGTGCACGTGGTAGAAAT 
BamA K43* fw CAATCATCTCTAGTTCATCTACGTTTTAATAGCTTGGCTGTTTTG 
BamA K43* rv CAAAACAGCCAAGCTATTAAAACGTAGATGAACTAGAGATGATTG 
*42-SVA fw TACCACAATCATCTCTAGTTCATCTACGTTTSVATAGCTTGGCTGTTTTG 
*42-SVA rv CAAAACAGCCAAGCTATBSAAACGTAGATGAACTAGAGATGATTGTGGTA 
A32 insert fw ATGGCTGCACGCTGTACCTGTGCCACCACAATCATC 
A32 insert rv GATGATTGTGGTGGCACAGGTACAGCGTGCAGCCAT 
A35 insert fw CTGTACCTGTACCACAATCGCGATCTCTAGTTCATCTACGT 
A35 insert rv ACGTAGATGAACTAGAGATCGCGATTGTGGTACAGGTACAG 
A39 insert fw GTACCTGTACCACAATCATCTCTAGTTCAGCGTCTACGTTTTAAAAGC 
A39 insert rv GCTTTTAAAACGTAGACGCTGAACTAGAGATGATTGTGGTACAGGTAC 
S38 del fw ACCTGTACCACAATCATCTCTAGTTCTACGTTTTAAAAGCTTG 
S38 del rv CAAGCTTTTAAAACGTAGAACTAGAGATGATTGTGGTACAGGT 
MBP fwd (sequencing 
primer) 
ATGAAGCCCTGAAAGACG 
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2.9.3 Heterologous PZN production 
To heterologously produce PZN and analogs, E. coli cells containing a fosmid harboring 
the PZN biosynthetic gene cluster ΔbamA were transformed with purified pBAD24-MBP-BamA 
or a variant thereof. Transformants were selected using Luria-Bertani (LB) agar supplemented 
with ampicillin (50 g mL–1) and chloramphenicol (12.5 g mL–1). Individual colonies were used 
to inoculate 10 mL cultures of LB broth supplemented with ampicillin (50 g mL–1) and 
chloramphenicol (12.5 g mL–1) in test tubes. Cultures were grown on a roller drum at 37 °C to an 
OD600 measurement of 0.6, at which point cells were harvested by centrifugation (4,000 x g) and 
resuspended in 1 mL of the LB supernatant. To induce production of PZN or analogs, 300 L of 
cell suspension was spread on a 15 cm plate of LB agar supplemented with ampicillin (50 g mL–
1), chloramphenicol (12.5 g mL–1), rhamnose (10 mM) to increase copy number of the fosmid 
(29), and arabinose (10 mM) to induce expression of MBP-BamA from the Para promoter of 
pBAD24. These cultures were grown at 30 °C for 40 h. Cells were harvested by resuspension in 
TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) and subsequent centrifugation (4,000 x g).  
 
2.9.4 PZN extraction  
Crude PZN or analogs were obtained by a non-lytic, methanolic cell surface extraction, 
similar to methods described previously (27). Briefly, cells were resuspended in MeOH (10 mL), 
agitated by vortex for 45 s, and equilibrated for 15 min at 22 °C. Cells were harvested by 
centrifugation (4,000 x g), and the MeOH supernatant was rotary evaporated to near dryness. The 
crude extract was resuspended in deionized water and lyophilized to dryness. Dried, crude extracts 
were resuspended in 500 L of 80% (v/v) aqueous MeCN for purification by HPLC or in 500 L 
MeOH for analysis of crude extract by MALDI-MS. 
 
2.9.5 Screening of mutant panels  
To screen BamA mutant panels for production of PZN variants, purified polyclonal 
plasmid libraries or individual plasmid sequences were used to transform chemically competent 
E. coli cells containing the entire PZN biosynthetic gene cluster (including bamA) on a fosmid, as 
described above. Individual colonies were used to inoculate 10 mL cultures of LB broth 
supplemented with ampicillin (50 g mL–1) and chloramphenicol (12.5 g mL–1) in test tubes. 
70 
 
Cultures were grown on a roller drum at 37 °C to an OD600 of 0.6, at which point PZN production 
was induced by addition of rhamnose (10 mM) and arabinose (10 mM) to the liquid cultures. 
Following induction, cultures were grown with shaking at 30 °C for 24 h. Cells were harvested by 
centrifugation (4,000 x g), washed with TE buffer, and harvested again (8,000 x g). PZN variants 
were extracted analogously to the procedure described above using 1 mL MeOH. Cells were 
harvested by centrifugation (8,000 x g), and the MeOH supernatant was evaporated in a speed-vac 
concentrator with minimal heating. Dry, crude extracts were resuspended in 10 L MeOH for 
analysis by MALDI-MS. Since the Quikchange™ site-directed mutagenesis method does not 
guarantee that all possible DNA sequences will be produced due to potential sequence biases, a 
sufficient number of clones were sequenced from each library to ensure 95% confidence in having 
detected all generated mutants, as calculated by 0.95 = 1–(1–f)n, where f = frequency of the least 
represented mutants and n = number of clones screened (54). 
 
2.9.6 Reverse phase HPLC purification  
Crude PZN or analogs [suspended in 80% (v/v) aqueous MeCN] were reverse phase 
purified as described previously (27) using a Thermo BETASIL C18 column (250 mm x 10 mm; 
pore size: 100 Å; particle size: 5 m) at a flow rate of 4 mL min–1. A gradient of 65-95% MeOH 
with 0.1% (v/v) formic acid over 32 min was used. The fractions containing PZN or an analog (as 
monitored by A266 and later verified by MALDI-MS) were collected into 20 mL borosilicate vials 
and the solvent was removed in vacuo. Purified PZN analogs were quantified by A260 in DMSO 
solution. 
 
2.9.7 Mass spectrometry  
MALDI-MS analysis used a Bruker Daltonics UltrafleXtreme MALDI-TOF/TOF 
instrument operating in reflector/positive mode using sinapic acid as the matrix. LC-MS analysis 
used an Agilent 1200 HPLC system coupled to a G1956B quadrupole mass spectrometer with an 
electrospray ionization (ESI) source. LC used a 2.1 mm x 150 mm Grace Vydac Denali C18 column 
(120 Å, 5 m) with a gradient of 65-95% MeOH with 0.1% (v/v) formic acid over 25 min, with 
the analytes eluted directly into the MS.  
HPLC-purified samples for high-resolution and tandem mass spectrometry were 
resuspended in 12 L of 80% (v/v) MeCN with 1% (v/v) formic acid. An Advion Nanomate 100 
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directly infused the sample to a ThermoFisher Scientific LTQ-FT hybrid linear ion trap, operating 
at 11 T (calibrated weekly). The FTMS was operated using the following parameters: minimum 
target signal counts, 5000; resolution, 100,000; m/z range detected, dependent on target m/z; 
isolation width (MS/MS), 4-5 m/z; normalized collision energy (MS/MS), 35; activation q value 
(MS/MS), 0.4; activation time (MS/MS), 30 ms. 
 
2.9.8 Antibacterial activity assay  
Determination of MIC values for PZN analogs was performed as described previously (27) 
for B. anthracis Sterne with the only modification being that PZN analogs were added from DMSO 
solutions to a maximum final concentration of 32 g mL–1 in bacterial cultures. Hydrolyzed 
samples were prepared by incubation of purified PZN analogs (suspended in MeOH) with 0.2% 
(w/v) HCl for 4 h at 23 °C, followed by removal of solvent in a speed-vac concentrator and 
subsequent resuspension in DMSO. 
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CHAPTER 3: 
In vitro biosynthesis and substrate tolerance of the plantazolicin family of natural products1 
 
3.1 Introduction 
 Natural products are a rich source of chemically and mechanistically diverse antibiotics 
(1). Within this broad space, the ribosomally synthesized and post-translationally modified peptide 
(RiPP) natural products comprise a class garnering increased attention (2). Plantazolicin (PZN) is 
an anti-B. anthracis RiPP produced by Bacillus velezensis (formerly Bacillus amyloliquefaciens) 
FZB42 (3-6) and a member of a subclass of RiPPs termed the linear azol(in)e-containing peptides 
(LAPs) (7, 8). LAPs, thiopeptides, and azol(in)e-containing cyanobactins can also collectively be 
referred to as thiazole/oxazole-modified microcins (TOMMs) (2). During TOMM biosynthesis, a 
trimeric heterocycle synthetase (BCD) converts select Cys, Ser, and Thr residues in the C-terminal 
(core) region of the precursor peptide to thiazole, oxazole, and methyloxazol(in)e moieties (Figure 
3.1A) (7). The D-protein (a member of the YcaO superfamily), in partnership with the C-protein, 
first installs azolines through an ATP-mediated cyclodehydration which proceeds through a 
phosphorylated hemiorthoamide (9, 10), and the B-protein [flavin mononucleotide (FMN)-
dependent dehydrogenase] then oxidizes select azolines to azoles (11). The C-protein serves to 
bind the N-terminal (leader) region of the precursor peptide, enhancing the rate of processing (12-
14). Following heterocyclization, the biosynthesis of PZN is completed by removal of the leader 
peptide, likely by the locally encoded type II CaaX protease (15, 16), and dimethylation of the new 
N-terminus by an S-adenosylmethionine (SAM)-dependent methyltransferase (17, 18). 
Though originating from a peptide, the structure of mature PZN after post-translational 
modification is remarkably non-peptide-like (Figure 3.1A), with two sets of five contiguous 
heterocycles conferring rigidity and hydrophobicity (4, 5). In addition to the PZN biosynthetic 
gene cluster (BGC) found in B. velezensis, homologous gene clusters have been identified in a 
number of other bacterial strains (Figures 3.1B, 3.2) (8), although only Bacillus pumilus has been 
demonstrated to produce PZN (4). The putative precursor peptides associated with these BGCs 
exhibit a highly conserved core region, which would result in similar groupings of contiguous 
heterocycles if indeed post-translationally modified like PZN (Figures 3.1C, 3.2). The unique 
structure of PZN endows it with an extremely narrow spectrum of activity and a membrane-
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targeting mode of action unlike other known antibiotics (19). PZN exhibits bactericidal activity 
against B. anthracis, the causative agent of anthrax, with a minimum inhibitory concentration 
(MIC) of 1–2 µg/mL, while not killing other species, even closely related ones (4, 19). It remains 
to be seen whether the other potential natural products in the PZN family, if produced, would 
display similar activities. 
 
Figure 3.1. (a) Structure of plantazolicin (PZN). (b) Biosynthetic gene clusters responsible for the 
production of PZN and an abridged list of homologous clusters. Bam, Bacillus velezensis FZB42; 
Bpum, B. pumilus ATCC 7061; Bbad, B. badius; Cur, Corynebacterium urealyticum DSM 7109. 
(c) Precursor peptide sequences for PZN and select related family members. Colors indicate post-
translational modifications in the mature product: green, Nα,Nα-dimethylarginine; red, thiazole; 
blue, (methyl)oxazole; brown, azoline; *, leader peptide cleavage site. A full listing of gene 
clusters and precursor peptides for the PZN family are shown in Figure 3.2. 
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Figure 3.2. (a) Biosynthetic gene clusters responsible for the production of PZN and putative 
PZN-like nature products. Bam, Bacillus velezensis; Bpum, B. pumilus ATCC 7061; Bsaf, B. 
safensis; Bbad, B. badius; Cms, Clavibacter michiganensis sepedonicus subsp. sepedonicus; Cur, 
Corynebacterium urealyticum DSM 7109; Blin, Brevibacterium linens; Nhap, Nocardiopsis 
halophila; Nbai, Nocardiopsis baichengensis; Nxin, Nocardiopsis xinjiangensis; Alop, 
Allosalinactinospora lopnorensis; Derm, Dermacoccus sp. DE3. (b) Precursor peptide sequences 
associated with the gene clusters shown in (a). Colors, same as Figure 3.1. 
 
 The characterization of structural analogs of bioactive compounds can benefit the study of 
mode of action and aid in the establishment of structure-activity relationships. RiPPs are 
particularly attractive natural product engineering targets, as their genetically encoded precursor 
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peptides provide an avenue for the facile introduction of diversity via mutagenesis of the coding 
gene. The RiPP biosynthetic enzymes can then be used to generate variant compounds from the 
unnatural precursor peptides, provided that the enzymes accept those peptides as substrates. 
Precursor peptide replacement has been employed to investigate and capitalize on the biosynthetic 
pathways of lanthipeptides (20-26), lasso peptides (27-29), and thiopeptides (30-35). The 
patellamide biosynthetic enzymes are notably permissive toward unnatural substrates, allowing 
for the generation of many new natural product analogs without the need for intensive total 
synthesis (36-40).  
Previously, we used an Escherichia coli expression system to examine the substrate 
tolerance of the PZN biosynthetic pathway and to generate analogs to explore structure-activity 
relationships (41). Heterologous production of PZN analogs in E. coli prevented the interception 
of biosynthetic intermediates and also, determination of the order of post-translational events. 
Nonetheless, the enzymes involved in PZN biosynthesis proved to be extremely selective for their 
substrates, with the cyclodehydratase in particular appearing incapable of processing any 
substrates with non-cyclizable residues in positions that were normally cyclized (41). In the present 
study, we reconstitute the PZN synthetase in vitro and use the expanded substrate scope of this 
cell-free system to more thoroughly probe the biosynthesis of PZN, including the identification of 
residues crucial for leader peptide binding. In addition, we demonstrate the production of new PZN 
analogs, including two novel natural products from other BGCs in the PZN family. 
 
3.2 In vitro reconstitution of the PZN heterocycle synthetase 
In order to determine the activity of the PZN heterocycle synthetase in vitro, the precursor 
peptide (BamA), dehydrogenase (BamB), and two-component cyclodehydratase (BamC, BamD) 
were each heterologously expressed in E. coli as fusions to maltose-binding protein (MBP) and 
affinity purified (Figure 3.3). Unfortunately, all attempts to express MBP-BamC yielded only 
degraded protein. A codon-optimized version of the gene for E. coli expression (BamCopt) was 
synthesized and heterologously expressed to yield a modest amount of enzyme (~2 mg/L, Figure 
3.3), but size-exclusion chromatography indicated that BamCopt did not form an observable 
complex with BamB and BamD, which could impair the activity of the synthetase (Figure 3.4A). 
In order to obtain more significant quantities of properly functioning protein, we elected to 
substitute BamC with a closely related homolog, which is an approach that has been successful for 
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other heterocycle synthetases (42, 43). The C-protein from the PZN BGC in Bacillus pumilus 
(BpumC, accession number WP_041117410; Figure 3.1B) shares 91% amino acid similarity (63% 
identity) with BamC (4), and when expressed as an MBP fusion protein in E. coli, yielded over 90 
mg/L following affinity purification (Figure 3.3). In contrast to BamCopt, BpumC formed a 
complex with BamB and BamD as assessed by size-exclusion chromatography (Figure 3.4B). 
Gratifyingly, when these MBP-tagged proteins (BamB, BpumC, and BamD) were combined with 
MBP-BamA, TEV protease (to remove the MBP tags), and ATP, matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) indicated a mass loss 
consistent with the formation of nine azoles and one azoline (-198 Da) onto the precursor peptide 
(Figure 3.5A). Subsequent Fourier transform ion cyclotron resonance tandem mass spectrometry 
(FT-ICR-MS/MS) was used to localize these modifications, which was identical to the bona fide 
natural product (Figure 3.6). While BamCopt did not appear to form a stable complex with other 
components of the synthetase (Figure 3.4A), overnight reactions with BamCopt did form the 
expected -198 Da product (Figure 3.7). Ultimately, the more robust protein yield and activity of 
BpumC warranted its usage in all subsequent assays. 
 
 
Figure 3.3. SDS-PAGE of enzymes used in this study. All proteins were purified as MBP fusions. 
BamCopt is the E. coli codon-optimized BamC (see methods).  
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Figure 3.4. Size-exclusion chromatography used to assess complex formation between the 
components of the Bam synthetase complex. (a) BamCopt is the E. coli codon-optimized BamC, 
yet it still does not form a significant amount of complex with BamB and BamD. (b) BpumC is 
the homolog of BamC from B. pumilus and more readily forms a complex with BamB and BamD 
than does BamC. (c) BamB-R93A does not bind the FMN cofactor, yet still forms a complex with 
BpumC and BamD. BamB-R93A is used when an inactive dehydrogenase is needed or in 
fluorescence polarization assays to avoid the inherent fluorescence of the flavin. * denotes void, 
including protein aggregate. The single-protein controls are duplicated in each panel for clarity in 
comparison with the complex. 
 
 
Figure 3.5. (a) Reaction of the PZN precursor peptide BamA with the Bam heterocycle synthetase 
in vitro results in the installation of nine azoles and one azoline, consistent with PZN produced 
from the native host. (b) Reaction of the precursor peptide CurA with the Cur heterocycle 
synthetase in vitro results in the installation of ten azoles. 
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Figure 3.6. (a) FT-ICR-MS of the [M+5H]5+ species of heterocyclized and TEV-cleaved BamA. 
(b) CID-based fragmentation of modified BamA, allowing localization of heterocycles. In 
subsequent MS/MS figures, the assignment of leader peptide fragment ions will be omitted for 
clarity. 
 
 
Figure 3.7. BamCopt (expressed from an E. coli codon-optimized construct) is less active than that 
of BpumC, as assessed by MALDI-TOF-MS. Values above peaks indicate the number of 
heterocycles installed on BamA after overnight reaction at 22 °C (100 µM BamA, 10 µM each 
BamB, BpumC or BamC, and BamD). 
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Bolstered by our success with in vitro reconstitution of the Bam heterocycle synthetase, we 
also set about reconstituting the homologous synthetase from Corynebacterium urealyticum (Cur, 
Figure 3.1B) (4, 8). Size-exclusion chromatography indicated that CurB, CurC, and CurD formed 
a complex (Figure 3.8), and combination of the MBP-tagged synthetase proteins with ATP, TEV, 
and MBP-CurA resulted in a mass loss of 200 Da for CurA, consistent with the installation of ten 
azoles (Figure 3.5B). 
 
Figure 3.8. Size-exclusion chromatography was used to assess complex formation between the 
components of the Cur heterocycle synthetase. * denotes void, including protein aggregate. 
 
Although some TOMM cyclodehydratase enzymes are capable of activity in the absence 
of their cognate dehydrogenase, or even in the absence of their cognate C-protein (9, 43), this was 
not the case for either the Bam or Cur cylodehydratases, as the exclusion of any one component 
of the synthetase from either BGC abolished activity (Figure 3.9). For these synthetases, all three 
components of the heterocycle synthetase were required for activity, as has been demonstrated for 
most other studied TOMM clusters, including microcin B17 and streptolysin S (7, 42, 44). Thus, 
in order to reveal the order of biosynthetic events, the enzymatic activities of the cyclodehydratase 
and dehydrogenase needed to be disentangled. Towards this goal, we prepared two inactive forms 
of the dehydrogenase, BamB-Y206A and BamB-R93A. BamB-Y206A contains an alanine 
substitution at a key active site residue (11, 45), while BamB-R93A no longer co-purified with 
FMN upon heterologous expression in E. coli but still associated with BpumC/BamD by size-
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exclusion chromatography (Figure 3.4C). When MBP-BamA was treated with BpumC, BamD, 
and either BamB-R93A or BamB-Y206A, the cyclodehydratase installed at most four azoline 
heterocycles, which were localized to the four most N-terminal positions in the core peptide 
(Figures 3.10, 3.11). Subsequent treatment of this species with synthetase containing an active 
dehydogenase yielded a fully-modified substrate (nine azoles and one azoline). While the four-
azoline species proved to be a competent in vitro intermediate, it is not necessarily a natural, on-
pathway biosynthetic intermediate. Nevertheless, one of these four azolines is most likely the first 
to be installed during the normal course of biosynthesis. All attempts to isolate additional 
intermediates from the Bam or Cur synthetase reactions were unsuccessful due to the apparent 
high processivity of the enzymes (Figure 3.12). However, the observation that the 
cyclodehydratase cannot install all ten azolines in the absence of an active dehydrogenase is 
strongly suggestive that during the normal reaction course, azole formation begins at the N-
terminal residues prior to completion of azoline formation at the C-terminal residues.  
 
Figure 3.9. The PZN pathways from both Bam (a) and Cur (b) require the presence of all three 
components of the heterocycle synthetase for precursor peptide modification. 
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Figure 3.10. Reaction of BamA (1) with a heterocycle synthetase containing the inactive BamB-
R93A results in the installation of up to four azolines, without their oxidation to azoles (2). 
Subsequent treatment of this species mixture with acid hydrolyzes the azolines to their original 
amino acids (3), whereas treatment with a fully wild-type synthetase yields the full complement 
of nine azoles and one azoline (4), comparable to treatment of unmodified BamA with wild-type 
synthetase (5). Substitution of the catalytically inactive BamB-Y206A for BamB-R93A yielded 
equivalent results. 
 
 
Figure 3.11. The use of apo BamB-R93A in the Bam synthetase enables the installation of up to 
four azolines without their oxidation to azoles. CID-based fragmentation of the 2-azoline (a), 3-
azoline (b), and 4-azoline (c) species localize the azolines to the first four heterocyclizable 
residues. Brown, azoline. The use of BamB-Y206A, which is catalytically inactive, in place of 
BamB-R93A yields comparable results. 
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Figure 3.11 (cont.): 
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Figure 3.12. The Bam synthetase appears to exhibit high processivity, preventing isolation of 
partially-cyclized intermediates, as assessed by MALDI-TOF-MS. Values above peaks indicate 
the number of heterocycles installed on BamA after reaction at 22 °C (100 µM BamA, 2 µM each 
BamB, BpumC, and BamD). 
 
3.3 Substrate tolerance of the PZN synthetase in vitro 
With the PZN heterocycle synthetase reconstituted in vitro, we next turned our attention to 
determining the parameters of substrate tolerance for these enzymes with variant precursor 
peptides. MBP-tagged precursors with core region substitutions were generated using site-directed 
mutagenesis and E. coli heterologous expression. After treating the panel of purified variant 
peptides with the heterocycle synthetase in vitro, the extent of processing was determined by 
MALDI-TOF-MS, with subsequent FT-ICR-MS/MS to localize the sites of post-translational 
modification (Figure 3.13). Overall, the ability of the synthetase to process variant substrates was 
increased over what was previously observed in E. coli (41), presumably due to a greater level of 
control over the reaction conditions (e.g. higher concentrations of reaction components are 
possible in vitro). Nonetheless, many of the variant peptides remained incompletely processed, 
reaffirming that the PZN cyclodehydratase is remarkably substrate selective. 
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Figure 3.13. Processing of mutant BamA peptides by the Bam synthetase in vitro. Mutated and 
uncyclized residues are shown in solid black circles; half-filled circles indicate a mixture of 
species. (a) Mutation of most residues to Pro prevents cyclization both C-terminal and in the -1 
position to the Pro. Wild-type BamA (WT) is shown for comparison. (b) Mutation of a normally-
cyclized position to Ala, or insertion of Ala between two wild-type residues, generally prevents 
cyclization C-terminal to the Ala. (c) A Cys residue in the next heterocyclizable position relative 
to Ala enables cyclodehydration of that residue, though Cys in a position not normally cyclized 
remains unmodified. (d) Deletion of a residue does not affect processing by the synthetase, though 
one residue must remain uncyclized at the C-terminus. (e) The Bam synthetase in vitro is capable 
of processing substrates with the core peptides of other members of the PZN family. 
 
Initially, we examined the limits of substrate scope for the Bam synthetase by creating a 
series of variant peptides wherein a Cys, Ser, or Thr residue was replaced with Pro, which has been 
used as a crude steric mimic for an azoline in previous studies (43, 46). While the Bam synthetase 
was able to install heterocycles in the expected positions N-terminal to the interrogated Pro residue, 
neither the residue proximal to Pro, nor any residues following Pro were cyclized (Figure 3.13A, 
Figures 3.14-3.19). Presumably, the conformational restriction imparted on the peptide backbone 
by the presence of Pro in the +1 position prevented the Bam cyclodehydratase from installing a 
heterocycle at that position, perhaps due to an inability to properly fit the substrate in the active 
site or some other catalytic deficiency. While such an intolerance for Pro in the +1 position is 
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consistent with previous studies using the cyclodehydratase from Bacillus sp. Al Hakam (43), the 
Cur cyclodehydratase, among other TOMM natural products (47, 48), is capable of accepting Pro 
in the –1 position (Figure 3.1C, Figure 3.5C). 
 
Figure 3.14. CID-based fragmentation of the [M+4H]4+ species of heterocyclized and TEV-
cleaved BamA-C4P. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6 for comparison. Red, thiazole; bold, mutated residue. 
 
 
Figure 3.15. CID-based fragmentation of the [M+4H]4+ species of heterocyclized and TEV-
cleaved BamA-T6P. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
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Figure 3.16. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-I7P. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
 
Figure 3.17. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-I8P. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
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Figure 3.18. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-S11P. (top) 5-azole species; (bottom) 6-azole species. Only a few of the major 
fragment ions from the leader peptide are labeled for clarity. Red, thiazole; blue, 
(methyl)oxazole; bold, mutated residue; *, unrelated peaks. 
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Figure 3.19. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-T13P. (a) 8-azole species; (b) 7-azole species. Only a few of the major fragment 
ions from the leader peptide are labeled for clarity. Red, thiazole; blue, (methyl)oxazole; bold, 
mutated residue. 
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Similar N-terminal but not C-terminal processing was also observed for a number of Ala 
substitutions, though the cyclodehydratase was able to cyclize residues with Ala in the +1 position 
(Figures 3.13B, 3.20-3.29). In a few cases involving Ala near the middle of the core peptide, the 
cyclodehydratase was capable of installing an azoline in the next heterocyclizable position after 
the Ala, but this was always a minor species, perhaps due in part to hydrolysis of the azoline. 
Dehydrogenation of this azoline to the azole was never observed in the position following Ala, nor 
was cyclodehydration observed in more than one position following Ala. This abortive trend was 
also observed in cases where an Ala residue was inserted between two wild-type residues, 
including between the two central Ile residues in the core peptide (^8A, ^12A; ^ indicates 
insertion). Together, these results further support the hypothesis that heterocyclization during PZN 
biosynthesis proceeds in an N- to C-terminal direction.  
 
Figure 3.20. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-T3A. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6. Red, thiazole; bold, mutated residue. 
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Figure 3.21. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-C4A. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
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Figure 3.22. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-T5A. (a) 4-ring species; (b) 3-ring species. Peaks due to fragmentation of the leader 
peptide are not labeled for clarity; see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; brown, 
azoline; bold, mutated residue. 
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Figure 3.23. CID-based fragmentation of the [M+4H]4+ species of heterocyclized and TEV-
cleaved BamA-T6A. Only a few of the major fragment ions from the leader peptide are labeled 
for clarity. Red, thiazole; blue, (methyl)oxazole; brown, azoline; bold, mutated residue. 
 
 
Figure 3.24. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-S9A/S11A. Peaks due to fragmentation of the leader peptide are not labeled for 
clarity; see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
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Figure 3.25. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-S11A. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
 
 
Figure 3.26.  CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-S12A. Only a few of the major fragment ions from the leader peptide are labeled 
for clarity. Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
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Figure 3.27. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-T13A. Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
 
 
Figure 3.28. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-^8A. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6. Contiguous heterocycles prevent fragmentation; thus, more core peptide fragments 
are observed when enzymatic processing is disrupted. Red, thiazole; blue, (methyl)oxazole; bold, 
mutated residue. 
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Figure 3.29. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-^12A. Only one major fragment ions from the leader peptide is labeled for clarity. 
Red, thiazole; blue, (methyl)oxazole; bold, mutated residue. 
 
The single notable exception to this trend of Ala preventing significant heterocyclization 
of C-terminal residues was in the case of the BamA-T3A substrate, for which the synthetase fully 
cyclized both Cys2 and Cys4 to thiazoles (Figures 3.13B, 3.20). Further heterocyclization C-
terminal to Cys4 was not observed, consistent with the other Ala-substituted precursor peptides. It 
is possible that the increased nucleophilicity of the Cys side chain relative to that of Ser/Thr, plus 
the more electrochemically favorable oxidation to thiazole relative to oxazole, were responsible 
for the ability of the synthetase to overcome the introduction of Ala in the preceding (–1) position. 
To test this hypothesis, three double substitutions were constructed and assayed for modification 
in which the Ala residue was followed by Cys in the next position normally heterocyclized: 
T5A/T6C, T6A/S9C, and S12A/T13C. In each of these cases, the synthetase was able to convert 
the unnatural Cys to a thiazole, though some Cys remained unprocessed in the S12A/T13C peptide 
(Figures 3.13C, 3.30-3.32). Together, these results demonstrate that the increased reactivity of 
Cys, in essence, chemically rescues processing when the activity of the synthetase would normally 
be halted by Ala. However, when Cys was placed at positions not heterocyclized in the wild-type 
PZN (i.e. I7C and I8C), susceptibility to iodoacetamide labeling demonstrated that these Cys 
residues remained unmodified, whereas other positions of BamA were processed as in the wild-
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type peptide (Figures 3.13C, 3.33). Such exquisite site-selectivity is consistent with that previously 
observed in E. coli (41). 
 
 
Figure 3.30. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-T5A/T6C. (a) 5-azole species; (b) 4-azole species. Peaks due to fragmentation of 
the leader peptide are not labeled for clarity; see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; 
bold, mutated residues. 
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Figure 3.31. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-T6A/S9C. Peaks due to fragmentation of the leader peptide are not labeled for 
clarity; see Figure 3.6. Red, thiazole; blue, (methyl)oxazole; bold, mutated residues. 
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Figure 3.32. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-S12A/T13C. (a) 9-azole species; (b) 8-azole species. Only a few of the major 
fragment ions from the leader peptide are labeled for clarity. Red, thiazole; blue, (methyl)oxazole; 
bold, mutated residues. 
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Figure 3.33. Iodoacetamide labeling of heterocyclized and TEV-cleaved BamA-I7C and BamA-
I8C demonstrates that one Cys residue in each peptide remains unmodified. The peak at m/z 5203 
in the labeled spectra represents a doubly-labeled species. 
 
To further examine the effects of disrupting the natural arrangement of heterocyclizable 
residues, several precursors with contracted core peptides were constructed and assayed for 
modification by the Bam synthetase. Shortening the precursor peptide by one residue in the center 
of either block of five heterocyclizable residues (C4Δ, S11Δ; Δ indicates deletion) did not 
significantly disrupt processing, as assessed by the MALDI-TOF-MS endpoint assay, resulting in 
the maximum of nine heterocycles installed (Figures 3.13D, 3.34, 3.35). Likewise, truncation of 
the precursor peptide to remove the C-terminal half of the core peptide (I8*; * indicates a stop 
codon) also led to the installation of five heterocycles (Figures 3.13D, 3.36). Finally, removal of 
the C-terminal Phe residue (F14*) prevented heterocyclization only at the preceding residue, Thr13 
(Figures 3.13D, 3.37), indicating that the Bam synthetase is unable to install a C-terminal 
heterocycle.  
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Figure 3.34. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-C4Δ. Only a few of the major fragment ions from the leader peptide are labeled for 
clarity. Red, thiazole; blue, (methyl)oxazole; brown, azoline. 
 
 
Figure 3.35. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-S11Δ. Only a few of the major fragment ions from the leader peptide are labeled 
for clarity. Red, thiazole; blue, (methyl)oxazole; brown, azoline. 
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Figure 3.36. MALDI-TOF-MS of heterocyclized and TEV-cleaved BamA-I8*, demonstrating 
installation of all five possible azoles. 
 
 
Figure 3.37. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-F14*. Peaks due to fragmentation of the leader peptide are not labeled for clarity; 
see Figure 3.6. Red, thiazole; blue, (methyl)oxazole. 
 
In addition to the precursors with one or two substituted residues, three potential substrates 
with more extensive alterations were also assayed. These chimeric peptides consisted of the leader 
peptide from BamA and the core peptides from three other BGCs in the PZN family. These 
peptides were previously assayed in E. coli, where no post-translational modifications were 
observed (41). However, the reaction conditions using purified enzymes now enabled modification 
of all three chimeric peptides (Figures 3.13E, 3.38-3.40). The ability of the synthetase to modify 
the BamA-CurA and BamA-BlinA chimeras is especially notable, as each contains an internal Pro 
residue. As previously demonstrated in this work, the presence of a Pro residue in the BamA core 
peptide prevented heterocyclization in positions C-terminal to the Pro (Figure 3.13A). Yet in the 
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case of BamA-CurA and BamA-BlinA, Pro8 is followed immediately by several Cys residues. We 
hypothesize that the increased nucleophilicity of the Cys sidechain again may be chemically 
rescuing an otherwise unprocessed substrate, as was the case for the Ala/Cys double mutants 
(Figure 3.13C). The processing of BamA-CurA also demonstrates site-selectivity on the part of 
the PZN dehydrogenase, as it did not oxidize the penultimate position to the thiazole, whereas 
CurB oxidized all azolines in CurA to the corresponding azoles (Figures 3.5B, 3.41). 
 
Figure 3.38. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-CmsA chimera. (a) 10-ring species; (b) 7-ring species. Peaks due to fragmentation 
of the leader peptide are not labeled for clarity; see Figure 3.6. Red, thiazole; blue, 
(methyl)oxazole; brown, azoline. 
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Figure 3.39. CID-based fragmentation of the [M+5H]5+ species of heterocyclized and TEV-
cleaved BamA-BlinA chimera. (a) 9-ring species; (b) 7-ring species. Peaks due to fragmentation 
of the leader peptide are not labeled for clarity; see Figure 3.6. Red, thiazole; blue, 
(methyl)oxazole; brown, azoline. 
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Figure 3.40. CID-based fragmentation of the [M+4H]4+ species of heterocyclized and TEV-
cleaved BamA-CurA chimera. (a) 10-ring species; (b) 9-ring species. Peaks due to fragmentation 
of the leader peptide are not labeled for clarity; see Figure 3.6. Red, thiazole; blue, 
(methyl)oxazole; brown, azoline. 
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Figure 3.41. CID-based fragmentation of the [M+4H]4+ species of heterocyclized and TEV-
cleaved CurA. Only a few of the major fragment ions from the leader peptide are labeled for clarity. 
Red, thiazole; blue, (methyl)oxazole. 
 
In addition to the heterocyclizable residues, the other key position in BamA at which 
substitution was not tolerated by the heterocycle synthetase in E. coli was Arg1 (41). Previously, 
it was unclear whether the intolerance toward even the most conservative substitution (Arg to Lys) 
at this position was due to selectivity by the cyclodehydratase or prevention of leader peptide 
cleavage. With the Bam synthetase reconstituted in vitro, its tolerance for alternative residues at 
the N-terminus of the core peptide could now be assessed in the absence of the leader peptidase. 
In vitro, the R1K construct was accepted by the Bam synthetase, though not robustly, as indicated 
by the presence of a number of incompletely cyclized species (Figure 3.42A). In addition to the 
“conservative” R1K substitution, a variety of other alterations to this position were also assayed. 
The Bam synthetase was revealed to be more permissive to small residues (R1G, R1S) than to 
bulky (R1I, R1F) or negatively-charged (R1D) residues, though only in the case of R1K could the 
synthetase install the full complement of ten heterocycles (Figure 3.42A). The initial enzymatic 
rate was also determined for the synthetase in the presence of each of these Arg1 mutants, and 
those substrates which permitted the installation of more heterocycles also generally had greater 
initial velocities (Figure 3.42B). The Bam synthetase thus appeared to strongly favor Arg1.  
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Figure 3.42. Processing of Arg1 mutants of BamA by the Bam synthetase in vitro. (a) MALDI-
TOF-MS of peptides after overnight treatment with the Bam synthetase. Numbers above peaks 
indicate the number of heterocycles installed. (b) Initial reaction rate for the substrates shown in 
(a), as determined by PNP assay for phosphate concentration (see Methods) and normalized to 
the wild-type rate. Error bars represent standard deviation; n=3. 
 
 In addition to determining the relative rates of processing for the Arg1 variants, several 
other precursor peptides were kinetically assayed using the Bam synthetase (Table 3.1). The 
observed Vo values for these substrate variants were relatively unperturbed regardless of the 
number of heterocycles installed or the substituted position in the core. Such similarity suggested 
that the first cyclodehydration event (Cys2) is the rate-determining step, and this result offers 
further support that modification proceeds in an N- to C-terminal direction. Indeed, many data 
reported herein would be difficult to reconcile if an alternative processing order was operating. 
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Meanwhile, in contrast to the similar Vo values, the apparent Km values varied greatly. Although it 
can be difficult to interpret kinetic parameters for a multistep reaction where substrate binding is 
primarily dictated at a location distal to the active site (i.e. the C-protein engages the leader peptide, 
vide infra) (12), lower apparent Km values correlated with an increased total number of 
modifications, such as with the native substrate and T13P (Figure 3.13A). Such a trend suggests 
that substrates receiving more modifications interact more productively with the active site, which 
is expected for any substrate with a lower Km. The higher apparent Km for the T3A and T6A 
variants also suggests that these Thr residues enhance productive interactions with the enzyme, 
perhaps through the β-methyl substituent on their side chains.  
 
Table 3.1. Kinetics of select BamA substrates with the Bam synthetase. 
Mutant Vo (µM Pi 
min-1) 
Apparent 
Km (µM) 
Heterocycles 
installed 
WT 1.76 ± 0.09 3.22 ± 1.08 10 
T3A 1.71 ± 0.13 26.8 ± 5.9 2 
T6A 2.74 ± 0.25 55.5 ± 11.3 4 
I8P 2.35 ± 0.12 7.61 ± 2.28 5 
S12A 2.35 ± 0.19 8.36 ± 2.86 8 
T13P 2.48 ± 0.09 5.73 ± 1.26 8 
C4Δ 1.88 ± 0.22 9.37 ± 4.3 9 
BamA-CurA 1.78 ± 0.12 12.3 ± 2.8 10 
 
3.4 Leader peptide recognition and binding by the PZN synthetase 
In order to more fully understand the substrate scope of the heterocycle synthetases, we 
next investigated the contribution of the leader peptide towards substrate binding and processing. 
Previous work has shown that CurC, and not CurD, interacts with a CurA leader peptide, 
exemplifying the previously described role for the C-protein component of the heterocycle 
synthetase in leader peptide binding via the RiPP recognition element (RRE) domain (12). 
Building on these previous results, we examined the interaction between an N-terminally FITC-
labeled BamA leader peptide (FITC-BamA-LP, Table 3.2) and the synthetase proteins by 
fluorescence polarization (FP). Unexpectedly, BpumC on its own was incapable of avid FITC-
BamA-LP binding, with an extrapolated Kd of approximately 100 µM (Figure 3.43). In the 
presence of BamD, the Kd decreased to 20 ± 2 µM, though BamD alone did not substantially bind 
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the leader peptide (Figure 3.43), indicating that BpumC was indeed the primary engaging protein, 
in line with previous results. The surprisingly weak binding by BpumC alone was not a result of 
the non-cognate nature of the BamA/BpumC interaction, since the binding of FITC-BpumA-LP 
(the cognate sequence) to BpumC gave comparable results (Kd ~100 µM, extrapolated; Figure 
3.43). In light of the observation that the full, trimeric PZN heterocycle synthetase was required to 
modify BamA (Figure 3.9), we hypothesized that BpumC requires its associated partners for 
efficient leader peptide binding. To test this, BamB-R93A, which lacks the FMN cofactor, was 
employed so that the intrinsic fluorescence of the flavin would not interfere in the FP assay. When 
BamB-R93A, BpumC, and BamD were combined to form the heterocycle synthetase, leader 
peptide binding was considerably enhanced (Kd = 1 ± 0.1 µM, Figure 3.43). This result is in stark 
contrast to several previously studied TOMM synthetases, where the C-protein, which contains 
the ~90 residue RRE, was sufficient for effective peptide binding (12, 46). We hypothesize that 
some C-proteins leverage their association with other synthetase components to induce structural 
rearrangements that potentiate leader peptide binding (49).  
 
Table 3.2. Sequences of fluorescent peptides used in this study. Fluorescein isothiocyanate 
(FITC)-conjugated peptides were synthesized (Genscript) with an amino hexyl linker (Ahx) and a 
single glycine spacer, followed by the leader peptide (LP) sequences of BamA, BpumA, CmsA, 
and CurA. FITC-CurA-LP represents the CurA leader peptide with an N(-26)S substitution 
(equivalent to the wild-type sequence for BlinA; Figure 3.2B). This peptide binds to CurC with 
the same affinity as the wild-type CurA peptide (12). 
 
Peptide Sequence 
FITC-BamA-LP FITC-Ahx-GMTQIKVPTALIASVHGEGQHLFEPMAA 
FITC-BpumA-LP FITC-Ahx-GMTKITIPTALSAKVHGEGQHLFEPMAA 
FITC-CmsA-LP FITC-Ahx-GMITTTALPRAAAVTTTVYGEGLHLFEPMA 
FITC-CurA-LP FITC-Ahx-GMSTLISKLPPAVSTDSSKIVSEVQAFEPT 
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Figure 3.43. Fluorescence polarization (FP) binding assay with BamB-R93A/BpumC/BamD and 
FITC-labeled BamA leader peptide (LP) (a) or FITC-labeled-BpumA-LP (b). Kd values not 
shown are >150 μM. Error bars represent s.d. of at least three independent measurements. Error 
on Kd values are given as the s.e.m. from regression analysis. For binding curves that do not 
reach saturation, Kd values were extrapolated. 
 
To investigate the importance of various precursor peptide regions for substrate binding, 
we constructed a series of C-terminal truncations (Table 3.3). The results indicated that not only 
did the core region not detectably contribute to the overall binding of the peptide, but also that the 
first 24 residues of the precursor peptide were minimally necessary to maintain wild-type binding 
affinity. Next, Ala scanning of BamA was performed to identify individual residues of the leader 
peptide (designated by negative numbers) responsible for interactions with the synthetase. As 
measured by a competition FP assay (Table 3.3), BamA and BpumA had nearly equal IC50 values 
for the synthetase, which were also similar to the Kd of their fluorescent derivatives. Overall, most 
of the single Ala substitutions had only modest effects on the binding of the peptide, although P(-
21)A and L(-18)A had a much more substantial effect, which was borne out by kinetic assays 
(Table 3.3).  
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Table 3.3. Binding and processing of leader peptide mutants. 
Peptide IC50 (μM) in vitro (%)b in vivoc  
BamA-WT 2.8 ± 0.3 100 ± 9.8 +++ 
BamA-T(-26)A 5.4 ± 0.6 108 ± 6.7 +++ 
BamA-Q(-25)A 4.4 ± 0.6 94 ± 9.8 ++ 
BamA-I(-24)A 5.5 ± 0.7 117 ± 5.4 + 
BamA-K(-23)A 5.9 ± 0.6 89 ± 5.1 ++ 
BamA-V(-22)A 4.8 ± 0.3 102 ± 1.0 + 
BamA-P(-21)A >100 54 ± 8.6 –d 
BamA-T(-20)A 5.5 ± 0.7 95 ± 2.7 ++ 
BamA-L(-18)A >100 63 ± 2.9 – 
BamA-I(-17)A 2.7 ± 0.3 99 ± 7.1 ++ 
BamA-S(-15)A 9 ± 2 100 ± 1.3 + 
BamA-V(-14)A 8.2 ± 0.9 110 ± 11.7 + 
BamA-H(-13)A 13 ± 3 106 ± 1.4 + 
BamA-G(-12)* 58 ± 8 n.d. n.d. 
BamA-Q(-9)* 13.5 ± 2.7 n.d. n.d. 
BamA-F(-6)* 6.8 ± 1 n.d. n.d. 
BamA-M(-3)* 2.4 ± 0.3 n.d. n.d. 
BpumA-WT 1.9 ± 0.1 105 ± 5.3 + 
CurA-WT 22 ± 4 108 ± 4 n.d.e 
CurA-N(-26)Sa 24 ± 4 100 ± 9 n.d. 
CurA-P(-23)A >150 7.1 ± 0.7 n.d. 
CurA-P(-22)T 53 ± 9 105 ± 1 n.d. 
CurA-V(-20)A >150 44.4 ± 0.3 n.d. 
aCurA-N(-26)S represents leader sequence of BlinA. bNormalized to wild-type BamA or CurA, respectively. 
cDefined relative to that of the plasmid-borne wild-type BamA: 100–75% (+++), 75–25% (++), 25–5% (+). 
dLimit of detection estimated to be 5% based on requiring that the signal be 3 times greater than baseline noise. 
en.d., not determined. 
To ensure that these observations were not in vitro artifacts, a previously described E. coli 
heterologous production system was used to assess processing of the BamA variants in vivo (41). 
In this assay, the production of the mature PZN-I7V variant (a known, well-tolerated core peptide 
substitution) from a plasmid-borne copy of the bamA gene containing a leader peptide substitution 
was compared to the production of the wild-type PZN from a fosmid-borne copy, as measured by 
MALDI-TOF-MS (Table 3.3; Figure 3.44). Overall, these in vivo results corroborated those 
obtained in vitro, indicating that two residues, Pro(-21) and Leu(-18), are primarily responsible for 
the peptide’s interaction with the synthetase in what appears to be a -21PXXL-18 recognition motif. 
Interestingly, in other precursor peptides within the PZN family, this Pro is highly conserved, 
whereas the Leu is less so (Figure 3.2B). Furthermore, these results indicate that the conserved 
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residues at the C-terminus of the leader region (FEPXAA), which are likely part of a conserved 
protease recognition motif, contribute only modestly to the overall peptide affinity. 
 
 
Figure 3.44. Representative MALDI-TOF-MS spectra for in vivo production of BamA leader 
peptide mutants, demonstrating how the ratio between m/z 1322 and m/z 1336 was used to 
determine the acceptance of the indicated leader peptide substitution by the synthetase. 
 
Select CurA peptides with substitutions at the equivalent positions in the leader peptide 
were also assayed for binding and processing by the Cur synthetase in vitro (Table 3.3). In line 
with the conserved nature of the position (Figure 3.2B), Pro(-23) in CurA was crucial for binding, 
but not the neighboring non-conserved Pro(-22). Unsurprisingly, the binding of CurA-N(-26)S, 
whose leader peptide is identical to that of BlinA (12), was virtually no different from that of wild-
type CurA. Taken together with the leader peptide binding experiments using the Bam synthetase, 
these results identify the critical residues that mediate recognition by the PZN heterocycle 
synthetases.  
Beyond being necessary for leader peptide binding, we next sought to determine if these 
key residues were sufficient for binding by assaying a variety of precursor peptides from the PZN 
family with non-cognate synthetases. In the FP assay, the Bam synthetase exhibited weakened 
binding to CmsA compared to BamA or BpumA and none to BlinA, while CurC (sufficient for 
precursor peptide binding) exhibited binding only to the highly similar BlinA and CmsC only to 
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CmsA (Table 3.4). These observations were borne out by a MALDI-TOF-MS processing assay, 
which demonstrated that the Bam synthetase was capable of installing ten heterocycles on either 
BamA or BpumA, but only six on the less-similar CmsA, and none on either BlinA or CurA 
(Figure 3.45). Likewise, the Cur synthetase installed heterocycles only on CurA or BlinA, and not 
on BamA, BpumA, or CmsA (Figure 3.45). As the C-protein provides the main contact for binding 
to the leader peptide, it was feasible that substituting the C-protein in these synthetase complexes 
could enable binding, and thus processing, of non-cognate precursor peptides. However, these 
“hybrid synthetases” were not active, likely due in part to the inability to form productive 
complexes between a C-protein and its non-cognate partners (Figure 3.46). Additional attempts to 
confer binding of non-cognate substrates through simply swapping the RRE domains of these C-
proteins were unsuccessful (data not shown). 
 
Table 3.4. Dissociation constants (Kd, µM) measured by FP assay between various leader 
peptides and C-proteins. Error is the standard error of the mean. 
 
  BamA-LPa BpumA-LP CmsA-LP CurA-LP 
BpumC ~100b ~100 >150 >150 
CmsC >150 >150 14 ± 3 >150 
CurC >150 >150 >150 7 ± 1 
BlinC >150 >150 >150 13 ± 1 
PznBCDb 1.0 ± 0.1 0.8 ± 0.1 ~75 ~150 
aLP, fluorescein-tagged leader peptide; see Table 3.2  
b~, extrapolated 
cPznBCD = BamB-R93A, BpumC, BamD 
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Figure 3.45. Evolutionarily divergent PZN peptides are not modified by the Bam synthetase. (a) 
The maximum number of heterocycles installed on a given peptide correlates with the sequence 
identity (b) of its cognate C-protein to the C-protein employed for in vitro enzymatic reactions 
(BpumC or CurC). (c) MALDI-TOF-MS spectra from which the results in panel (a) were derived. 
Numbers above peaks indicate the number of heterocycles installed. #, unrelated peaks. 
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Figure 3.46. BpumC, CmsC, BlinC, and CurC were each tested with BamB/D and with CurB/D 
to see if an alternative C-protein would be capable of expanding the substrate scope of the 
synthetase. (a) Most non-cognate C-proteins could not form a complex with the other partner 
proteins as assessed by size exclusion chromatography. Dashed lines indicate the elution time of 
the complex; * indicates void, including protein aggregate. (b) Proteins which could not form a 
trimeric heterocycle synthetase resulted in little or no processing of alternative peptide 
substrates. Numbers above peaks indicate the number of heterocycles installed. 
 
These non-cognate experiments demonstrated that relatively few conserved leader peptide 
residues [i.e. Pro(-21) in BamA] are necessary but not sufficient for modification. These results 
also suggest that synthetase recognition is encoded across the length of the peptide, even though 
affinity is primarily localized to a few “hot spots” (50). Even though most single substitutions had 
a minor effect, multiple residue differences in the leader peptide (e.g. between BamA and CurA) 
clearly prevented non-cognate processing, as the Bam synthetase was able to fully process non-
cognate core peptides when its cognate leader was present (Figure 3.13E). Interestingly, CmsA 
does not contain the important Leu(-18) relative to BamA but can still be partially processed by 
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the Bam synthetase, likely due to the overall greater similarity between leader peptides for CmsA 
and BamA, compared to BamA and CurA (Figure 3.45). Overall, the ability of these various 
synthetases to process non-cognate substrates appears to correlate with evolutionary distance.  
 
3.5 Production of novel PZN analogs 
 Having investigated the substrate tolerance of the Bam synthetase, it was of interest 
whether these variant precursor peptides could be used to generate mature PZN analogs. Following 
heterocyclization, the next biosynthetic step is removal of the leader peptide, which is putatively 
performed by the protease encoded in the BGC (bamE, Figure 3.1B) (15, 16). As a predicted type 
II CaaX protease, BamE is thought to be an integral membrane protein (51); thus, we treated BamA 
that had been heterocyclized in vitro with a crude preparation of B. velezensis membranes. 
Unfortunately, no proteolytic product was observed (data not shown). To facilitate the in vitro 
production of PZN analogs, we introduced a cleavage site for a soluble, commercial protease, as 
has been previously successful for the production of other RiPPs (52-55). Using site-directed 
mutagenesis, Ala(-1) was changed to one of several other residues: Lys (trypsin), Phe 
(chymotrypsin), Glu (endoproteinase GluC), and Met (cyanogen bromide, CNBr). A(-1)M was the 
best-tolerated substitution in combination with enzymatic heterocyclization, as determined by 
MALDI-TOF-MS (Figure 3.47A). Subsequent treatment of the heterocycle-containing peptide 
with CNBr in the presence of formic acid (56, 57) yielded a species whose mass was consistent 
with that of hydrolyzed desmethylPZN, indicating cleavage of the leader peptide (Figure 3.47B). 
Unfortunately, the acidic conditions necessary for the CNBr reaction also hydrolyzed the 
methyloxazoline normally present in PZN (Figure 3.1A). 
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Figure 3.47. (a) Bam synthetase processing of Ala(-1) mutants for determining the best 
engineered leader peptide cleavage site. (b) CNBr cleavage of synthetase-treated BamA-A(-1)M 
removes the leader peptide to yield the 9-azole and 8-azole analogs of desmethylPZN (dmPZN). 
*, leader peptide cleavage site; red, thiazole; blue, (methyl)oxazole. 
 
 The A(-1)M substitution was introduced into select BamA variants, in addition to CurA, to 
enable chemical removal of the leader peptide. Following CNBr treatment, these peptides were 
then subjected to N-terminal dimethylation by the SAM-dependent methyltransferase involved in 
PZN biosynthesis (BamL), whose activity had previously been reconstituted in vitro (16-18). 
BamL dimethylated each of these PZN variants, including the CurA variant, as determined by 
MALDI-TOF-MS (Figure 3.48). Though the methyltransferase has significant substrate selectivity 
owing to its narrow substrate-binding channel (17), all of the PZN variants used in these reactions 
contained both the N-terminal Arg and at least one azole, which is minimally necessary for robust 
methyltransferase activity. Although enzymatic dimethylation was successful, more robust 
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modification was achieved by reductive alkylation with formaldehyde and borane-pyridine (Figure 
3.49) (58). Regardless of the method of dimethylation, this sequence of reactions enabled the 
production of a new collection of PZN variants beyond what was previously achievable in vivo 
(41). 
 
 
Figure 3.48. Enzymatic dimethylation by BamL of heterocyclized BamA after leader peptide 
removal, as assessed by MALDI-TOF-MS. (a) BamA; (b) BamA-S12A; (c) BamA-T13P; (d) 
BamA-F14*; (e) CurA; (f) BamA-I8*. Red, desmethyl species; blue, dimethylated species. Note 
different X-axis scale in (f). 
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Figure 3.49. Chemical dimethylation of heterocyclized BamA after leader peptide removal, as 
assessed by MALDI-TOF-MS. (a) BamA; (b) BamA-C4Δ; (c) BamA-S11Δ; (d) BamA-S12A; 
(e) BamA-T13A; (f) BamA-T13P; (g) BamA-S12A/S13C; (h) BamA-F14*; (i) CurA; (j) BamA-
I8*. Red, desmethyl species; blue, dimethylated species. Note different X-axis scale in (j). 
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 Through the system of treating CurA-A(-1)M with the Cur synthetase, CNBr-based 
removal of the leader peptide, and reductive alkylation of the N-terminus, we obtained sufficient 
quantities of the PZN-like natural product from C. urealyticum to enable FT-ICR-MS/MS analysis 
of the purified compound, which corroborated the proposed structure containing ten azoles and N-
terminal dimethylation (Figures 3.50A, 3.51). 1H NMR also established the presence of sharp 
singlets consistent with azole formation (Figure 3.52). Similar to the name “plantazolicin,” we 
have named this anticipated natural product “coryneazolicin” (CZN). Our production of CZN 
demonstrates the use of in vitro biosynthesis to generate a predicted natural compound whose 
production has not been observed from the native producer. To establish if CZN is naturally 
produced will require further investigation. 
 
 
Figure 3.50. Proposed structures for the novel natural products coryneazolicin (CZN) (a) and 
badiazolicin (BZN) (b), as supported by FT-ICR-MS/MS (see also Figures 3.51 and 3.54). 
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Figure 3.51. CID-based fragmentation of the [M+H]+ species of CZN. 
 
 
Figure 3.52. 1H NMR spectral expansion indicating presence of azole moeities in CZN. The 
singlets correspond to the presence of thiazole (seven) and oxazole (one) C-H groups. 
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 After obtaining CZN, we next turned our attention to recently identified PZN-like BGCs 
from other bacteria (Figure 3.2). Several of these BGCs encode precursor peptides with 
substitutions in the core region compared to BamA, the products of which could aid in further 
determination of the structure-activity relationships of the PZN class of natural products. Although 
the unannotated precursor peptide from Bacillus badius, BadA, lies in a different location relative 
to other genes in the cluster (Figure 3.1B), it only differs from BamA by two residues in the core 
region (Figure 3.1C). Methanolic extracts of B. badius contained an m/z 1300 species consistent 
with the expected mass of the precursor peptide with PZN-like modifications. Furthermore, a less 
intense species was found with m/z 1318, consistent with a PZN-like compound where the 
methyloxazoline moiety was hydrolyzed (Figure 3.53) (3). Purification of “badiazolicin” (BZN) 
enabled FT-ICR-MS/MS analysis, which supported a PZN-like structure containing nine azoles, 
one azoline, and N-terminal dimethylation (Figure 3.50B, 3.54). After quantification by 1H NMR, 
BZN exhibited a minimum inhibitory concentration (MIC) of 2 µg/mL against B. anthracis by 
microbroth dilution assay, but no growth inhibitory activity towards B. subtilis (MIC > 16 µg/mL) 
or methicillin-resistant S. aureus (MIC > 32 µg/mL).  
 
Figure 3.53. MALDI-TOF-MS of methanolic extract from Bacillus badius ATCC 14574, 
indicating the presence of BZN. The core peptide from the PZN gene cluster in this strain is 
shown with the same color coding as in Figure 3.1C to indicate post-translational modifications. 
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Figure 3.54. CID-based fragmentation of the [M+H]+ species (a) and [M+2H]2+ species (b) of 
BZN. (c) Fragmentation of the [M+H]+ species in (a). (d) Structure of BZN based on fragmentation 
in (c). 
 
 In conclusion, we have demonstrated the in vitro reconstitution of two heterocycle 
synthetases involved in the biosynthesis of PZN by B. velezensis and CZN by C. urealyticum. 
Overall, the synthetases in vitro afforded a greater degree of biosynthetic insight than previous 
work with PZN biosynthesis in cells, enabling characterization of synthetase complex assembly 
and substrate binding properties. Using the Bam heterocycle synthetase, we have explored 
substrate tolerance in the PZN precursor peptide and proposed that cyclodehydration occurs in an 
N-terminal to C-terminal direction. These synthetases were then used to achieve the total in vitro 
biosynthesis of a number of PZN variants, culminating in the isolation of two novel natural 
products, CZN and BZN. 
 
3.6 Methods 
3.6.1 General methods 
All general molecular biology reagents were purchased from Fisher Scientific or Gold 
Biotechnology. Chemicals were purchased from Sigma-Aldrich. DNA sequencing was performed 
by the Roy J. Carver Biotechnology Center (UIUC). Restriction enzymes and dNTPs were 
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purchased from New England Biolabs (NEB), and PfuTurbo DNA polymerase was purchased 
from Agilent. Oligonucleotide primers were synthesized by Integrated DNA Technologies (IDT). 
Synthetic genes and fluorescent peptides were synthesized by GenScript. 
 
3.6.2 Cloning, protein expression, and protein purification 
The coding sequences for BamA, BamB, BamD, BpumA, BpumC, CurB, and CmsA were 
PCR amplified from genomic DNA of their respective producing organisms (Bacillus 
methylotrophicus FZB42, Bacillus pumilus ATCC 7061, Corynebacterium urealyticum DSM 
7109, or Clavibacter michiganensis subsp. sepedonicus) with Taq or Pfu polymerase and the 
primers listed in Table 3.5. PCR amplicons were then digested and ligated using standard methods 
into a modified pET28b vector containing the sequence of maltose-binding protein (MBP) and the 
cleavage site for tobacco etch virus (TEV) protease (41, 43). The coding sequence for BamCopt 
(vide infra) was synthesized by GenScript and likewise subcloned into the modified pET28b 
vector. Equivalent expression vectors for CurA, CurC, CurD, BamA-CmsA, BamA-BlinA, and 
BamA-CurA have been previously reported (12, 41).  
All site-directed mutagenesis was performed on the pertinent construct using the 
Quikchange™ method with Pfu Turbo polymerase (Agilent) and primer pairs listed in Tables 3.6 
and 3.7. DNA sequencing used a custom MBP forward primer (5’-GAGGAAGAG 
TTGGCGAAAGATCCACGTA-3’) and/or T7 reverse primer. 
 Expression and purification of MBP-tagged proteins from the pET28 construct were 
performed as previously described using amylose affinity resin (43). Select BamA variant 
precursor peptides were expressed and purified from previously described pBAD24 constructs 
(41) using the same protocol as for pET28 constructs with the exception that IPTG induction was 
performed for 2 h at 30 °C. 
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Table 3.5. Oligonucleotide primers used for cloning in this study. 
BamA BamHI fw AAAAGGATCCATGGAGGAGGTAACAATTATGACTCAAATTAAAGTGC 
BamA NotI rv AAAAGCGGCCGCTTAAAACGTAGATGAACTAGAGATGATTGTGGTACAGG 
BamB BamHI fw AAAAGGATCCATGAAAGAGATTGAAAGGCATGCCACTAATTTGG 
BamB NotI rv AAAAGCGGCCGCTCATGTTCCTGCAACTAAAGTATATATAGGGGCATC 
BamB R93A fw GACAAGTGTATCATTAGATGAAGTTATTCAAAATGCGAGAAGTATCGAACAGTT 
BamB R93A rv AACTGTTCGATACTTCTCGCATTTTGAATAACTTCATCTAATGATACACTTGTC 
BamB Y206A fw GCTAGCTTTTGGAGGTCAAGGTTTAAAGCTGGCCATCGTTCAT 
BamB Y206A rv ATGAACGATGGCCAGCTTTAAACCTTGACCTCCAAAAGCTAGC 
BamC(opt) BamHI fw AAAGGATCCATGAGCCAACAAACGCATAG 
BamC(opt) NotI rv AAAGCGGCCGCTTATTTAGCCACTTCGCCG 
BamD BamHI fw AAAAGGATCCATGGTGAGTAAATGGACGACATTAGAAGATTCATGG 
BamD NotI rv AAAAGCGGCCGCTTATGGGAATGGATGAGGTACTGGATTAAGTGTTTC 
BpumA BamHI fw AAAAGGATCCATGACTAAAATTACAATTCCAACTGCTTTG 
BpumA NotI rv AATTGCGGCCGCTTAGAAAGTTGAAGAACTTGAGATGATTG 
BpumC BamHI fw AAAAGGATCCATGTTTGTTAAAGAACAAGAAAGCACG  
BpumC NotI rv AAAAGCGGCCGCTTAATTTTTCACCTCACCATGAAACC 
CurB BamHI fw AAAGGATCCATGTCATCCGCAGCCGAAGC 
CurB NotI rv AAAGCGGCCGCTCATGTCTCAGATCCTAAGAGCACCAC  
CmsA BamHI fw AAAAGGATCCATGATCACAACCACCGCTC 
CmsA NotI rv AAAAGCGGCCGCTCAACCCCAGGTGCAC 
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Table 3.6. Oligonucleotide primers used for mutagenesis of leader peptide residues in this study. 
BamA T(-26)A fw ATGGAGGAGGTAACAATTATGGCTCAAATTAAAGTGCCAACTG 
BamA T(-26)A rv CAGTTGGCACTTTAATTTGAGCCATAATTGTTACCTCCTCCAT 
BamA Q(-25)A fw CAATTATGACTGCAATTAAAGTGCCAACTGCTCTTATTGCA 
BamA Q(-25)A rv GGCACTTTAATTGCAGTCATAATTGTTACCTCCTCCATGGA 
BamA I(-24)A fw GAGGAGGTAACAATTATGACTCAAGCTAAAGTGCCAACTGCTCTTATTGC 
BamA I(-24)A rv GCAATAAGAGCAGTTGGCACTTTAGCTTGAGTCATAATTGTTACCTCCTC 
BamA K(-23)A fw TGACTCAAATTGCAGTGCCAACTGCTCTTATTGCAAGTGTA 
BamA K(-23)A rv GCAGTTGGCACTGCAATTTGAGTCATAATTGTTACCTCCTC 
BamA V(-22)A fw CTCAAATTAAAGCGCCAACTGCTCTTATTGCAAGTGTACAC 
BamA V(-22)A rv AGAGCAGTTGGCGCTTTAATTTGAGTCATAATTGTTACCTC 
BamA P(-21)A fw CAATTATGACTCAAATTAAAGTGGCAACTGCTCTTATTGCAAGTGTA 
BamA P(-21)A rv TACACTTGCAATAAGAGCAGTTGCCACTTTAATTTGAGTCATAATTG 
BamA L(-18)A fw TGCCAACTGCTGCTATTGCAAGTGTACACGGAGAAGGTCAA 
BamA L(-18)A rv ACACTTGCAATAGCAGCAGTTGGCACTTTAATTTGAGTCAT 
BamA I(-17)A fw CAACTGCTCTTGCTGCAAGTGTACACGGAGAAGGTCAACAT 
BamA I(-17)A rv TGTACACTTGCAGCAAGAGCAGTTGGCACTTTAATTTGAGT 
BamA S(-15)A fw CTCTTATTGCAGCTGTACACGGAGAAGGTCAACATTTATTC 
BamA S(-15)A rv TCTCCGTGTACAGCTGCAATAAGAGCAGTTGGCACTTTAAT 
BamA V(-14)A fw TTATTGCAAGTGCACACGGAGAAGGTCAACATTTATTCGAG 
BamA V(-14)A rv CCTTCTCCGTGTGCACTTGCAATAAGAGCAGTTGGCACTTT 
BamA H(-13)A fw TTGCAAGTGTAGCCGGAGAAGGTCAACATTTATTCGAGCCA 
BamA H(-13)A rv TGACCTTCTCCGGCTACACTTGCAATAAGAGCAGTTGGCAC 
BamA G(-12)A fw TCTTATTGCAAGTGTACACGCAGAAGGTCAACATTTATTCG 
BamA G(-12)A rv CGAATAAATGTTGACCTTCTGCGTGTACACTTGCAATAAGA 
BamA E(-11)A fw ATTGCAAGTGTACACGGAGCAGGTCAACATTTATTCGAG 
BamA E(-11)A rv CTCGAATAAATGTTGACCTGCTCCGTGTACACTTGCAAT 
BamA H(-8)A fw TGTACACGGAGAAGGTCAAGCTTTATTCGAGCCAATGGCT 
BamA H(-8)A rv AGCCATTGGCTCGAATAAAGCTTGACCTTCTCCGTGTACA 
BamA F(-6)A fw TGTACACGGAGAAGGTCAACATTTAGCCGAGCCAATGGCT 
BamA F(-6)A rv AGCCATTGGCTCGGCTAAATGTTGACCTTCTCCGTGTACA 
BamA E(-5)A fw AAGGTCAACATTTATTCGCGCCAATGGCTGCACGC 
BamA E(-5)A rv GCGTGCAGCCATTGGCGCGAATAAATGTTGACCTT 
BamA P(-4)A fw GGTCAACATTTATTCGAGGCAATGGCTGCACGCTG 
BamA P(-4)A rv CAGCGTGCAGCCATTGCCTCGAATAAATGTTGACC 
BamA G(-12)stop fw AAGTGTACACTGAGAAGGTCAACATTTATTCGAGCCA 
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Table 3.6. (cont.)  
BamA G(-12)stop rv GACCTTCTCAGTGTACACTTGCAATAAGAGCAGTTG  
BamA Q(-9)stop fw CGGAGAAGGTTAACATTTATTCGAGCCAATGGCTG 
BamA Q(-9)stop rv CTCGAATAAATGTTAACCTTCTCCGTGTACACTTGCAATAAG  
BamA F(-6)stop fw CAACATTTATAGGAGCCAATGGCTGCACGCTGTAC 
BamA F(-6)stop rv CCATTGGCTCCTATAAATGTTGACCTTCTCCGTGTAC 
BamA M(-3)stop fw ATTCGAGCCATAGGCTGCACGCTGTACCTGTAC  
BamA M(-3)stop rv GCGTGCAGCCTATGGCTCGAATAAATGTTGACC  
BamA A(-1)E fw AGCCAATGGCTGAACGCTGTACCTGTACCACAATCATCTCTAG 
BamA A(-1)E rv CAGGTACAGCGTTCAGCCATTGGCTCGAATAAATGTTGACC 
BamA A(-1)F fw AGCCAATGGCTTTCCGCTGTACCTGTACCACAATCATCTCTAG 
BamA A(-1)F rv CAGGTACAGCGGAAAGCCATTGGCTCGAATAAATGTTGACC 
BamA A(-1)K fw GCCAATGGCTAAACGCTGTACCTGTACCACAATCATCTCTAG 
BamA A(-1)K rv CAGGTACAGCGTTTAGCCATTGGCTCGAATAAATGTTGACC 
BamA A(-1)M fw AGCCAATGGCTATGCGCTGTACCTGTACCACAATCATCTCTAG 
BamA A(-1)M rv CAGGTACAGCGCATAGCCATTGGCTCGAATAAATGTTGACC 
BamA A(-1)M/C4Δ fw GCCAATGGCTATGCGCTGTACCACCACAATCATCTCTAGT 
BamA A(-1)M/C4Δ rv GTGGTACAGCGCATAGCCATTGGCTCGAATAAATGTTGACC 
BamA A(-1)M/I8* fw GTACCACAATCTAGTCTAGTTCATCTACGTTTTAAGCGGCC 
BamA A(-1)M/I8* rv GATGAACTAGACTAGATTGTGGTACAGGTACAGCGCATAGC 
CurA N(-26)S fw CCACACTAATCTCCAAGCTGCCTCCCGCAGTTTCAACTGAT 
CurA N(-26)S rv GGAGGCAGCTTGGAGATTAGTGTGGACATGGATCCGGATTG 
CurA P(-23)A fw TCAACAAGCTGGCTCCCGCAGTTTCAACTGATTCTTCAAAG 
CurA P(-23)A rv GAAACTGCGGGAGCCAGCTTGTTGATTAGTGTGGACATGGA 
CurA P(-22)T fw ACAAGCTGCCTACCGCAGTTTCAACTGATTCTTCAAAGATT 
CurA P(-22)T rv GTTGAAACTGCGGTAGGCAGCTTGTTGATTAGTGTGGACAT 
CurA V(-20)A fw TGCCTCCCGCAGCTTCAACTGATTCTTCAAAGATTGTTTCC 
CurA V(-20)A rv GAATCAGTTGAAGCTGCGGGAGGCAGCTTGTTGATTAGTGT 
CurA A(-1)M fw AGCCTACCGCTATGCGTTGCTCCTGCACCACAATCCCGTGC 
CurA A(-1)M rv CAGGAGCAACGCATAGCGGTAGGCTCGAATGCCTGAACTTC 
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Table 3.7. Oligonucleotide primers used for mutagenesis of core peptide residues in this study. 
BamA R1D fw CAATGGCTGCAGACTGTACCTGTACCACAATCATCTCTAGT 
BamA R1D rv GTACAGGTACAGTCTGCAGCCATTGGCTCGAATAAATGTTG 
BamA R1F fw CAATGGCTGCATTCTGTACCTGTACCACAATCATCTCTAGT 
BamA R1F rv GTACAGGTACAGAATGCAGCCATTGGCTCGAATAAATGTTG 
BamA R1G fw CAATGGCTGCAGGCTGTACCTGTACCACAATCATCTCTAGT 
BamA R1G rv GTACAGGTACAGCCTGCAGCCATTGGCTCGAATAAATGTTG 
BamA R1I fw CAATGGCTGCAATCTGTACCTGTACCACAATCATCTCTAGT 
BamA R1I rv GTACAGGTACAGATTGCAGCCATTGGCTCGAATAAATGTTG 
BamA R1K fw CAATGGCTGCAAAATGTACCTGTACCACAATCATCTCTAGT 
BamA R1K rv GTACAGGTACATTTTGCAGCCATTGGCTCGAATAAATGTTG 
BamA R1S fw CAATGGCTGCAAGCTGTACCTGTACCACAATCATCTCTAGT 
BamA R1S rv GTACAGGTACAGCTTGCAGCCATTGGCTCGAATAAATGTTG 
BamA T3A fw CTGCACGCTGTGCCTGTACCACAATCATCTCTAGTTCATCT 
BamA T3A rv ATTGTGGTACAGGCACAGCGTGCAGCCATTGGCTCGAATAA 
BamA T5A fw GCTGTACCTGTGCCACAATCATCTCTAGTTCATCTACGTTT 
BamA T5A rv GAGATGATTGTGGCACAGGTACAGCGTGCAGCCATTGGCTC 
BamA T5A/T6C fw GTACCTGTGCCTGTATCATCTCTAGTTCATCTACGTTTTAA 
BamA T5A/T6C rv CTAGAGATGATACAGGCACAGGTACAGCGTGCAGCCATTGG 
BamA T6A/S9C fw CCGCAATCATCTGTAGTTCATCTACGTTTTAAGCGGCCGCA 
BamA T6A/S9C rv GTAGATGAACTACAGATGATTGCGGTACAGGTACAGCGTGC 
BamA I8P fw GTACCACAATCCCGTCTAGTTCATCTACGTTTTAAGCGGCC 
BamA I8P rv GATGAACTAGACGGGATTGTGTACAGGTACAGCGTGCAGC 
BamA S9A/S11A fw GCTGTACCTGTACCACAATCATCGCTAGTGCATCTACGTTTTAA 
BamA S9A/S11A rv TGCGGCCGCTTAAAACGTAGATGCACTAGCGATGATTGTGGTACAGGTACAGC 
BamA S11A fw TCATCTCTAGTGCATCTACGTTTTAAGCGGCCGCACTCGAG 
BamA S11A rv TAAAACGTAGATGCACTAGAGATGATTGTGGTACAGGTACA 
BamA S12A fw TCTCTAGTTCAGCTACGTTTTAAGCGGCCGCACTCGAGCAC 
BamA S12A rv GCTTAAAACGTAGCTGAACTAGAGATGATTGTGGTACAGG 
BamA S12A/T13C fw CTAGTTCAGCTTGCTTTTAAGCGGCCGCACTCGAGCACCAC 
BamA S12A/T13C rv GCCGCTTAAAAGCAAGCTGAACTAGAGATGATTGTGGTACA 
BamA T13A fw CTAGTTCATCTGCGTTTTAAGCGGCCGCACTCGAGCACCAC 
BamA T13A rv GCCGCTTAAAACGCAGATGAACTAGAGATGATTGTGGTACA 
BamA T13P fw CTAGTTCATCTCCGTTTTAAGCGGCCGCACTCGAGCACCAC 
BamA T13P rv GCCGCTTAAAACGGAGATGAACTAGAGATGATTGTGGTACA 
BamA ^8A fw CTGTACCTGTACCACAATCGCGATCTCTAGTTCATCTACGT 
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Table 3.7. (cont.)  
BamA ^8A rv ACGTAGATGAACTAGAGATCGCGATTGTGGTACAGGTACAG 
BamA ^12A fw GTACCTGTACCACAATCATCTCTAGTTCAGCGTCTACGTTTTAAAAGC 
BamA ^12A rv GCTTTTAAAACGTAGACGCTGAACTAGAGATGATTGTGGTACAGGTAC 
BamA C4Δ fw GGCTGCACGCTGTACCACCACAATCATCTCTA 
BamA C4Δ rv TAGAGATGATTGTGGTGGTACAGCGTGCAGCC 
BamA S11Δ fw CAATCATCTCTAGTTCTACGTTTTAAGCGGCCGCACTCGAG 
BamA S11Δ rv GCTTAAAACGTAGAACTAGAGATGATTGTGGTACAGGTACA 
BamA F14* fw GTTCATCTACGTAATAAGCGGCCGCACTCGAGCACCACCAC 
BamA F14* rv GCGGCCGCTTATTACGTAGATGAACTAGAGATGATTGTGGT 
 
3.6.3 Size exclusion chromatography 
Formation of protein complexes between the various PZN biosynthetic proteins was 
assessed using size exclusion chromatography. 25 µM of each MBP-tagged protein was prepared 
individually or in combinations as indicated with storage buffer and allowed to incubate at room 
temperature for at least 15 minutes. Following incubation, 5 µL of each sample was injected onto 
an analytical Yarra SEC-3000 column (300 × 4.6 mm, Phenomenex) pre-equilibrated with storage 
buffer and was monitored at 280 nm using a 1200 HPLC (Agilent) with a flow rate of 0.6 mL/min. 
Traces were normalized to the highest absorbance value in each sample. 
 
3.6.4 In vitro synthetase assays 
Heterocycle synthetase reactions to assess substrate tolerance or necessity of individual 
components contained 100 µM of MBP-tagged precursor peptide, 10 µM of each of the pertinent 
MBP-tagged synthetase enzymes, and 40 µg/mL TEV protease in synthetase buffer [50 mM Tris 
(pH 7.5), 125 mM NaCl, 20 mM MgCl2, 10 mM dithiotreitol, and 3 mM ATP] (9). Reactions were 
carried out in 100 µL volume for 18 h at 22 °C, at which point they were quenched by addition of 
100 µL MeCN to precipitate the large proteins. After centrifugation for 5 min at 16,000 x g, the 
supernatant was either dried by speedvac or diluted to 12.5% MeCN by addition of water to 
facilitate desalting before analysis by mass spectrometry. 
 For synthetase reactions where isolation of intermediates was attempted, synthetase 
enzymes were pre-treated with TEV to remove MBP and present at 2 µM in the reaction. Other 
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components were present at the concentrations listed above, and the reaction was quenched by 
addition of 100 µM MeCN at 10 and 30 minutes. 
 
3.6.5 Mass spectrometry 
For MALDI-TOF-MS, peptide samples were desalted by C18 ZipTip according to 
manufacturer instructions and analyzed using a Bruker Daltonics UltrafleXtreme MALDI-
TOF/TOF instrument operating in reflector/positive mode with α-cyano-4-hydroxycinnamic acid 
as the matrix. 
For high-resolution mass spectrometry and MS/MS, desalted peptides were resuspended in 
80% (v/v) MeCN, 1% AcOH and centrifuged at 11000 x g for 5 min prior to analysis by direct 
infusion Fourier transform mass spectrometry (FT-MS). An Advion NanoMate 100 was used to 
directly infuse samples to an LTQ-FTMS/MS (ThermoFisher) operating at 11 T. The MS was 
calibrated weekly, following the manufacturer’s instructions, and tuned daily using Pierce LTQ 
Velos ESI Positive Ion Calibration Solution (ThermoFisher). Spectra were collected with a 
resolution of 100,000. Ions were selected for ion trap fragmentation or FT-MS/MS fragmentation 
based on signal intensity, and spectra were collected using the following parameters: isolation 
width of 5 m/z, normalized collision energy of 35, activation q value 0.4, activation time 30 ms. 
Data analysis was performed using the Qualbrowser application within ThermoFisher Xcalibur v 
2.2. 
 
3.6.6 In vitro kinetics assay 
Peptide processing kinetics were measured using a previously described purine nucleoside 
phosphorylase (PNP)-coupled assay to detect ADP production from ATP hydrolysis (9, 59). 
Because ATP consumption is 1:1 with heterocycle formation, this assay provides a measure of the 
rate of heterocycle formation. In general MBP-BamB, MBP-BpumC, and MBP-BamD were 
pretreated with TEV protease at room temperature to cleave the tag, but for the Cur synthetase 
proteins, TEV treatment was performed at 4 oC because extended incubation at room temperature 
caused protein precipitation. After adding the enzyme cleavage mixture to a cuvette for a final 
concentration of 5 µM BCD, enzymatic reactions were initiated by the addition of a peptide 
substrate mixed with synthetase buffer, 200 µM 7-methyl-6-mercapto-7-methylpurineriboside 
(Berry and Associates), and 0.2 U of PNP at 22 oC. Maximal initial rates were determined by 
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averaging the slope over the first two minutes of the reaction. The rate of processing for leader 
peptide mutants was determined with 30 µM BamA/BpumA or 25 µM for CurA and their 
respective synthetase complexes whereas the BamA-R1X mutants were tested at 100 µM. Kinetic 
parameters for the Bam/Bpum complex were determined using variable substrate concentrations 
and were calculated using the nonlinear Michaelis-Menten fit with OriginPro9.1 (OriginLab). All 
experiments were performed in triplicate. 
 
3.6.7 Fluorescence polarization binding assay 
The interaction between FITC-conjugated precursor peptides and different synthetase 
proteins was measured with a previously employed fluorescence polarization (FP) assay (12). In 
brief, the assay was performed in nonbinding-surface, 384-black-well polystyrene microplates 
(Corning) with serial dilutions of the indicated protein(s) and 25 nM of the indicated fluorescent 
peptide in storage buffer. After 30 minutes of incubation at room temperature, the dilutions were 
measured using a FilterMax F5 multimode microplate reader (Molecular Devices) with λex = 485 
nm and λem = 538 nm. All assays were performed in triplicate and Kd values were determined from 
a non-linear dose-response curve in OriginPro9.1 (OriginLab). Error bars represent standard error 
of the mean. 
To assess the interaction of non-fluorescent peptides with the PZN synthetase, a 
competition FP binding assay was used as previously described (49). MBP-tagged precursor 
peptides were serially diluted and mixed with 25 nM of a fluorescent peptide and synthetase 
component(s). The BamA/BpumA peptides were competed with FITC-BamA-LP to bind to 3 μM 
BamB-R93A, BpumC, and BamD whereas the CurA mutants were competed with FITC-CurA-
LP to bind 25 µM CurC. IC50 values were determined from the 50% inhibition point calculated 
using a dose response curve with Origin Pro 9.1 (OriginLab). 
 
3.6.8 In vivo PZN production from alanine substituted precursor peptides 
A previously designed screen for the production of PZN analogs (41) was repurposed to 
examine how certain positions of the leader contributed to processing of BamA by the native 
PZN biosynthetic machinery in vivo. In the original system, chemically competent E. coli cells 
containing the entire PZN biosynthetic gene cluster (including bamA) on a fosmid were 
transformed with a plasmid bearing a BamA variant. Production of the plasmid-borne variant 
134 
 
could be compared to production of wild-type PZN as an indication of how relatively well-
tolerated the mutant was. To assess the effect of leader mutants, a well-tolerated substitution 
(I7V) was incorporated into the plasmid-borne BamA and subsequently subjected to alanine 
scanning mutagenesis in the leader peptide. The ability of the biosynthetic machinery to tolerate 
the mutant could then be assessed by the relative production of PZN-I7V compared to the wild-
type PZN originating from the fosmid, as determined by MALDI-TOF-MS analysis of 
methanolic extracts from the transformed E. coli cells after culturing these in 10 mL of Luria-
Bertani (LB) media, as previously described (41). 
 
3.6.9 Leader peptide cleavage 
Dried precursor peptide (after synthetase reaction and MeCN precipitation) was 
resuspended in 60% formic acid and 1-2 small crystals of cyanogen bromide (CNBr) were added. 
The reaction was allowed to proceed for 4 h at 22 °C, at which point it was quenched by addition 
of 5 volumes of water and desalted by ZipTip, then dried by speedvac. 
 
3.6.10 Methylation 
Enzymatic dimethylation using BamL was performed using <50 µM peptide (exact 
concentration not known), 10 µM MBP-BamL, 10 µM Pfs, and 3 mM S-adenosylmethionine in 50 
mM Tris (pH 8), for 18 h at 37 °C, as described previously (17). Chemical dimethylation was 
performed using <1 mM peptide (exact concentration not known), 200 mM formaldehyde, and 
300 mM borane-pyridine in 10 mM NH4CO3 with 50% MeOH, for 18 h at 22 °C (58). 
 
3.6.11 Production of CZN 
Synthetase reactions using MBP-tagged CurA, CurB, CurC, and CurD were performed as 
described above, with the exceptions that 250 µM MBP-CurA was used, the buffer contained 6 
mM ATP, and reactions were carried out in replicates of 200 µL each. After precipitation with 
MeCN and centrifugation, the supernatants were dried by speedvac, then resuspended and pooled 
in 60% formic acid (v/v) for CNBr digestion as described above. After the CNBr reaction was 
quenched with water, the solvent was removed by blowing air. The dried reaction mixture was 
then resuspended in water to remove water-soluble components and centrifuged for 10 min at 
16,000 x g, after which the supernatant was removed and the remaining solids resuspended in 
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MeOH to extract CZN. After centrifugation for 10 min at 16,000 x g, the MeOH supernatant 
(containing crude CZN) was removed and used in the chemical methylation reaction as described 
above.  
This crude CZN solution in 50% MeOH (v/v) was reverse phase purified using a Thermo 
BETASIL C18 column (250 mm x 10 mm; pore size: 100 Å; particle size: 5 m) at a flow rate of 
4 mL min-1. A gradient of 40-95% MeOH with 10 mM NH4HCO3 in the aqueous phase over 41 
min was used. The fractions containing CZN (as monitored by A254 and later verified by MALDI-
TOF-MS) were collected into 20 mL borosilicate vials and the solvent was removed in vacuo.  
 
3.6.12 Production of BZN 
Bacillus badius ATCC14574 was grown in Luria-Bertani (LB) broth (10 mL/18mm glass 
culture tube) at 37 ˚C overnight. Sterilized aluminum trays (16-7/16” x 11-5/8” cake pans) 
containing nutrient agar (1 L/tray) were inoculated with 3 mL of overnight culture and incubated 
for 48 h at 37 ˚C. Cells were harvested with a razor blade and Tris-buffered saline (TBS) (160 
mL/tray) and pelleted by centrifugation (4,000 x g, 20 min, 10 ˚C). The supernatant was decanted 
and the pellets were stored at –20 ˚C until extraction. 
Crude BZN was extracted by resuspending the pellets in MeOH (160 mL/tray) through 
vortex agitation, and the resuspended cells were equilibrated for 4 hours at 22 ˚C on a shaking 
platform. The supernatant was retained after centrifugation (4,000 xg, 20 min, 10 ˚C), vacuum 
filtered with Whatman filter paper, and concentrated by rotary evaporation. Lyophilization of the 
extract yielded a yellow solid (200 mg/tray). The crude material was dissolved in 50% MeCN, 
where the sample separated into two layers. Both layers were added to Celite, which was dried by 
rotary evaporation. The dried Celite was packed into a cartridge for solid loading of BZN onto a 
RediSep Rf 130g C18 column (Teledyne Isco) for purification by MPLC using a Combiflash 
system (30-95% MeCN/10 mM aqueous NH4HCO3 over 16 column volumes). The fractions 
containing BZN were pooled, concentrated by rotary evaporation, and lyophilized to dryness. BZN 
was then reverse phase purified using the same method as for CZN, except that a gradient of 85-
95% MeOH with 10mM aqueous NH4HCO3 over 20 min was used. The fractions containing BZN 
were collected in 20 mL borosilicate vials and the solvent removed in vacuo.  
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3.6.13 NMR 
Samples were dissolved in 600 µL of CD3OD (99.95 atom % D, Cambridge Isotope Labs). 
NMR spectra were obtained with an Agilent VNMRS 750 MHz narrow bore magnet spectrometer 
equipped with a 5 mm triple resonance (1H-13C-15N) triaxial gradient probe and pulse-shaping 
capabilities. Samples were held at 298 K during acquisition. Standard Varian pulse sequences were 
used; a relaxation delay (d1) of 28 s was used during acquisition for quantitative NMR (qNMR), 
and 90° pulse widths were calibrated and used (8.50 µs for CZN acquisition; 8.75 µs for BZN 
acquisition). 320 transients were recorded for BZN; 2048 transients were recorded for CZN. 
Apodization (0.4 Hz line-broadening), phase correction, integration, integral normalization, and 
automated baseline correction were applied prior to qNMR processing. Spectra were recorded with 
VNMRJ 4.2 software, and data was processed using MestReNova 8.1.1. Chemical shifts (δ, ppm) 
were referenced internally to the solvent peak (methanol). For quantitative NMR, the probe was 
calibrated using the qEstimate tool VNMRJ on the standard 31P sample (48.5 mM 
triphenylphosphate in CDCl3, Varian part #: 00-968120-97).  
 
3.6.14 Antibacterial activity assays 
The concentration of BZN was calculated by qNMR, which has been used for accurate 
quantification of microgram quantities of natural products (60). The native qNMR functionality 
within VNMRJ 4.2 was used to quantify BZN based on the average integration of its azole peaks, 
which occur as distinct singlets in the aromatic region. Determination of MIC values for BZN was 
performed as described previously (19). 
 
3.7 Sequences 
3.7.1 Coding sequence of BamCopt 
ATGAGCCAACAAACGCATAGCATTCAAACGGTCGTCCGCTTCAAACTGTCCCCGCACATCACCCTGGGCGAACTGGAA
GGTAGCCTGCTGTCATTTAAAGCACAGTCGATTACCAAAGTGGATGGCGAAGGTATTGTTGAATTTTTCGAAGCTATC
AGTGAATATCTGGTGTGCGAAAATGGCGTTTCCATCGAAGAACTGCATCAGCGCTTCAACCTGGAAAAAGATCAACTG
CGTAATGTCTTTGACTTCCTGGTGACCAACGGTCTGTGTATTCAGAGCACCTCTAATTTTGATATGACGGCGTTCCTG
GCATACGAACGTGCGGGCGGTCAGGTCGAAGTGAACCAAATTCTGCATCGTCTGAAAACGAGCATCGTGGAAGTGGTT
GCACACGGCGAAAACAATCTGGCTATTAACCTGACCAATTCTCTGCAGGAAACGGGCCTGAATATCGATTGGAAAGAA
AAACCGGACAACGGTAAACCGAGCATTCGCATCGCCGTTGCGGCCTCTCATCTGGACCCGCTGCTGGAACAGGTCAAC
GATCAAAGCCTGGAAGACCACGTTCCGTGGCTGTGCGTCATTCCGTATGACGGCCAGACCGCGTGGGTGGGTCCGTTT
TTCATCCCGCATAAATCAGCGTGCCTGCACTGTTACAACCTGCGCAAAAGTGCCAATTTTTCCGATGAAGTTTTCCGT
TCCGAACTGATGAAAGTGAAACCGGTTAATGCAGCTAAACAGCCGGTGTATAACCAACCGGTCCATCTGGTGCAGGCA
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GGCATTGCTAACAATCTGGTTACCGAATGGATCACGCTGCGTGATTACGCACCGTCAGCAGTCCCGGGCGGTTTTATC
ACGGTGAATCTGGATGACCGTGGCGTGAGCGTGGATAACCACCGTGTTTATCGCGTCCCGCGTTGCCAAAAATGTTCT
CCGGCTGCTGACACGGGTTTTCCGCAAGTTTGGTATCACGGCGAAGTGGCTAAATAA 
 
3.7.2 Translation of BamCopt  
330 amino acids, identical to WP_012117036.1 
MSQQTHSIQTVVRFKLSPHITLGELEGSLLSFKAQSITKVDGEGIVEFFEAISEYLVCENGVSIEELHQRFNLEKDQL
RNVFDFLVTNGLCIQSTSNFDMTAFLAYERAGGQVEVNQILHRLKTSIVEVVAHGENNLAINLTNSLQETGLNIDWKE
KPDNGKPSIRIAVAASHLDPLLEQVNDQSLEDHVPWLCVIPYDGQTAWVGPFFIPHKSACLHCYNLRKSANFSDEVFR
SELMKVKPVNAAKQPVYNQPVHLVQAGIANNLVTEWITLRDYAPSAVPGGFITVNLDDRGVSVDNHRVYRVPRCQKCS
PAADTGFPQVWYHGEVAK 
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APPENDIX A: 
HIV protease inhibitors block streptolysin S production1 
A.1 Introduction 
The ribosomally synthesized and post-translationally modified peptides (RiPPs) comprise 
a rapidly expanding class of natural products that includes a wide variety of structural 
modifications.2 These modifications impart RiPPs with diverse activities, giving rise to a range of 
products from antibacterials3-5 to anticancer agents.6 The installation of azole and/or azoline 
heterocycles is one such modification common to many RiPPs, forming a sub-class of natural 
products called the thiazole/oxazole-modified microcins (TOMMs).7 The azoles are 
biosynthesized by the cyclodehydration and subsequent dehydrogenation of cysteine, serine, and 
threonine residues to form thiazole and (methyl)oxazole rings on the C-terminal portion, or “core”, 
of a ribosomally produced precursor peptide.7 The azole-containing peptides will often undergo 
further processing, including the proteolytic removal of the N-terminal “leader” portion of the 
peptide and export of the mature product.8 Although recent discoveries have shed light on the 
mechanism of azole formation,9-11 the proteolytic processing step of most TOMMs has yet to be 
investigated. 
Streptolysin S (SLS), a key virulence factor of Streptococcus pyogenes, is one such TOMM 
whose biosynthesis is incompletely understood.12 S. pyogenes is the causative agent of diseases 
ranging in severity from pharyngitis to necrotizing fasciitis13 and is a major global health burden, 
causing over 600 million infections and 500,000 deaths annually.14 SLS is the cytolytic toxin 
responsible for the classic β-hemolytic phenotype when S. pyogenes is grown on blood agar15 and 
has been shown to be critical to pathogenesis in mammalian infection models.16-18 Although a few 
strains of non-β-hemolytic, pathogenic S. pyogenes have been described, such as the Lowry 
strain,19 the vast majority of S. pyogenes isolates produce SLS.20 The toxin is biosynthesized by a 
9-gene biosynthetic operon that encodes the precursor peptide (sagA), cyclodehydratase and 
dehydrogenase enzymes (sagBCD), a putative leader peptidase (sagE), a multicomponent ABC-
transporter (sagGHI), and a protein of unknown function (sagF) (Figure A.1A).15 The SagBCD 
heterocycle synthetase is known to install azol(in)e rings on the core region of the precursor 
peptide,21, 22 which is followed by proteolytic removal of the leader peptide prior to export of the 
mature, bioactive natural product (Figure A.1B,C). The final molecular weight of SLS has been 
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inferred from classic gel filtration studies to be 2.8 kDa,23 which is consistent with the 
bioinformatic prediction of the scissile bond being C-terminal to a Gly-Gly motif based on the 
similarity to bacteriocins from other Gram-positive bacteria.24 Additionally, proteolysis following 
small residues is common in RiPPs with known cleavage sites.8 Although SLS was first defined 
nearly 80 years ago,25 with the β-hemolytic phenotype being known since the late 1800s,26 a 
detailed mechanism of SLS biosynthesis and the structure of the mature toxin remain elusive. 
Thus, effective SLS biosynthetic inhibitors could serve as powerful chemical tools to shed more 
light on the biochemistry of SLS and the infection biology of S. pyogenes. 
 
Figure A.1. TOMM gene clusters and the biosynthetic pathway. (A) Open reading frame diagram 
showing the organization of several TOMM gene clusters, grouped by function of the mature 
TOMM. The letters over each gene correspond to the name of the sag genes in S. pyogenes. The 
function of each gene is color-coded in the legend. (B) Sequences of the precursor peptides from 
the clusters shown in panel A. The putative (*) or known (-) cleavage sites are shown. The residues 
substituted in SagA to generate SagA-VLPLL are shown in red. SagA, from S. pyogenes; ClosA, 
from C. botulinum; StaphA, from S. aureus; LlsA, from L. monocytogenes; BamA, from B. 
amyloliquefaciens. (C) Generalized mechanism of TOMM maturation with SLS as the example. 
The proteins putatively responsible for each step are shown above each arrow. 
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Gaining a better understanding of how pathogens employ their various virulence factors 
also aids in the development of selective treatment strategies that could help to increase the lifespan 
of clinically important antibiotics. Unlike traditional broad-spectrum antibiotic treatment, 
specifically targeting virulence would retain the human microbiota, helping to eradicate secondary 
infections and, in some cases, could theoretically reduce the evolutionary pressure for the 
development of resistance.27 Previous approaches to targeting virulence have included disruption 
of quorum sensing, which often regulates virulence factor expression, blocking toxin delivery or 
function, and inhibition of bacterial adhesion.27 Several compounds designed around these 
approaches have been efficacious in vivo and have prompted further study,27, 28 but the selective 
nature of targeting virulence requires a tailored therapy for each pathogen, which when developed, 
would stimulate vast improvements in clinical diagnostics. SLS is an interesting anti-virulence 
target, as it plays a major role in paracellular invasion, immune evasion, and host-metabolism 
manipulation.12, 29 Furthermore, additional roles of SLS in iron acquisition have been suggested 
but require further confirmation.12 Due to the importance of SLS in a multitude of pathogenic 
processes, chemical inhibitors developed to probe the biosynthesis of SLS may find future roles in 
virulence attenuation strategies that protect the vital microbiota and limit the spread of antibiotic 
resistance in other pathogens that employ SLS-like toxins (i.e. S. pyogenes and specific strains of 
Listeria monocytogenes, Clostridium botulinum, and Staphylococcus aureus). 
In this study, we identified inhibitors SLS biosynthesis in S. pyogenes by searching for 
compounds that block an essential proteolytic maturation step. This proteolysis event has been 
proposed to be performed by SagE, a putative peptidase with homology to a large family of 
proteases referred to as the CaaX proteases and bacteriocin-processing enzymes (CPBP; often 
confusingly annotated as abortive infection proteins, Abi), which includes the eukaryotic type II 
CaaX proteases as well as prokaryotic proteins with putative bacteriocin-related functions.30, 31 
The type II CaaX proteases are involved in the processing of a number of C-terminally prenylated 
proteins in eukaryotes and have been much more thoroughly studied than their prokaryotic 
counterparts.32-34 Type II CaaX proteases were initially believed to be cysteine proteases,35 but the 
presumed catalytic cysteine was later proven to be unnecessary for activity.34 In contrast, 
conserved glutamate and histidine residues were shown to be important for activity, leading to the 
hypothesis that type II CaaX proteases were metalloproteases.34 Many of the prokaryotic members 
of the CPBP family, including SagE, have been annotated as immunity proteins due to the role in 
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bacteriocin self-immunity of the family members in Lactobacillus plantarum and L. sakei.36 
However, the production of viable allelic exchange mutants of sagE and the homolog in Listeria 
monocytogenes (llsP) indicates that SagE may not be serving an immunity role or may be 
redundant with other uncharacterized immunity mechanisms.15, 37 Thus, it is plausible that the 
prokaryotic CPBPs actually act as proteases and that this function is exploited to provide self-
immunity in certain cases. The results presented herein support a role for SagE as a protease 
through the discovery and characterization of a family of small molecule inhibitors of SLS 
biosynthesis. Appealingly, these inhibitors were identified through the repurposing of existing 
drugs by an examination of known off-target effects. This approach facilitated the rapid 
identification of lead compounds without the need to perform expensive and laborious high-
throughput screens, as well as aiding in the synthesis of analogs by leveraging previous work on 
the compounds.38-40 
 
A.2 Evidence for the role of SagE as a protease 
Reconstitution of SagE in vitro would be the most direct means of testing for the predicted 
protease activity and for the screening of inhibitors. Unfortunately, numerous attempts to 
heterologously express SagE proved unsuccessful and alternative assays were developed to 
address this issue. We attribute much of the difficulty in expressing SagE to the predicted 
transmembrane nature of the protein; topology modeling of SagE with SPOCTOPUS41 predicted 
five transmembrane helixes and an N-terminal signal peptide (Figure A.2). With this in mind, 
crude membranes from S. pyogenes were prepared from total cellular lysates by 
ultracentrifugation. The resultant samples were then assessed for proteolytic activity towards 35S-
labeled SagA, generated through in vitro transcription/translation. Robust proteolysis of SagA to 
the predicted molecular weight23 was observed after treatment with the membrane fraction (Figure 
A.3A). SagA processing in the whole cell lysate and supernatant fractions was much less extensive 
and often not observable (Figure A.4). To test the substrate specificity of proteolysis, a mutant 
version of SagA with residues Ala20, Gly22, and Gly23 mutated to leucines (SagA-VLPLL) was 
generated (Figure A.1B). These residues are directly N-terminal to the predicted leader peptide 
cleavage site and were expected to be important for protease recognition. Pro21 was left intact to 
avoid inducing a drastic structural change on the peptide. When treated with isolated S. pyogenes 
membranes, SagA-VLPLL was processed at a rate slower than wild-type SagA (Figure A.3A), 
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suggesting that the cleavage was performed by a membrane protease specifically recognizing the 
SagA cleavage site (other membrane-bound proteases may also be minor contributors to the 
observed proteolysis). 
 
 
Figure A.2. Hydropathy plot of SagE. The membrane topology of SagE was modeled using the 
SPOCTOPUS program41 and is predicted to be an integral membrane protease with 5 
transmembrane helices. The eukaryotic homologue Rce1 from Methanococcus maripaludis is 
known to also be an integral membrane protein with eight transmembrane α-helices (PDB ID 
4CAD).42 
 
 
Figure A.3. The role of SagE in the processing of pre-SLS. (A) Purified S. pyogenes membranes 
display proteolytic activity towards SagA. Both wild type (WT) SagA, and to a reduced extent, the 
predicted cut site mutant SagA-VLPLL, function as cleavage substrates. (B) Lytic activity of E. 
coli expressing the SLS biosynthetic machinery after a 2 h induction. The hemolytic activity of 
extracted SLS on erythrocytes is measured by a colorimetric readout of hemoglobin release. 
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Figure A.4. Cleavage of Flag-tagged SagA with the S. pyogenes membrane fraction. Proteins 
present within S. pyogenes membranes harbor proteolytic activity towards MBP-Flag-SagA (Flag 
tag is on the N-terminus of SagA). A cleavage band is not seen for MBP-SagA-Flag as the Flag 
tag here is appended to the much smaller C-terminal core peptide, which migrates with the dye 
front. WCL, whole cell lysate; Sol, soluble fraction; Ins, insoluble (crude membrane) fraction. 
 
To provide additional evidence for the role of SagE, a previously reported multi-plasmid-
based expression system for the generation of SLS in Escherichia coli was used. In that study, a 
lytic entity was generated by the expression of a maltose-binding protein (MBP)-tagged SagA in 
conjunction with SagB-D from pETDuet vectors after extended induction times.43 SLS produced 
in this system could be extracted with bovine serum albumin (BSA) and applied to blood using 
procedures long established for S. pyogenes.44 The heterologously produced SLS was presumably 
exported by generalized transporters after non-specific proteolysis of the MBP tag or was released 
via E. coli cell death following buildup of the toxin. Using this system, no lytic activity was 
observable after a considerably shorter induction time (2 h) from a strain expressing only SagA-
D; however, E. coli expressing SagA-F was highly lytic after 2 h (Figure A.3B), indicating that 
SagEF expedite SLS maturation. The additional inclusion of SagF was required for this effect, 
although its functional role is unknown. SagF shares no homology to any known proteins but has 
previously been demonstrated to be necessary for SLS biosynthesis15 and may aid in the folding 
or localization of the other modification machinery. To support the role of SagE as a protease 
involved in SLS maturation, two highly conserved glutamine residues (Glu131 and Glu132) that 
are critical for activity in mammalian CPBP family members31, 34 were mutated to alanine, 
resulting in the complete loss of the observed lytic activity. 
 
A.3 Aspartyl protease inhibitors block SagA proteolysis 
A small panel of general mechanism-based protease inhibitors was screened for inhibition 
of SagA leader proteolysis using the membrane cleavage assay with S. pyogenes membranes. This 
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assay was preferred over the E. coli multi-plasmid system to avoid potential issues with membrane 
penetration or general toxicity of the inhibitors. From the panel, only the aspartyl protease inhibitor 
pepstatin displayed inhibitory activity (Figure A.5), which was unexpected given that SagE bears 
no similarity to known aspartyl proteases and that members of the type II CaaX protease family 
were previously hypothesized to function as zinc-dependent metalloproteases.34 However, 
inhibition of a metalloprotease by aspartyl protease inhibitors has literature precedent, as several 
inhibitors of HIV protease were found to also inhibit the type I CaaX protease ZMPSTE24, which 
is a known zinc metalloprotease.45-47 Lipodystrophy is a possible side effect of treatment with 
certain HIV protease inhibitors and also occurs from genetic deficiencies in ZMPSTE24, leading 
to the discovery of this off-target effect for these drugs.45 Although type I and II CaaX proteases 
do not share sequence similarity, they redundantly process some of the same substrates and share 
similar substrate-binding site architectures.42, 48 Given this, we reasoned that HIV protease 
inhibitors might be repurposed as inhibitors of SLS production. 
 
Figure A.5. Inhibition of SagA proteolysis by general-mechanism based inhibitors. Proteolysis of 
WT [35S]-MBP-SagA by S. pyogenes membranes treated with general mechanism-based protease 
inhibitors. Bestatin, metalloproteases; pepstatin, aspartyl proteases; pefabloc, serine proteases; E-
64, cysteine proteases. 
 
A.4 HIV protease inhibitors block SLS production 
A whole-cell assay in S. pyogenes based on the extraction of SLS with BSA was used to 
screen a panel of nine FDA-approved HIV protease inhibitors (Figure A.6). Nelfinavir, ritonavir, 
saquinavir, and lopinavir were found to inhibit the production of SLS when tested at 50 µM, while 
indinavir, amprenavir, atazanavir, and darunavir did not inhibit SLS production (Figure A.7A). 
Interestingly, tipranavir caused significant growth suppression in S. pyogenes, and treated cultures 
never reached late exponential phase (Figure A.8), which is when SLS becomes detectable in 
vitro.49 The efficacies of the HIV protease inhibitors shown to inhibit SLS production in the initial 
screen were evaluated by determining 50% inhibition concentration (IC50) values. The IC50 of 
nelfinavir (6 µM) was lower than those of ritonavir (35 µM), saquinavir (25 µM), and lopinavir 
(25 µM). Owing to its greater potency, nelfinavir (Figure A.7B) was selected for further study. 
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Figure A.6. Structures of the FDA-approved HIV protease inhibitors. The structures of all FDA-
approved HIV protease inhibitors are shown (U.S. brand name in parentheses) with the exception 
of fosamprenavir calcium (Lexiva), a pro-drug of amprenavir. Any previously reported activity for 
each drug on the CaaX protease ZMPSTE24 is listed,46, 47 along with the activity for SLS 
production inhibition. 
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Figure A.7. Inhibition of SLS production. (A) Hemolytic activity of SLS extracts from S. pyogenes 
treated with HIV protease inhibitors. Tipranavir is shown separated by a dashed line due to 
significant growth effects during treatment (Figure A.8). Asterisks indicate a P-value < 0.01 
relative to the DMSO control. (B) The structure of nelfinavir (1). (C) The proteolytic effect of S. 
pyogenes membranes treated with nelfinavir on MBP-SagA, relative to a DMSO-treated control. 
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Figure A.8. Growth effects of HIV protease inhibitors on S. pyogenes. S. pyogenes M1 5448 was 
grown in the presence of the indicated HIV protease inhibitor at 50 µM and the optical density at 
600 nm was recorded. Tipranavir was found to significantly inhibit growth. 
 
Nelfinavir was evaluated in the membrane proteolysis assay to determine if the observed 
loss of β-hemolysis was due to inhibition of the proteolytic processing step of SLS maturation. As 
expected, treatment with nelfinavir greatly reduced the proteolytic activity toward SagA contained 
within S. pyogenes membranes (Figure A.7C, the membrane fraction used in this experiment was 
prepared on a different day than the fraction used in Figure A.3 and displayed much higher 
activity). Evidence that nelfinavir was not drastically perturbing normal cellular function came 
from the observation that the growth rates of S. pyogenes treated with nelfinavir were identical to 
the DMSO control (Figure A.8). Additionally, minimum inhibitory concentration (MIC) testing 
revealed no growth inhibition up to the highest concentration tested (64 µM) for a range of 
bacterial species (Table A.1). Transmission electron microscopy (TEM) was used to examine the 
morphology of S. pyogenes treated with nelfinavir, with no apparent changes compared to the 
control sample (Figure A.9). The transcription levels of a panel of virulence factor genes, as 
assessed by qRT-PCR, were also not significantly impacted (Table A.2). Notably, the levels of 
sagA and sagB expression were unchanged. These data indicate that nelfinavir inhibited peptide 
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processing directly, rather than through transcriptional regulation or by significantly perturbing 
other cellular processes. 
 
Table A.1. The minimum inhibitory concentrations of nelfinavir against a range of bacterial 
species, including Gram-positive and Gram-negative organisms, are shown. No growth inhibition 
was seen for any species up to the solubility limit of nelfinavir after 16 h of growth. 
 
Bacterial strain MIC (µM) 
Streptococcus pyogenes M1 5448 >64 
Listeria monocytogenes 4b F2365 >64 
Clostridium sporogenes ATCC 19404 >64 
Staphylococcus aureus USA300 >64 
Enterococcus faecium U503 >64 
Bacillus subtilis 168 >64 
Klebsiella pneumoniae ATCC 27736 >64 
Pseudomonas aeruginosa PA01 >64 
Escherichia coli MC4100 >64 
 
 
Figure A.9. Transmission electron microscopy (TEM) of nelfinavir-treated S. pyogenes. TEM 
images of S. pyogenes M1 5448 treated with (A) DMSO or (B) 25 µM nelfinavir. Scale bars are 
100 nm. These images are representative of the entire sample, where more than 100 cells were 
closely examined. 
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Table A.2. Changes in virulence factor expression as measured by qRT-PCR with S. pyogenes 
M49 NZ131 during treatment with nelfinavir versus a DMSO control. Values are from three 
biological replicates averaged from three technical replicates each. The 16S rRNA gene was used 
as an internal control gene and relative gene expression was calculated by a comparative CT 
method.50 Positive and negative values represent up- and down-regulation upon nelfinavir 
treatment, respectively. The primers used are given in the supplemental methods. A transcription 
change was not considered significant if the log2 ratio was < 1.5 fold or if the P value was > 0.01. 
Based on these criteria, none of the genes were significantly altered upon nelfinavir treatment. 
Similar results were obtained for an additional strain, S. pyogenes M1 5448. 
 
Gene Log2 ratio 
(treated/untreated) 
Virulence factor 
emm49 -1.98 ± 0.77 M protein 
slo 0.02 ± 1.22 streptolysin O (SLO) 
sagA 0.32 ± 0.20 streptolysin S (precursor peptide) 
sagB 0.10 ± 0.70 streptolysin S (dehydrogenase) 
scpA -0.86 ± 0.26 C5A peptidase 
ska -1.23 ± 0.83 streptokinase 
speB 1.38 ± 0.92 streptococcal pyrogenic exotoxin B (SpeB) 
nga -1.30 ± 0.90 NAD glycohydrolase 
spd3 -0.83 ± 0.28 streptodornase 
 
A.5 Structure-activity relationships 
A series of nelfinavir analogs was synthesized to gain a better understanding of the 
structure-activity relationships (SAR) for inhibition of SLS maturation. If nelfinavir were to 
interact with the SLS leader peptidase in a manner analogous to HIV protease, the secondary 
hydroxyl group would function as a tetrahedral intermediate mimic, as is the case for many aspartyl 
and metalloprotease inhibitors (Figure A.10). Synthetic routes to nelfinavir have been thoroughly 
explored and a route that allowed facile derivatization was adapted for this study (Scheme A.1).38 
The efficacy of each analog at 25 µM was evaluated using the hemolysis assay (Table A.3 and 
Table A.4). 
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Figure A.10. Aspartyl and metalloproteases share a common intermediate. Both types of protease 
activate water, which performs a nucleophilic attack on the scissile amide bond. This attack results 
in a gem-diol intermediate shared between the two mechanisms, unlike the covalent acyl-enzyme 
intermediate formed by serine, threonine, and cysteine proteases. Nelfinavir and other aspartyl and 
metalloprotease inhibitors usually mimic the intermediate with the non-hydrolyzable secondary 
hydroxyl group. However, our data suggest that nelfinavir does not inhibit the SLS leader 
peptidase in this fashion. 
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Scheme A.1. Synthesis of nelfinavir. a, i-BuOCOCl, Et3N, THF; CH2N2, Et2O (62%); b, HCl, 
Et2O; c, NaBH4, THF (62% over two steps); d, KOH, EtOH (91%); e, 6, KOH, IPA, 80 °C (84%); 
f, 3-hydroxy-2-methylbenzoic acid, EDC, HOBt, THF (66%). 
 
Nelfinavir has peptidomimetic features, including an S-phenyl-ethyl group intended to 
replace the side chain of phenylalanine commonly found in the P1 position of the HIV protease 
substrate. Since the putative P1 position of SagA is a much smaller glycine residue (Figure A.1B, 
Gly23), we surmised that smaller substituents at this location on nelfinavir might improve the 
observed anti-SLS activity. Instead, removal of the side chain (8) abolished detectable activity. It 
is possible that the cleavage site is closer to the N-terminus, however, and that Pro21 or an aliphatic 
residue preceding it resides in the P1 position. Accordingly, analogs mimicking these amino acids 
(9, 10) were synthesized, but these compounds did not exhibit detectable inhibitory activity. Even 
retention of the phenyl ring in a phenylalanine mimic (11) was insufficient to maintain activity. 
Conversely, a tryptophan mimic (12) was inhibitory, albeit weakly, suggesting that a relatively 
large group in that position may be necessary for activity. 
The lack of detectable activity with the series of P1 position analogs prevented the rigorous 
establishment of SAR. Modifications to other portions of the molecule were prepared in order to 
enhance the inhibitory activity to address this pitfall. As installation of the benzamide is the final 
step of the synthesis (Scheme A.1), preparation of analogs at this location was convenient. Initial 
analogs revealed that neither the hydroxyl nor the methyl groups (13–15) were important for 
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activity but that the ring itself was necessary (16). Replacement of the ring with bulkier naphthyl 
and cyclohexyl groups (17, 18) provided >5-fold increases in potency, indicating that this part of 
the pharmacophore may reside in a hydrophobic pocket not fully occupied by the single planar 
ring. However, increasing the size of this moiety to an anthracene (19) greatly reduced activity. In 
general, electron-deficient rings had improved activity relative to electron-rich rings (Table A.4), 
although hydrophobicity appeared to be a more significant contributing factor towards potency. 
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Table A.3. Relative activity of nelfinavir analogs for SLS inhibition. 
aThe activity of each analog is reported qualitatively relative to nelfinavir due to variability in 
commercial blood lots and extraction effectiveness. Inhibitory activity that is >3-fold than 
nelfinavir is designated as (+++); activity that is equal to nelfinavir is (++); detectable activity that 
is <3-fold than nelfinavir is (+); non-detectable activity is denoted (-). 
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Table A.4. Relative activity of additional nelfinavir analogs for SLS inhibition. The activity of 
each analog is reported qualitatively relative to nelfinavir due to lot variation in the commercial 
sources of blood and the BSA extraction efficiency. Activity >3-fold that of nelfinavir is 
designated as (+++); activity that is equal to nelfinavir is (++); detectable activity that is <3-fold 
that of nelfinavir is (+); non-detectable activity is denoted (-). 
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Table A.4. (cont.) 
 
 
 
Given the enhanced activity of the naphthylamide-bearing compound (17), this group was 
incorporated into the collection of P1 position analogs (Table A.3; Table A.4), increasing the 
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activity of these analogs to detectable levels. The tryptophan mimic with the naphthylamide (20) 
displayed considerably increased potency relative to the 3-hydroxy-2-methylbenzamide analog 
(12). Within the naphthylamide series, the phenylalanine and leucine mimics (21, 22) were 
equivalently active to nelfinavir, while the glycine mimic (23) displayed weak SLS-inhibitory 
activity. The proline mimic (24) remained devoid of activity, possibly due to structural 
perturbations enforced by the ring. These data support a trend of larger substituents imparting 
higher activity that was foreshadowed by the initial SAR. 
To further probe the pseudo-P1 position of nelfinavir, the stereochemical configurations of 
both the side chain and the secondary hydroxyl group were varied. Surprisingly, inverting 
stereocenters with this series of analogs (25–27) did not result in large changes in activity. Many 
of the derivatives were still highly potent, suggesting that nelfinavir may not inhibit SagE through 
mimicking the proteolytic tetrahedral intermediate (Figure A.10). This is further supported by the 
retention of activity in acetylated derivatives (28, 29). Overall, the sum of the SAR analysis 
resulted in the development of an analog with significantly improved potency (17, IC50 = 1 µM). 
Additionally, the activity trends led us to believe that nelfinavir might serve as an inhibitor for the 
protease in other TOMM natural product biosynthetic clusters in which the precursor peptides do 
not always contain a predicted Gly-Gly cleavage motif (Figure A.1B). 
 
A.6 Biosynthesis inhibition of other TOMMs 
SLS is the best-studied member of a group of related cytolysins produced by a number of 
bacteria, including pathogens such as L. monocytogenes and C. botulinum.12, 21 The SLS-like 
biosynthetic gene clusters in these strains are highly similar to that of S. pyogenes and include 
orthologs of sagE (Figure A.1A, Figure A.11). The SLS-like toxin from L. monocytogenes, 
listeriolysin S (LLS), is known to be expressed during oxidative stress; therefore, a strain with LLS 
under the control of a constitutive promoter was used in the blood lysis assay to determine if 
nelfinavir could also inhibit LLS production.51 The strain was deficient in production of an 
unrelated cytolysin, listeriolysin O (LLO), to ensure any hemolysis observed derived from LLS 
production. When treated with nelfinavir, this strain produced significantly less LLS (Figure 
A.12A). The LLO-/LLS- strain of L. monocytogenes was included as a negative control to 
demonstrate the observed hemolysis was indeed LLS-dependent (Figure A.12A). 
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Figure A.11. Amino acid sequence alignment of select bacterial CaaX proteases and bacteriocin-
processing enzymes (CPBPs). A Clustal Omega alignment of SagE and related proteases in other 
natural product gene clusters is shown. Conserved residues shown to be important for catalysis in 
eukaryotic homologues are highlighted in yellow and their proposed role in catalysis is shown in 
Figure A.18.34 The C-terminal 35 residues were manually aligned. Gene names and producing 
organisms: SagE, S. pyogenes; LlsP, L. monocytogenes; StaphE, S. aureus; ClosE, C. 
sporogenes/botulinum; BamE, B. amyloliquefaciens. 
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Figure A.12. Inhibition of the biosynthesis of other TOMMs by nelfinavir. (A) Lytic activity of 
extracts from an LLS-producing strain (LLS+) of L. monocytogenes treated with nelfinavir relative 
to a DMSO control (n = 3). Extracts from a separate strain with llsA deleted (LLS-) were also used 
as a control. (B) Lytic activity of extracts from a CLS-producing strain of C. sporogenes treated 
with nelfinavir relative to a DMSO control (n = 3). (C) Production of PZN by B. amyloliquefaciens 
treated with nelfinavir relative to a DMSO control (n = 4). Nelfinavir was used at 50 µM in all 
cases. Excluding LLS- negative control, P-values < 0.05 were obtained for all nelfinavir-treated 
samples relative to the corresponding DMSO positive controls. 
 
Similar to SLS and LLS, clostridiolysin S (CLS) is a hemolysin from C. botulinum as well 
as from certain strains of C. sporogenes, which are nearly identical to C. botulinum but do not 
produce botulinum toxin.22 The presence of the CLS cluster in an unsequenced strain of C. 
sporogenes (ATCC 19404) known to be hemolytic on blood agar was confirmed by PCR 
amplification of closC and closD (the cyclodehydratase genes). When C. sporogenes was grown 
in the presence of nelfinavir, the production of CLS was significantly reduced (Figure A.12B). The 
inhibition of not only SLS but also LLS and CLS production suggests that nelfinavir would likely 
inhibit the production of additional TOMM cytolysins. 
TOMM biosynthetic gene clusters are wide-spread among bacteria and archaea, and the 
products of the vast majority of these clusters have not been structurally or functional 
characterized.7 A bioinformatic analysis of TOMM clusters revealed that 22% (328 out of 1520 as 
of October 2014) contained a CPBP family member within the cluster, many of which are predicted 
or known to have non-cytolytic products. The presence of a CPBP member in these clusters led us 
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to postulate that nelfinavir would also inhibit TOMM production in these cases. Plantazolicin 
(PZN) is a TOMM produced by Bacillus amyloliquefaciens FZB42 with highly selective 
antibacterial activity against Bacillus anthracis and has a sagE-like gene (bamE) in its biosynthetic 
gene cluster (Figure A.1A, Figure A.11).52 The structure of PZN has been determined; thus the 
precise cleavage site is known (after Ala27, Figure A.1B), although no biochemical studies have 
directly linked BamE to leader peptide cleavage. Methanolic surface extracts from B. 
amyloliquefaciens were analyzed by liquid chromatography-mass spectrometry and the nelfinavir-
treated cultures were found to produce significantly less PZN than a DMSO control (Figure 
A.12C). Unlike the cytolysins, PZN can be readily observed and quantified by mass spectrometry, 
which permitted confirmation of the nelfinavir dose-dependent inhibition (Figure A.13). The 
nelfinavir-dependent inhibition in divergent organisms of additional TOMM cytolysins, as well as 
a functionally distinct antimicrobial TOMM, not only supports the assignment of the CPBP protein 
being responsible for leader peptide removal during maturation, but also suggests that nelfinavir, 
and analogs thereof, could be generally useful for inhibition of TOMM production in a large 
number of hitherto uncharacterized clusters. 
 
 
Figure A.13. Dose-dependent inhibition of PZN by nelfinavir. The production of plantazolicin 
by B. amyloliquefaciens is reduced in a dose-dependent manner when treated with nelfinavir, 
relative to a DMSO control. *P<0.05, **P<0.005. 
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Additional CPBP family members are also present in bacteria beyond TOMM biosynthetic 
gene clusters. One such family member is PrsW from Bacillus subtilis, which is involved in 
cleaving the peptide RsiW (anti-σ factor) during a signaling cascade following cell envelop 
stress.53 It is believed that PrsW is responsible for sensing antimicrobial peptides and other cell 
envelop stressing agents.53 Since PrsW is a more divergent CPBP family member and is not 
expected to be involved in TOMM biosynthesis, we were interested in determining if it would also 
be inhibited by nelfinavir. Previously reported strains of B. subtilis containing an IPTG inducible, 
FLAG-tagged rsiW with and without prsW genetically deleted53 were grown in the presence or 
absence of nelfinavir. After induction of prsW, the cells were treated with small amounts sodium 
hydroxide as a model cell envelop stressing agent. Rather than observing nelfinavir-dependent 
inhibition of PrsW, however, nelfinavir appeared to activate the protease even in the absence of 
sodium hydroxide (Figure A.14). While this could indicate that nelfinavir is binding to the protease 
but resulting in activation instead of inhibition, it is also possible that nelfinavir is simply acting 
as a mild cell envelop stressing agent. This would result in non-specific activation of PrsW, 
complicating any attempts to determine the interaction between nelfinavir and the protease. 
Nevertheless, it appears that the strong inhibitory activity of nelfinavir towards CPBP family 
members likely does not extend significantly beyond members in TOMM biosynthetic gene 
clusters. 
 
Figure A.14. Cleavage of RsiW by PrsW. The CPBP family member PrsW cleaves RsiW under 
conditions of cell envelop stress, created here by sodium hydroxide. The WT strain is CDE743, 
containing a FLAG-tagged rsiW under IPTG controlled induction. The ΔprsW strain is CDE744, 
a modified version of CDE743 with prsW genetically deleted.  
 
A.7 Target validation studies 
Although the previous data strongly support SagE as the target of nelfinavir in SLS 
biosynthesis inhibition, we sought to further validate this hypothesis through affinity pulldown 
with a photoactivatable crosslinker probe. The previously described synthesis (Scheme A.1) was 
utilized to install photoactivatable moieties as well as terminal alkynes for subsequent azide-alkyne 
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cycloaddition click chemistry. As the most facile position to modify, replacement of the benzamide 
was initially investigated. The installation of a photoactivatable benzophone moiety at this position 
unfortunately yielded a barely active compound (140), but installation of the smaller aryl alkyne 
did not significantly affect activity (141). Thus, as leucine-mimic analogs of nelfinavir had been 
determined to be active (22, 89, 114), an analog derived from D-photo-leucine containing a 
photoactivatable diazirine moiety was synthesized with the aryl alkyne in the benzamide position. 
The D-form of photo-leucine was chosen rather than the L-form as head-to-head comparisons of 
22 and 114 consistently indicated that the R stereochemistry at the side chain of the P1 position 
was more active. The probe (150, Figure A.15A) was determined to retain inhibitory activity via 
the hemolysis assay, albeit weakly, and was thus used for subsequent affinity pulldown studies. 
Cultures of S. pyogenes were treated with 150 before irradiation with UV light, cell lysis, and 
conjugation to biotin via copper mediated azide-alkyne cycloaddition. The lysates were then 
passed over streptavidin resin for affinity pulldown or were visualized directly by western blotting. 
Unfortunately, it became quickly apparent that copious non-specific crosslinking was occurring 
due to the presence of numerous bands by western blot (Figure A.15B), none of which were 
diminished in competition experiments with nelfinavir. As SagE was shown to be active in E. coli, 
a strain overexpressing SagE was utilized for labeling and also displaying non-specific 
crosslinking (Figure A.15C). A proteomics analysis of the labeled proteins revealed that several 
of the most abundant cellular proteins were crosslinking to the probe (150), including EF-tu and 
protein S9. These abundant housekeeping proteins overwhelmed the analysis and no proteins that 
would reasonably be expected to be involved in SLS biosynthesis were detected. It is probable that 
150, as well as nelfinavir, non-specifically stick to many different cellular components, likely 
contributing to the range of known off-target activities of nelfinavir. 
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Figure A.15. Cell extracts photocrosslinked with 150. (A) Structure of probe 150. (B) Western 
blot of the insoluble fraction of lysates from S. pyogenes M1 WT cells labeled with probe 150. (C) 
Western blot of total lysate (lane 1) and the insoluble fraction (lane 2) from E. coli labeled with 
probe 150. 
 
Although initial attempts to heterologously express and reconstitute SagE were 
unsuccessful, we believed it might be possible to generate properly folded SagE in the presence of 
lipid nanodiscs as the protein is expected to normally be membrane bound (Figure A.2). Lipid 
nanodiscs are portions of lipid bilayer solubilized by the action of membrane scaffolding proteins 
that wrap around the hydrophobic tails of the lipids.54 The nanodiscs have been shown to be 
effective platforms for stably reconstituting otherwise intransigent membrane proteins in vitro. 
SagE was generated through a coupled in vitro transcription/translation system in the presence of 
lipid nanodiscs. The reactions were then tested for their ability to cleave an MBP-SagA substrate. 
Although intact SagE could be visualized by western blotting, no cleavage activity could be 
detected (Figure A.16). 
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Figure A.16. Representative example of the lack of MBP-SagA cleavage by SagE expressed in 
vitro with lipid nanodiscs. Each lane of the western blot represents a different reaction condition 
for the in vitro transcription/translation (TNT) of SagE or for the cleavage of MBP-SagA. (1) no 
DNA, 30 °C TNT, 37 °C cleavage; (2) pET28-Mistic-SagE, 30 °C TNT, 37 °C cleavage; (3) 
pET28-Mistic-SagE, 18 °C TNT, 37 °C cleavage; (4) pCOLA- SagE-SagF-Stag, 30 °C TNT, 37 
°C cleavage; (5) pCOLA- SagE-SagF-Stag, 18 °C TNT, 37 °C cleavage; (6) pET28-Mistic-SagE, 
30 °C TNT, 18 °C cleavage; (7) pET28-Mistic-SagE, 18 °C TNT, 18 °C cleavage; (8) pCOLA- 
SagE-SagF-Stag, 30 °C TNT, 18 °C cleavage; (9) pCOLA- SagE-SagF-Stag, 18 °C TNT, 18 °C 
cleavage. No cleavage is seen in any condition. 
 
In a final effort to validate SagE as the target of nelfinavir, sagE (with and without sagF) 
was cloned into the S. pyogenes overexpression vector pIB184 under constitutive control.55 If 
inhibition of SagE by nelfinavir causes a bottleneck in SLS biosynthesis, overexpression of SagE 
may abrogate the inhibition. The amount of SLS produced by strains containing the sagE vectors 
was compared to an empty vector control in the presence or absence of nelfinavir via the hemolysis 
assay. No difference in the amount of SLS produced between sagE-containing or empty vectors 
could be detected in any instance (Figure A.17). Taking the opposite approach, overexpression 
vectors containing antisense sequences to sagE were created, transformed into S. pyogenes, and 
tested in the hemolysis assay. Again, however, no synergistic inhibition of SLS biosynthesis was 
observed (Figure A.17). qRT-PCR analysis of strains containing the overexpression vectors 
against empty vector controls indicated that the presence of the vectors was resulting in a several 
fold increase in sagE RNA quantities (Table A.5). Therefore, it is likely that the levels of SagE 
were being effectively modulated but that this was having no effect on SLS biosynthesis in the 
presence of nelfinavir. It is possible that SagE requires other cellular components to function that 
are more limiting than the quantity of SagE. If nelfinavir only binds to SagE in the context of this 
interaction, modulating the expression of SagE would not be expected to have a significant effect 
on nelfinavir inhibition. However, it is also possible that nelfinavir does not directly inhibit SagE 
or that the inhibition of nelfinavir biosynthesis is achieved through the interaction of nelfinavir 
and a different target. Even in this latter scenario, it is still possible that nelfinavir inhibits 
proteolysis via SagE, but that this simply isn’t a limiting factor in the biosynthesis of the mature 
cytolysin. 
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Figure A.17. Over- and under-expression of SagE does not affect SLS biosynthesis inhibition by 
nelfinavir. Lytic activity of extracts from S. pyogenes containing pIB184 vectors with sagE/F or 
antisense sagE treated with nelfinavir relative to DMSO controls (n = 2).This subset of data is 
representative of the overall trend. 
 
Table A.5. Changes in SagE/F expression as measured by qRT-PCR with S. pyogenes M1 5448 
transformed with pIB184 vectors. Values are from three biological replicates averaged from three 
technical replicates each, except for the pIB184-sagEF vector which was only one biological 
replicate (indicated by a *). The sagB gene was used as an internal control gene and relative gene 
expression was calculated by a comparative CT method.50 Positive values represent up-regulation 
of the genes. sagE appears to be upregulated with the antisense vector as the primers used cannot 
differentiate between normal sagE RNA and antisense sagE RNA. The primers used are given in 
the supplemental methods. 
 
Vector Gene Log2 ratio (treated/untreated) 
pIB184-sagE sagE 4.54 ± 1.32 
pIB184-sagEF sagE 3.11* 
pIB184-sagEF sagF 2.55* 
pIB184-sagF sagF 4.63 ± 0.72 
pIB184-AntiEfull sagE 6.07 ± 0.41 
 
A.8 Discussion 
In this work, the FDA-approved HIV protease inhibitor nelfinavir was repurposed as the 
first small molecule inhibitor of SLS production in S. pyogenes, displaying low micromolar 
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activity. Nelfinavir was identified as a lead compound by leveraging the extensive basic and 
clinical research data accumulated on the effects of the drug. Lipodystrophy, a known side effect 
of nelfinavir and several other HIV protease inhibitors, had been previously linked to the off-target 
inhibition of the CaaX protease ZMPSTE24. We surmised that the HIV protease inhibitors would 
also inhibit SagE due to its homology with CaaX proteases, allowing us to rapidly identify a lead 
compound for the inhibition of SLS production. This strategy for lead identification negated the 
need for high-throughput screening or for a crystal structure of the target for in silico and structure-
based design. Utilizing a drug with synthetic routes that have been thoroughly explored also greatly 
accelerated the creation of analogs for SAR efforts that yielded compound 17, with an improved 
IC50 value of 1 µM. 
Nelfinavir and related compounds are inhibitors of SLS biosynthesis, most likely through 
inhibition of proteolytic cleavage of the protoxin by the CPBP family member SagE. Although in 
vitro reconstitution was unsuccessful, the necessity for SagE during SLS production in the multi-
plasmid expression system in E. coli provides considerable evidence for its role in proteolytic 
processing. Like many CPBP members, SagE is commonly referred to as an immunity protein in 
the literature,15, 16 but inhibition by nelfinavir did not have any effect on the growth of S. pyogenes, 
providing evidence that SagE is not involved in self-immunity. Alternatively, compensatory 
mutations that abolish SLS production may arise when SagE is inactivated, as has been previously 
suggested.16 The original annotation of SagE as an immunity protein stems from its similarity to 
PlnP from Lactobacillus plantarum. PlnP and several related proteins are found downstream of 
bacteriocin structural genes in L. plantarum and have been shown to provide immunity to the 
antibacterial effect of the respective bacteriocins.36 Yet, unlike these bacteriocins, SLS has not 
been demonstrated to possess any antibacterial activity against intact S. pyogenes cells. A large 
buildup of intracellular SLS might result in toxicity, but this would be expected to affect any S. 
pyogenes strains in which the transport machinery is inactivated as well, which has not been 
observed.15 Furthermore, treatment of SagA with the cyclization machinery (SagBCD) in vitro 
results in a lytic entity without cleavage of the leader peptide, indicating that while proteolysis is 
required for cellular export, it is unnecessary for lytic activity.21 These observations lead us to 
conclude that the principal function of SagE is to proteolytically mature SLS. 
In addition to experimentally supporting a biochemical role for SagE, we have also 
addressed the mechanism of proteolysis and the probable inhibition by nelfinavir. CPBP family 
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members have been postulated to function through a zinc metalloprotease mechanism based on the 
presence of two glutamates, two histidines, and an asparagine residue that are conserved across 
the family (Figure A.11).34 Mutation of these residues in the eukaryotic type II CaaX protease Ras-
converting enzyme (Rce1) has also demonstrated that these residues are critical for activity.34 We 
found that Glu131 and Glu132 were critical for the activity of SagE. Thus, it was initially 
unexpected that proteolysis was inhibited by pepstatin, a general aspartyl protease inhibitor, but 
not by bestatin, a metalloprotease inhibitor (Figure A.5). However, a recent report detailing the 
crystal structure of Rce1 from Methanococcus maripaludis provides compelling evidence that this 
family of proteases actually functions through a novel glutamate-dependent mechanism (Figure 
A.18).42 The authors hypothesized that a glutamate residue extending into the active site is 
responsible for deprotonating a water molecule, activating it for nucleophilic attack. Given the 
similarities between this proposed mechanism and the mechanism of aspartyl proteases, it is 
perhaps unsurprising that a CaaX protease homolog would be inhibited by aspartyl protease 
inhibitors, including nelfinavir. 
 
 
Figure A.18. Proposed mechanism for glutamate-dependent proteases. A potential mechanism for 
glutamate dependent proteases based on the crystal structure of Rce1 is shown.42 Glutamate and 
histidine activate water for nucleophilic attack while a second histidine residue and an asparagine 
residue labeled “Oxy” comprise the oxyanion hole. A second conserved glutamate near the active 
site is thought to be structurally important. A general mechanism for aspartyl proteases is shown 
for comparison. 
 
In addition to increasing the potency of inhibition with compound 17, our synthetic effort 
also yielded information on how nelfinavir may interact with SagE. The SAR analysis revealed 
that a rather large side chain in the pseudo P1 position of the structure was required for potent 
activity, with the original S-phenyl-ethyl group displaying the greatest inhibition. This result was 
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not anticipated, given that the P1 residue in the SagA substrate is putatively glycine. One possible 
explanation for this discrepancy is that the catalytic site architecture of SagE is highly conserved 
with the type II CaaX proteases, which normally cleave substrates with a prenylated cysteine in 
the P1 position. In this case, nelfinavir would be an ideal fit for the active site, as the core of the 
molecule closely resembles a cysteine with a hydrophobic group appended. An alternative 
explanation is that nelfinavir does not bind in the active site in the expected fashion (with the 
secondary hydroxyl interacting with the catalytic residues, Figure A.10) or does not bind in the 
active site at all. These possibilities are supported by the potent activity of several analogs with 
different stereochemical configurations, as these molecules would likely be forced into different 
conformations that do not allow the same favorable interactions with active site residues. In this 
scenario, binding of nelfinavir to the membrane protease may be driven by hydrophobic 
interactions. This explanation would also account for the attenuated activity of saquinavir, which 
is nearly identical to nelfinavir except for the presence of a more hydrophilic group at the 
benzamide position (Figure A.6, XLogP3 values from PubChem for nelfinavir and saquinavir are 
5.7 and 4.2, respectively). Comparisons to the other HIV protease inhibitors do not yield much 
additional information due to their low similarity to nelfinavir, as reflected in the Tanimoto 
similarity coefficients (Table A.6). 
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Table A.6. The Tanimoto similarity coefficients for the FDA-approved HIV protease inhibitors. 
Higher Tanimoto coefficients indicate higher similarity. Compounds that inhibited the production 
of SLS are highlighted in green. Abbreviations: ampr, amprenavir; ataz, atazanavir; daru, 
darunavir; indi, indinavir; lopi, lopinavir; nelf, nelfinavir; rito, ritonavir; saqu, saquinavir; tipr, 
tipranavir. 
 
 ampr ataz daru indi lopi nelf rito saqu tipr 
ampr 1.00 0.24 0.67 0.14 0.21 0.14 0.21 0.20 0.12 
ataz 0.24 1.00 0.22 0.15 0.20 0.13 0.21 0.20 0.11 
daru 0.67 0.22 1.00 0.13 0.20 0.13 0.20 0.19 0.11 
indi 0.14 0.15 0.13 1.00 0.15 0.18 0.14 0.22 0.10 
lopi 0.21 0.20 0.20 0.15 1.00 0.14 0.28 0.19 0.11 
nelf 0.14 0.13 0.13 0.18 0.14 1.00 0.10 0.40 0.09 
rito 0.21 0.21 0.20 0.14 0.28 0.10 1.00 0.17 0.10 
saqu 0.20 0.20 0.19 0.22 0.19 0.40 0.17 1.00 0.10 
tipr 0.12 0.11 0.11 0.10 0.11 0.09 0.10 0.10 1.00 
 
Unequivocal confirmation of the bacterial target of nelfinavir (and analogs) was 
unfortunately not possible in the present study, which can be attributed to the technical challenges 
inherent to the study of integral membrane proteins. Nelfinavir also likely interacts with multiple 
targets in S. pyogenes, as the drug is known to have multiple off-target effects in humans.45 A 
significant body of work in mammalian cell lines has demonstrated that nelfinavir displays 
promiscuous activity, such as interruption of Akt signaling and inhibition of the proteasome.56 
Target promiscuity likely also exists in bacteria, so possible interactions of nelfinavir with 
additional targets cannot be ruled out. Thus, nelfinavir may be inhibiting additional participants 
that indirectly result in the inhibition of SLS production in a mechanism unrelated to proteolysis. 
Further targets of nelfinavir may also exist that do not result in observable phenotypes. However, 
nelfinavir also inhibited the biosynthesis of other natural products that include a CPBP family 
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member in the gene cluster (i.e. LLS, CLS, and PZN). The fact that this inhibition occurred in a 
range of disparate bacterial species decreases the probability that another protease is responsible 
and provides substantial, albeit indirect, support that SagE is the primary target of nelfinavir in S. 
pyogenes. Finally, the HIV protease inhibitors found to inhibit SLS production parallel those 
capable of inhibiting the human CaaX protease ZMPSTE24 (Figure A.6),46, 47 providing additional 
evidence that nelfinavir and its analogs inhibit SLS production by blocking the action of SagE. 
 
A.9 Summary and Outlook 
Despite their prevalence, prokaryotic members of the CPBP family have not yet been 
thoroughly investigated. Many of the family members are incorrectly annotated or have a predicted 
function based solely on distant homology. The discovery of nelfinavir as an inhibitor of CPBPs 
has provided evidence that SagE functions as a protease and will aid in the assignment of functions 
to other family members, including other human pathogens such as S. aureus. Additionally, 
nelfinavir is the first reported inhibitor of the production of SLS and related toxins. Nelfinavir and 
improved analogs will provide a new tool to investigate toxin function without the need to create 
genetic deletions while also allowing for temporal control over toxin production. Reversible 
control of SLS production with nelfinavir analogs will also help to clarify the precise contribution 
of SLS to virulence in in vivo models of infection and may open the door to the development of 
virulence-targeting strategies for the control of S. pyogenes infections. Finally, the chemical 
knockdown effect of nelfinavir can be utilized for the discovery of natural products from the 22% 
of TOMM gene clusters that contain a CPBP family member, potentially accelerating the structural 
and functional characterization of these compounds. 
 
A.10 Methods 
A.10.1 Materials  
All chemicals were purchased from Sigma-Aldrich, VWR, Fisher Scientific, or Oakwood 
Products and used without further purification unless otherwise specified. HIV protease inhibitors 
were obtained from the NIH AIDS Research and Reference Program, Division of Aids, NIAID, 
NIH. Nelfinavir, ritonavir, saquinavir, indinavir sulfate, amprenavir, lopinavir, atazanavir sulfate, 
tipranavir, and darunavir were received through distribution by Thermo Fisher. 
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A.10.2 Plasmid construction  
The genes encoding Flag-SagA and SagA-Flag were generated in pDCerm via PCR 
utilizing primers specific to sagA and containing the Flag tag sequence and XbaI (Flag-sagA) or 
BamHI (sagA-Flag) restriction sites. For heterologous expression of these peptides in Escherichia 
coli, the genes of interest were subcloned into a pET28 vector containing an N-terminal maltose 
binding protein (MBP) fusion as previously described.21 The construction of the Duet vectors 
pETDuet-1-sagB-sagC and pACYCDuet-1-MBP-sagA-sagD has been previously described.43 The 
Duet vector containing sagE and sagF was constructed using the pCOLADuet-1 vector (EMD 
Millipore) in an analogous manner.43 Point mutations of SagA and SagE were introduced by the 
Quikchange site-directed mutagenesis kit (Agilent), following the manufacturer’s instructions. 
The genes encoding SagE, SagEF, and SagF were inserted into pIB184 using Gibson cloning 
following the manufacturer’s instructions (New England Biolabs) with the EcoRI cut site to 
generate pIB184-sagE, pIB184-sagEF, and pIB184-sagF respectively. Antisense RNA comprising 
the entire sequence of sagE and the first 150 bp of sagE was inserted into pIB184 in a similar 
manner to generate pIB184-AntiEfull and pIB184-AntiE150 respectively. 
A.10.3 Generation of SagA substrates  
35S-Methionine-labeled MBP-SagA was generated as previously described (from rabbit 
reticulocyte, T7-coupled in vitro transcription/translation, Promega).57 MBP-Flag-SagA and 
MBP-SagA-Flag were generated by heterologous expression and purification as previously 
described.21 
 
A.10.4 Preparation of S. pyogenes membranes  
An overnight culture (5 mL) of S. pyogenes M1 5448 ΔsagA16, 21 was grown in Todd-
Hewitt Broth (THB) at 37 °C and used to inoculate a 50 mL culture of THB. This culture was 
grown to an OD600 of 0.6 and harvested at 4,000 x g (5 min, 4 °C), and the cell pellet was transferred 
to a 1.7 mL microfuge tube using 1 mL of cell lysis buffer [50 mM MOPS (pH 7.6), 50 mM NaCl, 
5% (v/v) glycerol, 1500 U mutanolysin, and 5 mg lysozyme]. The cell wall was digested for 1 h 
at 37 °C with agitation before cooling to 4 °C, directly prior to cell disruption by sonication (3 
rounds for 30 s each, 30% power using a microprobe). The sample was then subjected to 3 rounds 
of freeze/thaw cycling using liquid nitrogen with cap venting upon warming to room temperature. 
A final round of sonication was then applied and any remaining intact cells were removed by a 
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low-speed centrifugation step (500 x g, 3 min, 4 °C). Omission of either the sonication or 
freeze/thaw cycling steps in this procedure gave poor membrane fraction preparations. The 
supernatant of the low-speed spin is referred to as the whole-cell lysate fraction. The majority of 
this fraction was transferred to a thick-walled microfuge tube prior to a subsequent high-speed spin 
(50,000 x g, 45 min, 4 °C), in which the membrane fraction was separated from the whole-cell 
lysate. The supernatant of this spin, referred to as the soluble fraction, was transferred to a clean 
microfuge tube. Proteins from the harvested membrane fraction were resolubilized in 300 µL of 
membrane extraction buffer [50 mM HEPES (pH 7.4), 125 mM NaCl, 5% (v/v) glycerol, and 1% 
(w/w) dodecyl maltoside] with light sonication (2 rounds for 1 s each, 10% power using a 
microprobe). The extraction was allowed to proceed for 1 h at 4 °C with rocking. Protein 
concentration in each sample (whole-cell lysate, soluble, and membrane fractions) were quantified 
using the Bradford assay, adjusted to the same concentration (3.8 mg/mL) and would typically 
produce a total of 1-2 mg of protein for each fraction. 
 
A.10.5 Localization of SagA/SLS proteolytic activity  
To S. pyogenes fractions (whole-cell lysate, soluble, and membrane, 13.2 µL, 50 µg protein 
each), was added TCEP (1 µL of 50 mM), purified 35S-methionine-labeled MBP-SagA, MBP-
Flag-SagA, or MBP-SagA-Flag protein pre-diluted in membrane extraction buffer (1 µL of 90 
µg/mL), and 14.8 µL of membrane extraction buffer for a total reaction volume of 30 µL. Aliquots 
were removed at specific times of reaction at 25 °C and quenched with SDS-PAGE loading buffer. 
Proteins were separated on a 10% SDS-PAGE gel with 25 ng of MBP-SagA protein loaded per 
lane. For samples utilizing 35S-methionine-labeled MBP-SagA, the gels were dried and visualized 
by autoradiography (typically requiring ~10 h of exposure at -80 °C using a Kodak BioMax low-
energy isotope intensifying screen). For samples utilizing MBP-Flag-SagA or MBP-SagA-Flag, 
protein was transferred to nitrocellulose membranes (Pierce) by electroblot. Membranes were 
blocked for 30 min at 25 °C in 4% non-fat milk in TBST [25 mM Tris (pH 7.6), 150 mM NaCl, 
0.1% (v/v) Tween 20] before anti-Flag antibodies (M2, mouse monoclonal, Sigma-Aldrich) were 
added at a 1:5,000 dilution directly to the buffer and allowed to bind for 1 h at 25 °C. The buffer 
was discarded and the membranes were washed 3 times for 5 min each with TBST. The membranes 
were then treated with anti-mouse horseradish peroxidase (HRP, GE Healthcare) at a 1:5,000 
dilution for 30 min at 25 °C followed by 3 washes for 5 min each with TBST. The membranes 
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were then treated with the SuperSignal West Pico Chemiluminescent substrate (Pierce) prior to 
film imaging. 
 
A.10.6 Expression of SLS in E. coli  
The three vectors comprising SagABCDEF were co-transformed into BL21-DE3 cells 
(Invitrogen) and plated on LB agar plates with 100 µg/mL ampicillin, 35 g/mL chloramphenicol, 
and 30 g/mL kanamycin. The resulting colonies were then chosen and tested for their ability to 
produce hemolytic activity. To perform hemolytic tests, 10 mL LB cultures with 100 µg/mL 
ampicilln, 35 g/mL chloramphenicol, and 30 g/mL kanamycin were grown overnight at 37C 
with shaking. Separate 10 mL LB cultures were inoculated 1:50 with each of these starter cultures 
and grown to OD600 0.7. Cultures were induced with 0.1 mM isopropyl--D-thiogalactopyranoside 
(IPTG) and bovine serum albumin (BSA, 10 mg/ml) was added to the induced cultures. An aliquot 
was removed at 2 and 8 h for hemolytic assay testing. Aliquots were centrifuged at 4,000 x g for 
15 min and supernatants were collected and directly added to washed, defibrinated sheep blood. 
 
A.10.7 Erythrocyte lysis assay 
Defibrinated sheep blood (Hemostat Laboratories) was rinsed by resuspension in 
phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·2H2O, 2 mM 
KH2PO4, pH 7.4) followed by centrifugation at 300 x g for 10 min at 4 °C. The supernatant was 
discarded and the pellet was rinsed again, repeating until the supernatant was nearly colorless. The 
blood was resuspended in fresh PBS to a concentration within the linear absorbance range at 405 
or 450 nm when treated with 0.1% Triton X-100. SLS extracts were applied to the blood in a 3:4 
ratio and incubated at 37 °C for 30 to 120 min. Lysed cells were removed by centrifugation at 300 
x g for 10 min at 4 °C and hemoglobin release was measured by A405 (FilterMax F5 plate reader) 
or A450 (Cary 4000 UV-Vis). 
 
A.10.8 Membrane proteolysis inhibition  
Purified membranes from S. pyogenes M1 5448 were used to digest [35S]-MBP-SagA in 
the presence of nelfinavir or mechanism-based protease inhibitors. A typical reaction (25 µL total 
volume) consisted of 18 µL of S. pyogenes membranes (5.0 mg/mL protein concentration), [35S]-
MBP-SagA, protease inhibitor, and TCEP (2 mM). The inhibitors tested were pepstatin A (for 
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aspartyl proteases, 60 µM), bestatin (for metalloproteases, 200 µM), E-64 (for cysteine proteases, 
200 µM), and pefabloc (for serine proteases, 400 µM). Nelfinavir was also tested in subsequent 
assays. Aliquots were removed at specific times of reaction at 25 °C, quenched with SDS-PAGE 
loading buffer, and analyzed by SDS-PAGE as described above. 
 
A.10.9 Effect of FDA-approved HIV protease inhibitors on S. pyogenes 
An overnight culture (5 mL) of S. pyogenes M1 5448 was grown in THB without shaking 
at 37 °C and used to inoculate multiple, identical 50 mL cultures of THB. Upon reaching an OD600 
of 0.2, the cultures were diluted two-fold using an equal volume of THB containing the desired 
concentration of protease inhibitor (initial screening was at 50 µM; nelfinavir analog screening 
was at 25 µM) from 10 mM stock solutions in DMSO. An equal volume of DMSO was used as a 
negative control for these assays. The OD600 of these cultures was measured in triplicate every 30 
min using a Cary 4000 UV-Vis spectrophotometer. For the cultures that reached an OD600 of 0.6, 
any SLS present on the cell surface was isolated using a BSA extraction procedure. SLS activity 
was then quantified by erythrocyte lysis assay. 
 
A.10.10 BSA extraction of SLS 
S. pyogenes M1 5448 was grown in THB at 37 °C as described above to an OD600 of 0.6. 
Cultures were harvested by centrifugation at 4000 x g for 10 min at 4 °C and the supernatant was 
discarded. The pellets were resuspended in fresh THB containing 10 mg/mL BSA and incubated 
at 37 °C for 1 h. The cultures were harvested by centrifugation at 4000 x g for 10 min at 4 °C and 
the supernatant was subsequently used in the erythrocyte lysis assay either undiluted or at a 1:3 
dilution in fresh THB containing 10 mg/mL BSA. 
 
A.10.11 Determination of IC50 values 
S. pyogenes M1 5448 was grown in the presence of inhibitors with a concentration range 
of 0.2 to 64 μM. SLS extracts were applied to the erythrocyte lysis assay alongside a DMSO treated 
control. Samples were centrifuged at 300 x g for 10 min at 4 °C and the supernatants were assayed 
for hemoglobin release when DMSO control treated blood had reached roughly 90% lysis. IC50 
values were defined as the concentration of inhibitor needed to prevent 50% of the hemolysis 
relative to the DMSO control over the given time course. 
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A.10.12 Minimum inhibitory concentration (MIC) testing 
Cultures of Bacillus subtilis 168 and E. coli MC4100 were grown in Luria-Bertani (LB) 
broth; cultures of Listeria monocytogenes 4b F2365, Staphylococcus aureus USA300 (MRSA), 
and Enterococcus faecium U503 (VRE) were grown in brain heart infusion (BHI) broth; cultures 
of S. pyogenes M1 5448 were grown in THB; cultures of C. sporogenes ATCC 19404 were grown 
in anaerobically prepared THB supplemented with 5 mM L-cysteine; cultures of Bacillus 
amyloliquefaciens RS6, Klebsiella pneumoniae ATCC 27736, and Pseudomonas aeruginosa 
PA01 were grown in Mueller Hinton broth. All strains were started as overnight cultures, were 
incubated at 37 °C, and were used at 1:100 dilutions to inoculate fresh cultures in the same media. 
The cultures were grown at 37 °C to mid-exponential phase prior to MIC testing. Nelfinavir was 
added to the cultures at 1 to 64 µM from a 10 mM DMSO stock. The treated cultures were 
incubated for 16 h at 37 °C and growth was visually examined. 
 
A.10.13 Electron microscopy 
An overnight culture of S. pyogenes M1 5448 was grown in THB at 37 °C and used to 
inoculate 5 mL cultures of THB containing 25 µM nelfinavir (from a 10 mM stock) or an 
equivalent amount of DMSO at a 1:20 dilution. The cultures were grown to an OD600 of 0.6, 
harvested by centrifugation (5,000 x g, 10 min, 25 °C), and fixed with a Karnovsky’s fixative in 
phosphate buffered 2% glutaraldehyde and 2.5% paraformaldehyde. Microwave fixation was used 
with this primary fixative and the tissue was then washed in cacodylate buffer with no further 
additives. Microwave fixation was also used with the secondary 2% osmium tetroxide fixative, 
followed by the addition of 3% potassium ferricyanide for 30 min. After washing with water, 
saturated uranyl acetate was added for enbloc staining. The sample was dehydrated in a series of 
increasing concentrations of ethanol. Acetonitrile was used as the transition fluid between ethanol 
and the epoxy. Infiltration series were done with an epoxy mixture using the epon substitute Lx112. 
The resulting blocks were polymerized at 90 °C overnight, trimmed, and ultrathin sectioned with 
diamond knives. Sections were stained with uranyl acetate and lead citrate and photographed with 
a Hitachi H600 Transmission Electron Microscope. 
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A.10.14 qRT-PCR of virulence gene expression 
An overnight culture of S. pyogenes M49 NZ131 was grown in THB at 37 °C and used to 
inoculate 2 mL cultures of THB containing 25 µM nelfinavir (from a 10 mM stock) or an 
equivalent amount of DMSO at a 1:20 dilution. The cultures were grown to an OD600 of 0.8 before 
RNA was isolated using an RNeasy Protect Bacteria Mini Kit (Qiagen) following the 
manufacturer’s instructions, except for the lysis step, which was extended to 1 h with the addition 
of 250 U mutanolysin. The absence of DNA contamination was confirmed by PCR with primers 
to the 16S rRNA and sagA genes. Isolated RNA was used to generate cDNA using the ImProm II 
kit (Promega) following the manufacturer’s instructions, running reactions both with and without 
reverse transcriptase (RT). RT negative reactions again confirmed the absence of DNA 
contamination. qRT-PCR reactions were initiated with 2 uL of cDNA (~2.5 ng/µL), 2 µL of 10 
µM forward primer, 2 µL of 10 µM reverse primer, 10 µL of iTaq Universal SYBR Green 
Supermix (Bio-Rad), and 4 µL of water and were run on a Lightcycler 480 (Roche). The fold-
change in gene expression was calculated using a comparative CT method.50 We defined a 
significant change in gene expression to be genes that were either up- or down-regulated by more 
than 1.5 fold (log2) with P-values <0.01. 
 
A.10.15 Inhibition of LLS production  
Overnight cultures (5 mL) of L. monocytogenes were grown in BHI media at 37 °C and 
used to inoculate a 50 mL culture of BHI at a 1:20 dilution. Upon reaching an OD600 of 0.2, the 
culture was used to create multiple, identical cultures diluted by twofold using an equal volume of 
BHI containing 50 µM nelfinavir from a stock solution of 10 mM in DMSO. An equal volume of 
DMSO was used as a negative control for these assays. L. monocytogenes F2365LLSC Δhly (LLO 
genetically deleted, LLS constitutively expressed) was used as the “+LLS” strain and L. 
monocytogenes F2365LLSC ΔhlyΔllsB (LLO and LLS genetically deleted) was used as the “-LLS” 
strain51. LLS was extracted in a manner analogous to SLS and applied to the erythrocyte lysis 
assay. 
 
A.10.16 Inhibition of CLS production 
Overnight cultures (5 mL) of Clostridium sporogenes ATCC 19404 were grown in 
anaerobically prepared THB containing 5 mM L-cysteine at 37 °C in an anaerobic chamber (Coy 
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Lab Products) and used to inoculate 5 mL cultures at a 1:40 dilution of anaerobically prepared 
THB containing 5 mM L-cysteine. The cultures were incubated at 37 °C until an OD600 of 0.15, at 
which point 50 µM nelfinavir from a stock solution of 10 mM in DMSO was added. An equal 
volume of DMSO was used as a negative control. CLS was extracted in a manner analogous to 
SLS and applied to the erythrocyte lysis assay. 
 
A.10.17 Inhibition of plantazolicin production  
10 mL cultures of B. amyloliquefaciens RS6 (sfp::ermAM bac::cmR, deficient in 
lipopeptides, polyketides, and bacilysin)58 were grown in LB broth at 37 °C to an OD600 of 0.2 or 
0.6 (early- to mid-log phase, respectively), at which point nelfinavir or an equivalent volume of 
DMSO was added to the liquid cultures. Following inhibitor addition, cultures were grown with 
shaking at 37 °C for 24 h. Cells were harvested by centrifugation (4,000 x g, 10 min, 4 °C), washed 
with Tris-buffered saline (TBS, pH 8), and harvested again (8,000 x g, 10 min, 4 °C). PZN was 
obtained by a non-lytic, methanolic cell surface extraction, as described previously.52, 59 Briefly, 
cells were resuspended in MeOH (1 mL), agitated by vortex for 30 s, and equilibrated for 15 min 
at 22 °C. Cells were harvested by centrifugation (8,000 x g, 10 min, 4 °C), and the MeOH 
supernatant was evaporated in a speed-vac concentrator with minimal heating. Dried, crude 
extracts were resuspended in 100 µL of MeOH and filtered through a 0.22 µm filter in preparation 
for analysis by liquid chromatography-mass spectrometry (LC-MS) using an Agilent 1200 HPLC 
system coupled to a G1956B quadrupole mass spectrometer with an electrospray ionization (ESI) 
source. LC used a 4.6 mm x 250 mm Thermo Scientific BetaSil C18 column (100 Å, 5 µm) with 
a gradient of 40-90% MeCN (with 10 mM NH4HCO3 in the aqueous phase) over 25 min, with the 
analytes eluted directly into the MS. PZN was quantified by integrating the total area under the 
curve for the single-ion monitoring (SIM) trace of m/z 668 ([M+H]2+), normalized to a negative 
control sample included in each set. 
 
A.10.18 Bioinformatics analysis of CaaX-like proteins in divergent TOMM clusters 
All YcaO superfamily proteins (InterPro IPR003776, SagD-like) were obtained from 
UniProt on October 28, 2014. Genome clusters were defined by using regions of 1000 bp on either 
side of the YcaO-like protein. Gene cluster families were created using MultiGeneBlast11 with a 
cutoff of total score above 10. TOMM clusters were defined as containing both a YcaO-like protein 
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and a SagC or SagA like ortholog. All gene clusters were manually examined with special attention 
toward stand-alone YcaO clusters such as bottromycin (i.e. lacking the C-protein). CaaX-like 
proteins were defined as being orthologous to the SagE protein and identified using a Hidden 
Markov Model (HMM) created with SagE orthologs from Clostridium and Bacillus. 
 
A.10.19 PrsW cleavage of RsiW 
B. subtilis strains CDE743 (B. subtilis PY79 amyE::Phyperspank-3xflag-rsiW) and 
CDE744 (B. subtilis PY79 amyE::Phyperspank-3xflag-rsiW  psrW::erm) were obtained from Craig 
Ellermeier (University of Iowa, Iowa City). Overnight cultures of CDE743 and CDE744 were 
grown in LB containing 5 µg/mL kanamycin (for maintenance of the rsiW-containing vector) at 
37 °C with shaking. An additional 25 µg/mL erythromycin was added to all cultures of CDE744. 
The overnight cultures were used to inoculate fresh 2 ml cultures in LB containing 5 µg/mL 
kanamycin at a 1:100 dilution. The cultures were grown at 37 °C with shaking to an OD600 of 0.1 
before the addition of 1 mM IPTG and either 50 µM nelfinavir or an equivalent amount of DMSO. 
The cultures were then grown to OD600 of 0.7 before 24 mM NaOH from a 100x stock was added 
to half of the cultures. The cultures were incubated at 37 °C with shaking for an additional 1 h. 
The cultures were pelleted and the supernatant was discarded. The pellets were resuspended in 375 
µL of TAE buffer (40 mM Tris HCl, 20 mM acetic acid, 1mM EDTA, pH 8.0) with 10 mg/mL 
lysozyme. After a 10 min incubation at room temperature, the samples were mixed with 4x 
reducing loading dye and heated at 65 °C for 10 min. The samples were run on 12% SDS-PAGE 
gels and protein was transferred to PVDF membranes (Pierce) by electroblot. Membranes were 
blocked overnight at 4 °C in 5% non-fat milk in TBST before horse radish peroxidase (HRP) 
conjugate anti-Flag antibodies (M2, mouse monoclonal, Sigma-Aldrich) were added at a 1:5,000 
dilution directly to the buffer and allowed to bind for 1 h at 4 °C. The buffer was discarded and 
the membranes were washed 5 times for 5 min each with TBST. The membranes were then treated 
with the SuperSignal West Pico Chemiluminescent substrate (Pierce) prior to film imaging. 
 
A.10.20 Affinity labeling with crosslinking probe 
S. pyogenes M1 WT and E. coli BL21-DE3 were grown in THB and LB, respectively, as 
above. Overnight cultures of each species were used to inoculate fresh 50 mL cultures in the same 
media. The cultures were grown to an OD600 of 0.9 at 37 °C and then pelleted at 4,000 x g for 10 
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min. The supernatants were discarded and the pellets were washed with 2 mL water before being 
resuspended in 1 mL of water. Probe 150 was added at 50 µM to each sample and the suspensions 
were incubated at 37 °C with shaking for 30 min. The samples were transferred to a 6-well plate 
and exposed to 365 nm light from a 4 W UV wand placed directly on the well for 20 min. The 
samples were transferred back to an Eppendorf tube and pelleted at 2,000 x g for 10 min. The 
pellets were resuspended in MOPS lysis buffer (50 mM MOPS, 50 mM NaCl, 5% glycerol, pH 
7.0) containing 15 µL/mL protease inhibitor cocktail (2 µM leupeptin, 200 µM PMSF, 2 mM 
benzamidine, 2 µM E64) and either 200 U/mL mutanolysin (for S. pyogenes) or 15 mg/mL (for E. 
coli). For S. pyogenes samples, cell lysis was carried out by a one hour incubation at room 
temperature followed by freezing, thawing, and sonicating the cells for 30s, with the 
freeze/thaw/sonicate cycle being repeated 4 times total. For E. coli samples, cell lysis was carried 
out by a 30 min incubation at room temperature followed by four rounds of sonication for 30 s 
each. Biotin-peg3-azide (Jena Bioscience, Jena, Germany; 100 µM), copper sulfate (10 mM), and 
sodium ascorbate (20 mM) were added to each sample. The samples were incubated for 1 h and 
were then used as total lysate or were centrifuged at 17,000 x g for 10 min. The supernatant was 
used as the soluble portion of the lysate while the pellet was used as the insoluble portion. The 
insoluble portion was resuspended in 100 µL MOPS lysis buffer with 1% CHAPS with a reducing 
loading dye before application to 12% SDS-PAGE gels. Protein was transferred to PVDF 
membranes (Pierce) by electroblot. Membranes were blocked overnight at 4 °C in 5% BSA in 
TBST before neutrAvidin-HRP (Pierce) was added at a 1:30,000 dilution directly to the buffer and 
allowed to bind for 1 h at 4 °C. The buffer was discarded and the membranes were washed 5 times 
for 5 min each with TBST. The membranes were then treated with the SuperSignal West Pico 
Chemiluminescent substrate (Pierce) prior to film imaging. 
 
A.10.21 Expression of SagE in lipid nanodiscs 
POPC lipid nanodiscs (disc concentration at 3uM, in 20mM tris, 0.1% NaCl, 15% glyercol) 
were obtained from Steven Sligar (University of Illinois, Urbana, IL). Coupled 
transcription/translation reactions were carried out with the Promega TNT T7 Coupled Rabbit 
Reticulocyte Lysate System (Progema product number L4610) following the manufacturer’s 
guidelines. Reactions contained 12.5 µL rabbit reticulocyte lysate, 1 µL TNT reaction buffer 
(supplied with kit), 0.5 µL T7 polymerase, 0.25 µL amino acid mix minus Met, 0.25 µL amino 
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acid mix minus Leu, 0.5 µL RNasin, 6.5 µL POPC nanodiscs, and 1 µg DNA. The DNA used for 
each reaction was either pET28-Mistic-SagE or pCOLA-SagE-SagF-Stag. Generation of the 
pCOLA is described above while the pET28 vector was generated in the Dixon lab (University of 
California, San Diego (UCSD), La Jolla, CA) by cloning from S. pyogenes M1 5448. The reactions 
were incubated at either 18 or 30 °C for 90 min before 2 µL of each reaction was mixed with 3 µL 
of 33.3 ng/µL MBP-SagA in various cleavage buffers (50 mM tris, 50-125 mM NaCl, 0-20 mM 
MgCl2, 0-50 µM ZnCl2, 2.5 mM TCEP or 10 mM DTT, 0-2.5% glycerol, 0-3 mM ATP, pH 7.5). 
The cleavage reactions were incubated at 18 °C or 37 °C for 2 h before being mixed with a reducing 
loading dye and applied to 12% SDS-PAGE gels. Protein was transferred to PVDF membranes 
(Pierce) by electroblot. Membranes were blocked overnight at 4 °C in 5% non-fat milk in TBST 
before anti-MBP primary antibodies (rabbit polyclonal, generated in the Dixon lab, UCSD) were 
added at a 1:2,000 dilution directly to the buffer and allowed to bind for 2 h at 4 °C. The buffer 
was discarded and the membranes washed twice with TBST for 30 s each. The membranes were 
placed in 10 mL fresh TBST and 1.5 µL of anti-rabbit-HRP goat secondary antibodies were added 
to the buffer. The membranes were incubated for 45 min at 4 °C. The buffer was discarded and the 
membranes were washed 5 times for 5 min each with TBST. The membranes were then treated 
with the SuperSignal West Pico Chemiluminescent substrate (Pierce) prior to film imaging. 
 
A.10.22 qRT-PCR of strains containing pIB184-sagE/F vectors 
Overnight cultures of S. pyogenes M1 5448 transformed with pIB184-sagE, pIB184-
sagEF, pIB184-sagF, or pIB184-AntiEfull were grown in THB at 37 °C with 50 µg/mL kanamycin 
and used to inoculate 2 mL cultures of THB. The cultures were grown to an OD600 of 0.65 before 
RNA was isolated using an RNeasy Protect Bacteria Mini Kit (Qiagen) following the 
manufacturer’s instructions, except for the lysis step, which was extended to 1 h with the addition 
of 250 U mutanolysin. The absence of DNA contamination was confirmed by PCR with primers 
to the 16S rRNA and sagE genes. Isolated RNA was used to generate cDNA using the ImProm II 
kit (Promega) following the manufacturer’s instructions, running reactions both with and without 
reverse transcriptase (RT). RT negative reactions again confirmed the absence of DNA 
contamination. qRT-PCR reactions were initiated with 2 uL of cDNA (~2.5 ng/µL), 2 µL of 10 
µM forward primer, 2 µL of 10 µM reverse primer, 10 µL of iTaq Universal SYBR Green 
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Supermix (Bio-Rad), and 4 µL of water and were run on a Lightcycler 480 (Roche). The fold-
change in gene expression was calculated using a comparative CT method.50 
A.10.23 Tanimoto similarity analysis 
The structure of each HIV protease inhibitor in ChemDraw (PerkinElmer) was converted 
to .sdf format. Tanimoto similarity coefficients were calculated in Discovery Study Client 2.5 
(Accelrys) using the .sdf files as input reference ligands for the Library Analysis protocol “Find 
Similar Molecules by Fingerprints”. ECFP_6 was used and the minimum similarity was set at zero. 
The compounds were all compared pair-wise. 
 
A.10.24 List of primers 
Table A.7. Primer sequences used in this study. Restriction endonuclease recognition sites are 
underlined. Lower-case letters indicate bases targeted for mutagenesis. The function of each gene 
analyzed by qRT-PCR is given in Table A.2. 
 
Primer Sequence (5’ to 3’) Description 
Construct Generation 
pDC-Flag-
SagA-fwd 
GAGTCTAGAATGGATTACAAGGATGA
CGACGATAAGTTCAAATTTACTTCAAA
TATTTTA 
Forward primer to append an 
N-terminal Flag tag to sagA 
pDC-SagA-
rev 
ACAGGATCCTTATTTACCTGGCGTATA
ACTTCC 
Reverse primer to append an 
N-terminal Flag tag to sagA 
pDC-SagA-
fwd 
GAGTCTAGAATGTTAAAATTTACTTCA
AATATTTTAG 
Forward primer to append a C-
terminal Flag tag to sagA 
pDC-SagA-
Flag-rev 
ACAGGATCCTTACTTGTCGTCGTCATC
CTTGTAGTCTTTACCTGGCGTATAACTT
CC 
Reverse primer to append a C-
terminal Flag tag to sagA 
Flag-SagA-
fwd 
AAAAGGATCCATGGACTACAAGGATG
ACGAC 
Forward primer to subclone 
Flag- sagA from pDCerm 
construct 
Flag-SagA-
rev 
AAAAGCGGCCGCTTATTTACCTGGCGT
ATAACTTCCG 
Reverse primer to subclone 
Flag- sagA from pDCerm 
construct 
SagA-Flag-
fwd 
AAAAGGATCCATGTTAAAATTTACTTC
AAATATTTTAGCTACTAGTGT 
Forward primer to subclone 
sagA-Flag from pDCerm 
construct 
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Table A.7. (cont.) 
SagA-Flag-
rev 
AAAAGCGGCCGCTTACTTGTCGTCGTC
ATCCTTGTA 
Reverse primer to subclone 
sagA-Flag from pDCerm 
construct 
MBP-fwd ATGAAGCCCTGAAAGACG Sequencing primer for pET28-MBP constructs 
SagE-fwd AAAACCATGGCGCCTTTGTCCATCCAATGC 
Forward primer to clone sagE 
into pCOLADuet-1 
SagE-rev AAAGCGGCCGCTCATGTCACCTCCTTCTTCTTTTTTG 
Reverse primer to clone sagE 
into pCOLADuet-1 
SagF-fwd AAAAAAAACATATGATGCTATTGGTTTTGCTGTCG 
Forward primer to clone sagF 
into pCOLADuet-1 
SagF-rev AAAACTCGAGCTAATACTCTTTGCAACTAATCATCAAATAAGTC 
Reverse primer to clone sagF 
into pCOLADuet-1 
SagE-E131A-
fwd 
GGCTATCCTTTATTACTAGCTTTATTTg
caGAGACGATTTATCG 
Forward primer for 
incorporation of alanine at 
position E131 in sagE 
SagE-E131A-
rev 
CGATAAATCGTCTCtgcAAATAAAGCTA
GTAATAAAGGATAGCC 
Reverse primer for 
incorporation of alanine at 
position E131 in sagE 
SagE-E132A-
fwd 
CTAGCTTTATTTGAAgcgACGATTTATC
GTTTTTTGTGG 
Forward primer for 
incorporation of alanine at 
position E132 in sagE 
SagE-E132A-
rev 
CCACAAAAAACGATAAATCGTcgcTTCA
AATAAAGCTAG 
Reverse primer for 
incorporation of alanine at 
position E132 in sagE 
SagA 
VAPGG-
VLPLL-fwd 
GCTACTAGTGTAGCTGAAACAACTCAA
GTTcttCCTctactcTGCTGTTGCTGCTGTAC 
Forward primer for 
incorporation of leucine at 
positions A20, G22, and G23 
in sagA 
SagA 
VAPGG-
VLPLL-rev 
GTACAGCAGCAACAGCAgagtagAGGaag
AACTTGAGTTGTTTCAGCTACACTAGT
AGC 
Reverse primer for 
incorporation of leucine at 
positions A20, G22, and G23 
in sagA 
G184-SagE-
fwd 
CCCGCGGTACCCGGGATGCCTTTGTCC
ATCCAATG 
Forward primer to clone sagE 
(and sagEF) into pIB184 
G184-SagE-
rev 
AGATCTCGAGCTCTAGTCATGTCACCT
CCTTCTTC 
Reverse primer to clone sagE 
into pIB184 
G184-SagF-
fwd 
CCCGCGGTACCCGGGATGATGCTATTG
GTTTTGC 
Forward primer to clone sagF 
into pIB184 
G184-SagF-
rev 
AGATCTCGAGCTCTAGCTAATACTCTT
TGCAACTAATCATC 
Reverse primer to clone sagF 
(and sagEF) into pIB184 
G184-AntiE-
fwd 
CCCGCGGTACCCGGGTCATGTCACCTC
CTTCTTC 
Forward primer to clone 
antisense sagE into pIB184 
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Table A.7. (cont.) 
G184-AntiE-
rev 
agatctcgagctctagATGCCTTTGTCCATCCA
ATG 
Reverse primer to clone 
antisense sagE-full into 
pIB184 
G184-
AntiE150-rev 
CCCGCGGTACCCGGGAATGTCATAAAT
CAGAGTTGCTC 
Reverse primer to clone 
antisense sagE-150 into 
pIB184 
 
qRT-PCR 
q16S-fwd GAGAGTTTGATCCTGGC Forward primer for qRT-PCR on the 16S rRNA gene 
q16S-rev TTGCCGAAGATTCCCTA Reverse primer for qRT-PCR on the 16S rRNA gene 
qM49-fwd TTAGTTTTCTTCTTTGCGTTTTAGA Forward primer for qRT-PCR on emm49 
qM49-rev CGAAGCTAAGAAAAAAGTAGAAG Reverse primer for qRT-PCR on emm49 
qSLO2-fwd GATGTGTTTGATAAATCAGTGAC Forward primer for qRT-PCR on slo 
qSLO2-rev TCAGTTCTGTTATTGACACC Reverse primer for qRT-PCR on slo 
qsagA-fwd ATGTTAAAATTTACTTCAAATATTTTAGCT 
Forward primer for qRT-PCR 
on sagA 
qsagA-rev TATTTACCTGGCGTATAACTTC Reverse primer for qRT-PCR on sagA 
qsagB-fwd ATGTCATTTTTTACAAAGGAACAA Forward primer for qRT-PCR on sagB 
qsagB-rev ATTGACGATGACTTCTTCG Reverse primer for qRT-PCR on sagB 
qscpA-fwd TTAGAAGATCGTTTCTCTAGAGTA Forward primer for qRT-PCR on scpA 
qscpA-rev TACTGTTCCATTGAAAATGTCA Reverse primer for qRT-PCR on scpA 
qska-fwd ATGAAAAATTACTTATCTTTTGGGAT Forward primer for qRT-PCR on ska 
qska-rev CTTGCAAAATCAATGACCTC Reverse primer for qRT-PCR on ska 
qspeB-fwd CTAAGGTTTGATGCCTACAA Forward primer for qRT-PCR on speB 
qspeB-rev TGTTGGTATTTCAGTAGACATG Reverse primer for qRT-PCR on speB 
qnga-fwd AAACAAAAAAGTAACATTAGCTCAT Forward primer for qRT-PCR on nga 
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Table A.7. (cont.) 
qnga-rev GTATTTAACATCAGCCTTTGC Reverse primer for qRT-PCR on nga 
qspd3-fwd ATGTCTAAATCAAATCGTCGT Forward primer for qRT-PCR on spd3 
qspd3-rev GTCATTTAAGCCGCTAAATTG Reverse primer for qRT-PCR on spd3 
qsagE-fwd GCCTTTGTCCATCCAAT Forward primer for qRT-PCR on sagE 
qsagE-rev AATCGTCTCTTCAAATAAAGCT Reverse primer for qRT-PCR on sagE 
qsagF-fwd TGCTATTGGTTTTGCTGT Forward primer for qRT-PCR on sagF 
qsagF-rev ATACTTAAGACTGGTTTATCTTGT Reverse primer for qRT-PCR on sagF 
Gene Verification 
ClosC-fwd ATGGAAAATAATACTATATACAAATTAAGCAATAATTTAA 
Forward primer for confirming 
the presence of closC 
ClosC-rev TTAAGAATTAATATCTTCTAAAATTTCATCCACAA 
Reverse primer for confirming 
the presence of closC 
ClosD-fwd ATGATAAAATTTTACCCAAGTTTTAATAATATATTAGAG 
Forward primer for confirming 
the presence of closD 
ClosD-rev TTAAGGCATTGGGTGCG Reverse primer for confirming the presence of closD 
 
A.10.25 Compound Syntheses 
 1H, 13C, and 19F NMR spectra were collected on Varian Inova 400 and 500 MHz 
spectrometers. All 1H and 13C spectra collected in CDCl3 were referenced to an internal 
tetramethylsilane standard. All 1H and 13C spectra collected in (CD3)2SO were referenced to the 
solvent peak. All 19F spectra were referenced to an external CFCl3 standard. High-resolution mass 
spectrometry (HRMS) data were obtained on a Micromass Q-TOF Ultima tandem quadrupole 
mass-spectrometer at the University of Illinois at Urbana-Champaign Mass Spectrometry 
Laboratory. 
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